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Abstract 
Dysregulated wound healing contributes to most currently unanswered ophthalmological 
morbidity. Opacification and structure altering contractures compromise the delicate 
ocular anatomy upon which ocular function and healthy vision are reliant. Glaucoma 
filtration surgery, corneal stromal injury, proliferative vitreoretinopathy and age-related 
macular degeneration are major contributors to ocular morbidity – all with myofibroblast 
transdifferentiation and pathognomonic scarring activity at their core. 
This thesis aims to revaluate the means by which dysregulated ocular wound healing is 
combated with evidence describing a novel strategy to mitigate its effects. A translational 
approach was used. An initial retrospective analysis of over ten thousand glaucoma 
surgeries found that perioperative NSAID exposure was significantly associated with 
surgical success. The current standard of care, corticosteroids, showed no such 
association. This was surprising and provided impetus to evaluate these clinical findings 
within the basic science lab.  
The subsequent project examined the relative effects of NSAIDs to that of corticosteroids 
on the in vitro wound healing activity of ocular fibroblasts. Relative to steroids, NSAID 
exposure resulted in more ordered extracellular matrix remodelling, less cell-mediated 
collagen contraction and greater impairment of myofibroblast associated protein 
expression.  
We hypothesized that these differences were due to NSAIDs more specific targeting of 
COX enzyme activity. By sparing lipoxygenase activity, competitive NSAIDs leave intact 
the biosynthetic machinery responsible for signaling the endogenous resolution of 
inflammation. This system involves the collective effects of the pro-resolving superfamily 
of lipid mediators and promotes the active resolution of inflammatory processes. 
To assess the anti-fibrotic potential of inducing resolution within inflammation-induced 
ocular fibroblasts, two COX2 Ser516 acetylating molecules were utilized to modify the 
COX2 enzyme such that it: 1) ceases prostaglandin production, and 2) gains the capacity 
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to produce pro-resolving lipid mediators. When applied to inflammation-induced ocular 
fibroblasts, a reduction in in vitro wound healing phenomena was observed with a 
corresponding shift in pro-/anti-fibrogenic transcription factor expression and 
downregulation of myofibroblast associated proteins. 
Together these findings suggest that the resolution of inflammation and the resolution of 
fibroproliferation may be controlled by a common signaling system, and that 
interventions promoting the production of resolving lipid mediators could have significant 
anti-cicatrizing properties. 
 
Keywords: wound healing, inflammation, fibrosis, scarring, ophthalmology, ocular, 
myofibroblast, fibroblast, transdifferentiation, immuno-suppression, immuno-
resolution 
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Chapter 1  
1 Introduction 
1.1 Ocular Wound Healing 
The mechanisms of wound healing within the anterior segment of the eye, 
specifically the subconjunctival tissues, are similar to most non-nervous tissues 
within the body.1–4 After hemostasis, tissues undergo repair in three stages: 1) 
inflammation / resolution, 2) proliferation and 3) remodeling. These stages are 
partially overlapping sequential events, controlled through the integration of 
information from several dynamic signaling networks. These signaling networks 
incorporate several diverse classes of signaling molecules, several cell types and 
physical cues from the extracellular matrix (ECM) and external environment. For 
healthy wound healing to occur, as opposed to an anatomically impairing 
fibroproliferative response, orderly and efficient transitions between each phase 
are required. A non-anatomically disruptive wound healing response after ocular 
insult is critical to maintaining vision, as the slightest contracture, thickening or 
opacification of delicate ocular anatomical structures can have dire 
consequences to a patient’s refractive status and/or ocular physiology. 
  
 2 
 
1.1.1 Inflammation and Resolution in Wound Healing 
Inflammation and its resolution are an endogenously controlled biological 
algorithm coding the intentional deviation and subsequent return to homeostasis 
that is required to overcome infection or trauma.5,6 The magnitude of tissue 
damage (fibrosis/scarring) that results from an inflammatory insult is directly 
proportional to the intensity and duration of the inflammatory reaction the body 
levies in response to that insult (Figure 1-1). In the eye, it is especially critical to 
ensure inflammatory responses are kept to a minimum – as the anatomy upon 
which healthy vision is dependent can easily be disrupted by inflammation and 
fibrosis induced changes to tissue architecture, often with permanent 
consequences.  
Inflammation is involved in both normal wound healing and the development of 
fibrosis. Tissue damage caused by infectious, ischemic, autoimmune, traumatic 
or surgical insults causes localized cell death. The intracellular components of 
Figure 1-1 Diagram illustrating the risk of local tissue damage during 
inflammation-induced deviations from homeostasis. Immunosuppressive 
interventions aim to block the molecular signals contributing to the original, 
inflammation-induced deviation from homeostasis. Immuno-resolvent 
interventions aim to reduce the risk of tissue damage by both dampening the 
inflammatory deviation from homeostasis and hastening the subsequent 
endogenously controlled return. 
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these necrotic cells are released into the interstitum. Surviving cells within the 
area express danger associated molecular pattern (DAMP) receptors, which can 
sense intracellular components such as DNA, RNA, histones, mitochondrial DNA 
and ATP among others within the interstitum.7–9 Once activated, DAMP receptors 
bind their ligands and initiate an intracellular signaling cascade culminating in 
secretion of IL-1β and the canonical commencement of inflammatory signaling.7,8 
The cardinal signs of inflammation have long been tied to the increased 
production of the prostaglandin (PG) and leukotriene (LT) classes of lipid derived 
signaling molecules. The secretion of these lipid mediators requires the actions of 
intracellular phospholipases (PL), such as PLA2, acting on membrane 
phospholipids to generate arachidonic acid (AA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA).10 These precursors are then oxygenated by 
cyclooxygenase 2 (COX2) to produce the prostaglandins and leukotrienes.11 The 
expression of both COX2 and PLA2 is induced by IL-1β.12 Due to their extremely 
potent chemokine and vasoactive properties, PGs and LTs function in wound 
healing mainly to perpetuate the inflammatory state, increase vascular 
permeability and increase platelet aggregation. Vascular permeability and platelet 
aggregation increase the relative numbers of local inflammatory cells, fibroblasts, 
pro-inflammatory growth factors and wound healing associated cytokines. 
Due to the difficulty of measuring lipid derived signaling molecules (LMs), 
relatively little is known about their role in wound healing. Recent developments 
in liquid chromatography tandem mass spectrometry (LC-MS/MS) have enabled 
more in depth study. Mice with impaired AA lipid metabolism exhibit delayed 
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wound closure,13 the PGF2α receptor has been shown to facilitate the 
development of pulmonary fibrosis,14 and the long term use of PG analogs was 
shown to induce ECM contraction, upregulate pro-fibrotic cytokine release and 
collagen expression in human eyes15 – thus it can be inferred that the AA derived 
LMs facilitate certain aspects of the wound healing process.   
  
Figure 1-2: Diagram of pro-inflammatory and pro-resolving lipid mediator 
synthesis pathways. COX2 is responsible for utilizing n3 and n6 
polyunsaturated fatty acid precursors to create PGs. The LOX enzymes 
cooperate to give rise to many different AA, EPA and DHA derived RMs. 
PLA2: phospholipase A2; AA: arachidonic acid; EPA: eicosapentaenoic acid; 
DHA: docosahexaenoic acid; PUFAs: polyunsaturated fatty acids; COX2: 
cyclooxygenase 2; LOX: lipoxygenase. 
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Over the past twenty years, our understanding of how inflammation undergoes 
spontaneous resolution has evolved. Previously, resolution was thought to occur 
through the passive diffusion and dilution of inflammatory mediators. However, it 
is now understood to be an active process; tightly controlled by a novel 
superfamily of lipid derived signaling molecules – the specialized pro-resolving 
mediators (RMs).5,16–18 RM synthesis is triggered (after a slight delay) by pro-
inflammatory mediators. They are generated in relatively large quantities and are 
extremely bioactive (nanomolar level). Grossly, they are derived from the actions 
of the lipoxygenase enzymes (as opposed to COX2) on AA, EPA and DHA 
(Figure 1-2).6,19,20 
In the eye, SPMs signal for the active termination of inflammatory processes such 
as inflammatory cell trafficking, activation and vascular permeability.21 At a 
cellular level, there are cell surface and nuclear receptors for SPMs,22–25 the 
activation of which downregulates PG production,21,26 vascular cell adhesion 
molecules, monocyte chemotactic protein 1, IL-8, IL-1β and TNFα signaling.21 
Their effects also stimulate resolution-associated processes such as 
macrophage-mediated phagocytosis of wound debris, inflammatory cell 
clearance and efferocytosis.6,27 Overall, SPMs function to protect tissues from an 
over exuberant inflammatory response via several cellular and organ-level 
mechanisms, facilitating an ordered return to homeostasis after inflammatory 
insult.28,29 
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1.1.1.1 Fibroblasts as inflammatory cells 
Fibroblasts can be conceptualized as sentinels of the immune system.30 They 
express functional toll-like receptors,31 DAMP receptors, and normally exhibit little 
cellular activity. However, fibroblasts are often the first cell type to encounter an 
inflammatory stimulus. Indeed, when activated by DAMPs9 and pathogen 
associated molecular patterns (PAMPs),30 fibroblasts begin to secrete their own 
inflammatory cytokines and chemokines such as TGFβ1, IL-1β, IL-6, IL-13 and 
IL-33 as well as exhibit strong induction of COX2.26,32 These protein based 
mediators act in a paracrine manner to activate nearby fibroblasts, vascular 
endothelial cells and recruit circulating inflammatory cells. They can also act in an 
autocrine manner to illicit transdifferentiation of fibroblasts into myofibroblasts – 
the main cellular drivers of fibrosis and scarring.1,33,34 
The effects of RMs on fibroblasts within an inflammatory and wound healing 
microenvironment are starting to be elucidated. The experimental overexpression 
of LOX enzymes was found to impair the scarring observed in a mouse model of 
pulmonary fibrosis and was attributed to increased LOX-mediated RM 
generation.35 Exogenous application of individual RMs has impaired the 
development of experimental renal fibrosis in an obstructed kidney model through 
the inhibition of fibroblast proliferation and a mitigation of the inflammatory 
response.36 Further studies have demonstrated that RMs have the capacity to 
interfere with TGFβ1-induced collagen production and fibroproliferation.37 These 
data would seem to suggest that RMs may function to attenuate fibroblast-
mediated tissue fibrosis and wound healing phenomena. 
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1.1.2 Proliferative Stage of Wound Healing 
The proliferative stage spans the end of the inflammatory and beginning of the 
resolution stages. Inflammation induces the secretion of growth factors which 
stimulate the proliferation of local fibroblasts and inflammatory cells. These cells 
deposit ECM molecules and generate new granulation tissue to fill lesions and 
restore barriers to the external environment.38 Contraction of the ECM is elicited 
by inflammation-induced myofibroblast transdifferentiation,39 with the novel 
expression of the contractile protein alpha smooth muscle actin (αSMA).40 As it is 
governed by growth factors secreted during the inflammatory stage, the duration 
and magnitude of the proliferative stage is determined by the duration and 
intensity of the inflammatory phase. Thus, the amount of collagen deposited 
within the wound, and the degree to which myofibroblast-mediated tissue 
contraction occurs can be reduced by attenuating the inflammatory stage of 
wound healing. 
In humans, attenuation of the inflammatory phase has been accomplished for 
over 100 years using an immuno-suppressive strategy. For example, 
corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), among 
others, are modalities of inflammation control that disrupt the generation of pro-
inflammatory mediators. This strategy ignores the fact that the resolution of 
inflammation is initiated by several of these very “pro-inflammatory” mediators 
that are suppressed.27 The result is a dampening of clinical inflammatory signs 
due to a lack of pro-inflammatory stimuli, however it may also induce a state of 
“frustrated resolution” – defined as the absence RM signaling after inflammation, 
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which hinders the ordered return to homeostasis.28 The discovery of RMs has 
brought to the forefront a novel strategy in which to shorten the duration and 
temper the intensity of inflammatory responses.17 Finding therapeutic means to 
stimulate the body’s own endogenous mechanisms of resolution will be the first of 
the immuno-resolvent interventions and have the potential to mitigate 
inflammation by working synergistically with human physiology as opposed to 
against it. 
1.1.3 Remodeling Stage of Wound Healing 
The remodeling stage usually begins about two to three weeks after the initial 
insult. Local inflammatory cell infiltrates are greatly reduced and eventually return 
to baseline levels.38 The remodeling stage begins during the resolution of 
inflammation and it can span for months to years after injury. During this phase 
fibroblasts and myofibroblasts respond to autocrine, paracrine and physical ECM 
cues to reorganize the extracellular matrix in an attempt to recover normal tissue 
architecture.41–44 Tension gradients within the matrix dictate the balance of matrix 
metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) eliciting 
degradation and re-synthesis of the ECM such that the stiffness and density of 
collagen fibers is increased.44 The degree of stiffening and increased density is 
directly proportional to the amount of cellular infiltrates as well as the duration 
and intensity of the preceding inflammatory and proliferative stages.45,46 Indeed, a 
novel class of RM termed resolvin conjugates in tissue regeneration (RCTRs) 
have been shown to improve regenerative wound healing by decreasing the 
duration and magnitude of inflammatory signaling during the inflammatory 
 9 
 
phase.22 Overall, the impact of RMs appear to be beneficial at all stages of the 
normal wound healing response, and their absence appears to lead to a state of 
frustrated resolution with less than optimal wound healing outcomes. 
1.2 Glaucoma and Glaucoma Surgery 
Glaucoma is the leading cause of irreversible blindness worldwide, with the 
global burden expected to rise to 111.8 million people by the year 2040.47 
Unfortunately, no definitive treatment for glaucoma exists. Currently, the only 
therapy known to slow the disease's progression is the lowering of intra-ocular 
pressure (IOP). Traditionally, first line therapy has been pharmacotherapy 48, 
despite a significant number of well documented challenges. Non-compliance,49–
52 difficulty with administration,53,54 local irritation of the ocular surface,55,56 as well 
as significant systemic side effects57,58 are well known barriers to successful 
medical management. Surgical interventions are often undertaken once medical 
management and laser-based procedures have failed to control IOP or are no 
longer tolerated by the patient (Figure 1-3). 
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Figure 1-3: Schematic representing the treatment algorithm for patients with 
glaucoma. Patients usually initiate therapy medically then progress to more 
invasive methods of IOP management. The final treatment modality is IOP 
lowering surgical intervention. Surgical failure rates with use of the current 
wound modulatory adjuvants are indicated. Failure rates were obtained from 
previous work65,66 and extrapolated to estimate the percentage of overall 
patients who require 1st, 2nd and 3rd revision surgeries. 
 11 
 
Glaucoma filtration surgery (GFS) functions to lower IOP through the creation of 
a fistula from the anterior chamber of the eye into a surgically created drainage 
space. A microshunt can be implanted at the time of surgery to guard the fistula 
that connects to the anterior chamber to the drainage structure. If draining into 
the subconjunctival space, these drainage structures are termed filtration blebs 
(Figure 1-4A). If draining into the potential space between the ciliary body and the 
sclera, they are termed superciliary lakes (Figure 1-4B).59 It is through these 
novel anatomic structures that aqueous exits the anterior chamber, collects within 
the surgically created space, diffuses through the interstitum and is removed from 
the eye by the venous and lymphatic systems – thus lowering a patient’s IOP.60,61 
Therefore, successful GFS depends on the incomplete healing of the surgical 
wound and establishment of a controlled, chronic wound within the 
subconjunctival or superciliary tissues.3,4 Maintaining the functional anatomy of 
this novel outflow pathway long-term in the face of acute surgical/chronic 
inflammation and aqueous humor driven wound healing, is a major challenge. 
 
  
A) 
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1.3 Consequences of Dysregulated Wound Healing in 
Glaucoma Surgery 
The overwhelming majority of surgical failures occur through an inflammatory and 
fibroproliferative mechanism within the tissues surrounding the surgically created 
drainage pathway. Clinically, the events preceding failure are characterized as an 
overactive wound healing response.2,62 The consequence is a fibroproliferative or 
contracture mediated obstruction of the surgical outflow tract - thereby hindering 
aqueous humor egress and ultimately the magnitude of IOP reduction achieved 
(Figure 1-5).3,4,63 Glaucoma surgeries performed without current anti-fibrotic 
adjuvants fail at a lifetime rate approaching 100%.64 Using current anti-fibrotic 
adjuvants, the lifetime surgical failure rate is approximately 30-50%.65,66 
 
B) 
Figure 1-4: A) sub-conjunctival filtration bleb, modified from Gardiner et al. 
(2010).59 B) superciliary lake, shown with the Cypass aqueous shunt implanted 
within, modified from Alcon Canada, Inc. 
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Failure occurs most frequently within the first three weeks of surgery,67 at 
approximately the same time as the inflammatory and proliferative phases of 
post-operative wound healing are occurring.3,46 As the outflow tract loses patency 
and the patient’s IOP begins to return to pre-surgical levels, the failure of GFS is 
managed in a progressive manner. In the early postoperative period, digital 
massage, scleral flap suture lysis and releasable suture removal can be 
attempted in order to restore the flow of aqueous. Glaucoma medical therapy is 
often subsequently reinstituted to control the patient's rising IOP. Tragically, these 
drugs themselves can lead to increased inflammation at the surgical site and can 
accelerate the deterioration of aqueous outflow capacity.68–72 In up to 30% of 
glaucoma surgery patients, outflow capacity decreases sufficiently to require a 
second glaucoma surgery.66,73 Subsequent surgeries experience even lower 
A B
Figure 1-5: A) Depicts an anterior segment optical coherence tomography (AS-
OCT) image of a functional subconjunctival filtering bleb superimposed over an 
anatomic diagram of the eye. B) Depicts a failing filtering bleb. Note the 
increased reflectance surrounding the fistula connecting the bleb to the anterior 
chamber, the tissue contracture, and the hypertrophic walls of the bleb. The 
patient subsequently underwent revision surgery. Modified from Shin 2010.63 
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odds of success - approximately 50% of these patients do not achieve their target 
IOP post-operatively.64 Repeated attempts at surgery, until success is achieved, 
is the only remaining treatment path for these patients – who face blindness as 
an alternative. 
The complication rate associated with scarring after glaucoma surgery is not only 
a burden to patients and surgeons but is also a major healthcare economic issue. 
The 5-year total treatment cost for glaucoma patients is similar when treated 
medically or surgically.74 The ongoing cost of drugs is the major contributor to 
medical management costs, which average approximately $6500 USD over a 5-
year span. The surgical treatment of the same patient would cost an average of 
approximately $6300 USD. Even with their increased expense and undesirable 
side effect profile, medications are the first line therapy due to the high risk of 
glaucoma surgery failure. This risk profile also contributes significantly to the 
overall cost – with management of post-surgical complications accounting for 
60% of surgical treatment costs.74 Reducing the risk of complications and/or 
revision surgery will dramatically reduce the total cost of glaucoma surgical 
interventions, and the reduced risks / costs could shift surgical interventions 
earlier in the treatment paradigm and would free patients from the burden of daily 
glaucoma medications – which would be a significant improvement to their quality 
of life.75–77 
To avoid function altering scarring, normal wound healing requires the ordered 
and appropriate interaction of a complex molecular signaling network – those 
involved in inflammation, its resolution, and proliferation / remodeling. In the 
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subconjunctival tissues of glaucoma surgery patients there exist several 
mechanisms known to disrupt these signaling networks. Pre-existing chronic 
inflammation due to a patient's topical glaucoma medication burden,55,78 co-
morbid inflammatory ocular disease,79 and/or the novel interaction of aqueous 
humor growth factors (AHGFs) with the mesenchymal subconjunctival tissues of 
the filtration bleb80–83 all contribute to the post-surgical scarring and fibrosis 
observed (Figure 1-6). In particular, the contribution of AHGFs to the failure of 
aqueous filtration cannot be ignored, as they include several iconic molecular 
instigators of inflammation and fibroproliferation.84 TGFβ1, TGFβ2, VEGF, CCN2, 
IL-1β, TNFα and INFɣ are all found in the aqueous humor, and further, are 
present at increased levels in glaucoma patients undergoing revision surgery 
compared to patients undergoing their first glaucoma surgery83–88 – providing a 
physiological explanation for the increased likelihood of failure in these patients. 
Therefore, wound healing phenomena within the filtration structure's 
microenvironment must be modulated pharmacologically for both the short- and 
long-term success of GFS. 
 16 
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1.4 Current Glaucoma Surgery Adjuvants 
Currently, the strategy used to mitigate post-operative scarring involves the intra-
operative application of cytotoxic agents, with or without the application of peri-
operative anti-inflammatory drops (Figure 1-7).89–91 Cytotoxic agents, such as 
mitomycin C (MMC) or 5-fluorouracil are dosed empirically, exerting their efficacy 
through the destruction of local fibroblasts through DNA intercalation. Thus, 
mitigating the post-operative wound healing response elicited by this cellular 
population within the surgical site. Due to the cytotoxic mechanism of action, 
these drugs are associated with complications that can be sight threatening.92  
  
Figure 1-7: Mitomycin C intercalates DNA and is lethal to all cell types. It 
functions as an anti-scarring adjuvant through its cytotoxic actions on the local 
subconjunctival population. Corticosteroids prevent transcription of PLA2, 
which is responsible for generating the substrates for all lipid mediators of 
inflammation and resolution. By dampening the inflammatory response, fewer 
inflammatory cells are recruited to the subconjunctiva to activate local 
fibroblasts. Further, corticosteroids have been shown to directly act on 
fibroblasts to inhibit their activity. 
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To illustrate the variability inherent to the application of MMC, one need only 
reference the therapeutic range that is currently employed: 0.2-0.4mg/ml is 
applied by an MMC soaked sponge intra-operatively on the freshly dissected 
conjunctiva, for one to four minutes (at surgeon discretion), at the start of 
surgery.93 Over application can lead to tissue necrosis, wound leak, corneal 
decompensation, hypotony and blindness. Under application results in loss of 
efficacy and causes the post-operative failure rate to approach 100%.64,94  
Anti-inflammatory drops such as corticosteroids are used post-operatively to 
attenuate the inflammatory phase of wound healing and provide the clinician with 
a titratable means to control subconjunctival wound healing phenomena over a 
patient’s post-operative course. Corticosteroids function indirectly to mitigate 
inflammation-induced activation of sub-conjunctival fibroblasts by preventing local 
inflammatory cell activation and recruitment.65 They have also been shown to 
exert direct anti-proliferative actions on sub-conjunctival fibroblasts, as well as 
illicit a decrease in fibroblast wound healing associated biomarkers.95 However, 
steroids are associated with adverse events such as cataract development, 
elevation of intraocular pressure (IOP) and increased infection risk.96–103 These 
risks add to the unpredictability of post-operative wound healing and fuel the 
search for viable alternatives to control post-operative inflammation and scarring. 
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1.5 Therapeutic modulation of ocular wound healing: 
current evidence and contemporary strategies 
The suppression of vascular endothelial growth factor (VEGF) signaling has 
become recently widespread in ophthalmology.104 Anti-VEGF therapy as an anti-
fibrotic intervention appears to be theoretically based on suppressing the 
proliferative stage of wound healing by blocking angiogenesis as well as 
interfering with VEGF’s direct stimulatory effects on fibroblasts.105 Several studies 
have evaluated subconjunctival injections of anti-VEGF antibodies as anti-fibrotic 
GFS adjuvants.105–107 The results from initial animal investigations demonstrated 
improvements in wound healing related outcomes after GFS and several small 
human trials were subsequently undertaken. A recently published meta-analysis 
of their results indicated uncertainty as to the efficacy of anti-VEGF adjuvant 
therapy in human GFS patients.108 Anti-VEGF therapy’s lack of anti-scarring 
efficacy fits well with findings from its official use in another ocular disease. Up to 
45% of patients receiving regular anti-VEGF injections for age related macular 
degeneration will experience progressive sub-retinal scarring, despite 
therapy.109,110 
Transforming growth factor beta (TGFβ) isoforms are perhaps the most canonical 
proteins associated with wound healing and fibroproliferation.111–114 Histological 
studies demonstrate significant elevation of TGFβ isoforms within the 
subconjunctival tissues of GFS patients post-operatively.115–117 In animal studies, 
exogenous TGFβ was found to significantly increase IOP and the failure rate of 
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GFS.118 Significant resources were spent at the in vitro, animal119,120 and human 
level121,122 to assess an anti-TGFβ2 antibody known as CAT-152 as an adjuvant 
for GFS. Ultimately the intervention failed, possibly attributable to the specificity 
of the CAT-152 antibody for the TGFβ2 isoform only. Interventions that 
incorporate a more broad blockade of both TGFβ1 and TGFβ2 isoforms, or the 
receptor that is shared by both are underway and have seen some success at 
pre-clinical stages.118,123 
Matrix metalloproteinases and their inhibitors (TIMPs) are fundamental to the 
remodeling stage of wound healing. In the subconjunctiva of GFS patients, the 
expression of these molecules is upregulated and contributes to scar 
formation.124 In vitro, an MMP inhibitor (ilomastat), was found to inhibit fibroblast-
mediated collagen contraction by subconjunctival fibroblasts.125 In two different 
animal models, ilomastat improved wound healing after GFS, prolonging bleb 
survival, lowering intraocular pressure, and reducing the amount of 
subconjunctival scar tissue to a similar degree as MMC.126,127 This appears to be 
one of the more promising avenues of wound modulation research at the current 
time. 
Ultimately, scarring and fibrosis appear to have redundant mechanisms for 
bypassing interventions targeting a single pathway. Suppressive strategies 
against specific mediators that each individually contribute to a redundant 
process is destined for difficulty. Such difficulties may be quite familiar to the 
cancer biologist, as similarly aberrant tumor growth is often fueled by multiple 
redundant intracellular signaling pathways.128 This can potentially explain the 
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current position of nonspecific anti-proliferative drugs and steroidal anti-
inflammatory agents as the gold standard adjuvants for GFS. More specific 
inhibitors of TGFβ signaling, MMP inhibitors, Nuclear Factor-κB signaling 
inhibitors, anti-oxidants and PPARγ agonists have all demonstrated promising 
wound modulating effects at various levels of in vitro, pre-clinical and clinical 
development.4 However, none of these applications have thus far been translated 
into clinical use. Ideally, a point of biochemical intervention that has multiple 
downstream effects and counters many of the redundant pathways involved in 
scarring and fibrosis could be identified. 
1.6 Thesis Overview 
Sixty years ago, Dr. Epstein first noticed what he then coined: the fibrosing 
response to aqueous.84 Since then dramatic improvements have been made in 
surgical success due to wound modulatory adjuvants. The aim of this thesis was 
to investigates potential means of improving these success rates still further – 
ideally in a more efficacious and/or safer manner than current standards of care. 
The investigative work begins in Chapter 2, with a retrospective cohort study. 
This was the first study of its kind that was adequately powered to assess 
perioperative risk factors associated with revision GFS – as opposed to the 
failure of IOP control. We uncovered the surprising finding that perioperative 
NSAID exposure was more strongly associated with surgical success than 
corticosteroids, the current standard of care. These results inspired the 
subsequent in vitro investigation in Chapter 3, which found that these drugs exert 
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differential effects on wound healing phenomena elicited by subconjunctival 
fibroblasts. Data from both chapters were used to write a successfully funded 
grant for a randomized controlled trial assessing the merits of NSAID use in 
human GFS patients (Appendix I). The results of this trial are outside the scope 
of this thesis, however it felt appropriate to “close the translational loop” and do 
what was within reach to bring the knowledge attained from our retrospective and 
in vitro work – back to human patients. 
While investigating the differences between NSAIDs and corticosteroids, a 
second manner in which to end this thesis presented itself. Based on the theory 
that corticosteroids more completely inhibit the endogenous generation of RMs 
than is observed with NSAIDs, I hypothesized that modulating the production of 
lipid mediators to resolve inflammation – rather than suppress it – is a better 
means to mitigate post-operative scarring. Such an approach works more 
synergistically with the body’s endogenous systems of inflammation and 
resolution, rather than against them. The following two chapters, Chapter 4 and 
Chapter 5, pursue this hypothesis and present data to support a novel 
therapeutic strategy which resolves inflammation and mitigates wound healing 
phenomena in vitro. 
Taken together, these investigations highlight novel strategies to combat scarring 
after glaucoma surgery. The first suggests a shift in the utilization of currently 
used ophthalmic drugs to improve patient outcomes. The subsequent strategies 
would require more lengthy safety approvals – however they demonstrate even 
more promising efficacy in vitro. The knowledge gained from this thesis is 
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uniquely powerful, as it should enjoy rapid translation to human patients at the 
same time as significantly advancing our understanding of how LMs and more 
specifically RMs influence wound healing phenomena.  
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Chapter 2  
2 Risk Factors for Secondary Surgical Intervention after 
Primary Glaucoma Filtration Surgery1 
 
 
This study focused on surveying the current contributors to GFS failure risk in 
order to establish theoretical grounds for future in vitro work. We examined 
patient factors, surgical history, the type of GFS performed, and most importantly, 
we investigated various perioperative drugs exposures for association with GFS 
failure rates. This study consisted of the following: 
1. Defining a cohort of filtration surgery patients within Ontario medical 
records spanning 2003 to 2015 
2. Following this cohort for 1-year after GFS  
3. Investigating candidate baseline / exposure variables for association with 
subsequent revisions procedures 
  
                                                 
1
 Parts of this chapter have been published: Armstrong, J.J., Welk, B.K., Reid, J.N.S., Kansal, V., Hutnik, 
C.M.L. Secondary surgical intervention after primary glaucoma filtration surgery: an Ontario population-
based study. Canadian Journal of Ophthalmology. 2018; 54(2): 212-222; DOI: 
https://doi.org/10.1016/j.jcjo.2018. 04.004. 
 25 
 
2.1 Introduction 
The failure of glaucoma filtration surgery is managed in a progressive manner. In 
the early postoperative period, digital massage, scleral flap suture lysis and 
releasable suture removal can be attempted. Medical therapy is often 
subsequently reinstituted, which itself may lead to increased inflammation at the 
surgical site and accelerate deterioration of aqueous outflow capacity.68,70–72,129 
Some of these patients are refractory to medical treatment and a secondary 
surgical intervention is the only remaining option.  
Several studies have reported rates of secondary surgical intervention after 
primary glaucoma filtration surgery.130–133 The Tube Versus Trabeculectomy 
study reported secondary surgical intervention rates of 2.8%130 within the first 
post-operative year and Cankaya et al. reported a rate of 8.5% in a randomized 
controlled trial of 59 patients.131 However, the event rate within these samples 
was too low to investigate factors associated with increased rates of secondary 
surgical intervention. Young age,134–138 previous intraocular surgery,135,139 chronic 
exposure to topical medications,68,70–72,129 and comorbid systemic disease136,138 
have all been previously associated with failure of intra-ocular pressure (IOP) 
control. However, few studies have reported on patient factors associated with 
increased rates of secondary surgical intervention. 
Such information is critical to establishing individualized patient treatment plans, 
as patients at high risk for secondary surgical intervention may be advised to 
delay surgery, to elect for any of the available less invasive surgical options 
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and/or to have modified perioperative adjunctive medical therapies. Further, even 
recent reports of secondary surgical intervention rates may not be representative 
of current surgical practices. The rapidly evolving surgical techniques, adjuvants 
and their place in the glaucoma treatment paradigm may confer different risks 
than those of past practice.140,141 To address these issues, our objective was to 
determine the rate of secondary surgical intervention after primary filtration 
surgery within the first post-operative year in a large cohort of older adults 
undergoing their first glaucoma filtration surgery. We hypothesized that patient 
and surgical factors, pre-existing filtration surgery in the contralateral eye, as well 
as exposure to peri-operative and anti-glaucoma medications, would influence 
the rate of secondary surgical intervention. 
2.2 Methods 
2.2.1 Design and Setting 
A retrospective, population-based cohort study was conducted using 
administrative healthcare data from the province of Ontario, Canada. As 
Canada’s most populated province, Ontario provides all citizens with universal 
health coverage through a single health care system. In addition, individuals ≥65 
years of age have universal access to a variety of prescription medications 
approved for coverage by the Ontario Drug Benefit (ODB) Plan, including most 
glaucoma medications. Individual patient level data were linked using a unique 
encoded identifier and were analyzed at the Institute for Clinical Evaluative 
Sciences (ICES) Western. Research approval is through the institutional review 
 27 
 
board at Sunnybrook Health Sciences Centre, Toronto, Ontario. Study reporting 
followed the STROBE/RECORD checklist (Appendix A).142 
2.2.2 Data Sources 
Several linked population based administrative databases were used: the Ontario 
Health Insurance Plan (OHIP) which captures greater than 95% of Ontario 
physician services;143 the Registered Persons Database (RPDB), which captures 
demographic data and vital statistics on all Ontario residents (approximately 13 
million people);144 the Canadian Institute for Health Information (CIHI) Discharge 
Abstract Database (DAD) and the Same Day Surgery (SDS) database, which 
contains detailed diagnostic and procedural information regarding all surgical 
procedures and hospital admissions;144 and finally the Ontario Drug Benefits plan 
database (ODB), which accurately captures all prescriptions filled by outpatients 
aged 65 and older.145 To identify certain systemic co-morbidities, we used 
databases derived from validated case definitions: the Hypertension Database 
(HYPER)146, the Ontario Diabetes Database (ODD)147 and the Ontario Asthma 
(ASTHMA) dataset.148 All these databases provide accurate data on the 
covariables assessed in this study and have been validated for many outcomes, 
exposures and diagnoses.144,145,149 All codes used for assembly of cohorts, as 
well as detection of covariables, are referenced in Appendix B-G. 
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2.2.3 Cohort Assembly 
Ontario residents who underwent a primary glaucoma filtration surgical procedure 
(no previous incisional glaucoma surgery in both eyes) between April 1, 2003 to 
March 30, 2015 were identified. A patient’s OHIP and CIHI records both had to 
indicate a glaucoma filtration procedure to be included in this study. Excluding 
any patients with conflicting records was a measure to reduce misclassification of 
patients and to increase the specificity of the cohort. Full coding definitions for 
cohort creation are referenced in Appendix B. In short: first, a physician billing 
record for a filtration procedure was required (from the OHIP database): a single 
OHIP surgeon fee code for “glaucoma filtration procedure” (E132) or “glaucoma 
filtering procedure and cataract extraction (same eye)” (E214). Second, a 
Canadian Classification of Health Interventions (CCI) procedural code for 
“drainage, anterior chamber (of eye)” (1.CJ.52.LA, 1CJ.52.LA-SJ, 1.CJ.52.LA-QB 
and 1.CJ.52.WJ) was required for the same patient in their CIHI-SDS/DAD 
hospital records. The date of this procedure was considered the index date. 
Notable patient exclusions were: patients less than 66 years of age and greater 
than 105 years of age were excluded (n=7,072) to retain all patients with an ODB 
database record (and therefore medication utilization information) at least 1 year 
in length; patients with evidence of prior filtration surgery were excluded 
(n=1,332) to remove revision filtration surgeries that may have been miss-coded 
as primary surgeries; and finally, patients who had evidence of a revision surgery 
on the same day as the primary filtration surgery were excluded (n=767) as these 
were not considered to be secondary surgical interventions. If patients underwent 
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additional filtration surgery on the contralateral eye during the 365-day follow-up 
(n=2,510), they were then censored from the original cohort and placed into a 
separate cohort. This sequential-bilateral surgery cohort was used to investigate 
the possibility of a different outcome rate among these patients. 
2.2.4 Outcome Measures 
Patients were followed for one year after the date of primary filtration surgery, to 
a maximum of March 30, 2016. Primary outcomes were (a) revision filtering 
surgery and (b) any procedure (excluding needling) encompassing conjunctival 
manipulation. Revision filtering surgery was defined by OHIP fee codes E983 or 
E984 and CCI intervention codes 1.CJ.52.LA, 1CJ.52.LA-SJ, 1.CJ.52.LA-QB, 
and 1.CJ.52.WJ (accompanied by the intervention attribute “revision”). OHIP fee 
codes E212 and E213 and/or CCI intervention codes 1.CS.80, 1.CS.72, 1.CS.84, 
1.CS.87, 1.CS.52, 1.CC.80, 1.CD.80 revision, 1.CJ.54, 1.CJ.55, 1.CJ.80, 
1.CJ.87, and 1.CD.52.LA revision were used to identify patients who required 
conjunctival manipulation (excluding needling). See Appendix B for complete 
definition. 
2.2.5 Covariables 
Patient factors assessed included demographic data (age, sex, year of cohort 
entry and income quintile), medical comorbidity, ophthalmic surgical history, eye 
drop medication history and eye drop preservative exposure. Income quintile was 
derived from Statistics Canada census data on the average income per single-
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person equivalent by postal code.150 Medical comorbidity was estimated using a 
Charlson-Deyo comorbidity index with a 5-year review of CIHI-DAD.151,152 
Patients with no CIHI-DAD record were assigned a score of 0 indicating 
negligible comorbidity. Previously validated algorithms were used to identify 
patients with diabetes,147 hypertension,146 asthma,148 stroke153 and sleep 
apnea154 (Appendix C). Ophthalmic surgical history was determined through 
OHIP billing codes (Appendix D) with a 5-year lookback window. Surgical 
procedures were grouped for analysis based on anatomic location. Data for eye 
drop prescription history were assessed for the 1-year period prior to the index 
event for glaucoma medications (Appendix E) and 30 days prior to index event 
for all other ocular medications (Appendix F) captured by the ODB. 
Exposure to the ophthalmic eye drop preservative, benzalkonium chloride (BAK), 
was assessed for a subset of the main cohort based on data availability. Drugs 
with known BAK concentrations are listed in Appendix G. All patients who 
received a prescription for an ophthalmic drug with unknown BAK concentration 
were excluded from this portion of the analysis. One-year cumulative BAK 
exposure was calculated as the volume of medication dispensed to a patient 
during the 365 days before the index event, multiplied by each medication’s BAK 
content (%vol). The resulting number was used to evaluate a patient’s 365-day 
cumulative exposure to BAK. 
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2.2.6 Statistical Analysis 
Data are reported as means and standard deviations unless otherwise indicated. 
Groups of patients <6 in size are not released in accordance with ICES privacy 
regulations, so some results are reported as “approximately or ≤5”. Significant 
differences between groups were initially assessed using Students t-test and chi 
square. Significant variables were then included in a multivariable cox 
proportional hazards model. Patients were censored on the date of a primary 
outcome, death, enucleation, evisceration or exenteration. A second primary 
filtration procedure on the contralateral eye within the observation window 
qualified patients for inclusion in the sequential-bilateral surgery cohort for 
separate analysis.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) 
were determined using a Cox proportional hazards model. The proportional 
hazards assumption was evaluated using Schoenfeld residuals, interaction with 
time covariables, and log-negative-log plots of the survival function.155 If the 
proportional hazards assumption was violated, then the hazard ratio at day zero 
of the 365 day follow up was reported along with their graphed functions. 
Immortality bias was assessed through a competing risk analysis with death 
during the follow-up period. Both the cause-specific and subdistribution hazard 
ratios were calculated, where the cause-specific model is the equivalent of our 
cox regression model (censoring death) for the primary outcome. All analyses 
were performed with SAS enterprise guide version 7.12 (SAS Institute, Cary, 
North Carolina) for UNIX. 
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2.3 Results 
A total of 10,097 primary filtration surgeries were identified after 12,787 patients 
were excluded based on predetermined criteria (Figure 2-1). The yearly volume 
of primary filtration surgeries varied over the study period, ranging from a 
minimum of 1,335 cases for the year April 1, 2013 to March 31, 2014 to a 
maximum of 1,916 between April 1, 2005 to March 31, 2006. The complete 
cohort consisted of 4,287 male (42.46%) and 5,810 female (57.54%) patients 
with a mean ± standard deviation (SD) age of 76.69 ± 6.45 years, and 
interquartile range (IQR) 72-81 years (Table 2-1). 
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Figure 2-1: Flow Diagram of Cohort Selection 
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Table 2-1: Cohort Characteristics (Overall, Secondary Surgical Intervention and 
No Outcome)* 
 
Variable 
Entire Cohort 
n=10,097 
Secondary Intervention 
n=349 
No Outcome 
N=9,748 
P 
Value 
Demographics     
 Age      
  Mean ± SD 76.7 ± 6.5 75.8 ± 6.3 76.7 ± 6.5  
  66-74 4,014 (39.8%) 162 (46.4%) 3,852 (39.5%) 0.01 
  75-90+ 6,083 (60.2%) 187 (53.6) 5,932 (60.4%)  
 Sex      
  Male (%) 4,287 (42.5%) 147 (42.1%) 4,140 (42.5%) 0.90 
  Female (%) 5,810 (57.5%) 202 (57.9%) 5,608 (57.5%)  
 Year of Primary Filtration Surgery     
  2003-2004 1,604 (15.8%) 49 (14.0%) 1,555 (16.0%) 0.09 
  2005-2006 1,916 (19.0%) 74 (21.2%) 1,842 (18.9%)  
  2007-2008 1,666 (16.5%) 76 (21.8%) 1,590 (16.3%)  
  2009-2010 1,661 (16.5%) 52 (14.9%) 1,609 (16.5%)  
  2011-2012 1,732 (17.2%) 49 (14.0%) 1,683 (17.3%)  
  2013-2014 1,335 (13.2%) 42 (12.0%) 1,293 (13.3%)  
  2015 183 (1.8%) 7 (2.0%) 176 (1.8%)  
 Income 
Quintile 
     
  1st (lowest) 2,024 (20.1%) 58 (16.6%) 1,966 (20.1%) 0.23 
  2nd 2,061 (20.4%) 84 (24.1%) 1,977 (20.3%)  
  3rd 2,012 (19.9%) 69 (19.8%) 1,943 (19.9%)  
  4th  1,879 (18.6%) 71 (20.3%) 1,808 (18.6%)  
  5th (highest) 2,121 (21.0%) 67 (19.2%) 2,054 (21.1%)  
 Charlson Comorbidity Index    
  Mean ± SD 0.6 ± 1.2 0.7 ± 1.1 0.6 ± 1.2 0.35 
  0 6,915 (68.5%) 221 (63.3%) 6,694 (68.6%) 0.18 
  1 1,372 (13.6%) 57 (16.3%) 1,315 (13.5%)  
  2 1,147 (11.4%) 47 (13.5%) 1,100 (11.3%)  
  ≥3 663 (6.5%) 24 (6.9%) 639 (6.6%)  
 Diabetes      
  Yes 2,024 (20.0%) 66 (18.9%) 1,958 (20.1%) 0.60 
  No 8,073 (80.0%) 283 (21.1%) 7,790 (79.9%)  
 Hypertension      
  Yes 6,041 (59.8%) 211 (60.5%) 5,830 (59.8%) 0.81 
  No 4,056 (40.2%) 138 (39.5%) 3,918 (40.2%)  
 Asthma      
  Yes 1,136 (11.3%) 44 (12.6%) 1,092 (11.2%) 0.41 
  No 8,961 (88.70%) 305 (87.4%) 8,656 (88.8%)  
 Stroke      
  Yes 704 (7.0%) 31 (8.9%) 673 (6.9%) 0.15 
  No 9,393 (93.0%) 318 (91.1%) 9,075 (93.1%)  
 Sleep Apnea      
  Yes 394 (3.9%) 11 (3.1%) 383 (3.9%) 0.46 
  No 9,703 (96.1%) 338 (96.9%) 9,365 (96.1%)  
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range. 
†Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of data cells containing 
fewer than 5 patients. 
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Table 2-1. continued. Cohort Characteristics (Overall, Secondary Surgical Intervention and No 
Outcome)*  
 
Variable 
Entire Cohort 
n=10,097 
Secondary Intervention 
n=349 
No Outcome 
N=9,748 
P 
Value 
Prior Ocular Surgery (5 years)     
  Yes 7,265 (72.0%) 255 (73.1%) 7,010 (72.0%) 0.64 
  No 2,832 (28.0%) 94 (26.9%) 2,738 (28.0%)  
Prior Conjunctival Disrupting Surgery (5 
years) 
    
  Yes 532 (5.3%) 20 (5.7%) 502 (5.3%) 0.69 
  No 9,565 (94.7%) 329 (94.3%) 9,236 (94.7%)  
 Scleral      
  †Yes ≤60 (0.6%) ≤5 (1.4%) 56 (0.6%) 0.48 
  †No ≥10,037 
(99.4%) 
≥344 (98.6%) 9,629 (99.4%)  
 Vitreous      
  Yes 444 (4.4%) 17 (4.4%) 427 (4.4%) 0.66 
  No 9,653 (95.6%) 332 (95.6%) 9,321 (95.6%)  
 Retinal     
  †Yes ≤100 (1.0%) ≤5 (1.4%) 97 (1.0%) 0.43 
  †No ≥9,097 
(99.0%) 
≥344 (98.6%) 9,651 (99.0%)  
 Conjunctival     
   †Yes 25 (0.3%) ≤5 (1.4%) 20 (0.2%) 0.74 
   †No 10,072 
(99.7%) 
≥344 (98.6%) 9,728 (99.8%)  
Prior Conjunctival Sparing Surgery (5 years)     
  Yes 7,230 (71.6%) 254 (72.8%) 6,976 (71.6%) 0.62 
  No 2,867 (28.4%) 95 (27.2%) 2,772 (28.4%)  
 Lens     
  Yes 2,609 (25.8%) 100 (28.6%) 2,509 (25.7%) 0.22 
  No 7,488 (74.2%) 249 (71.4%) 7,239 
(74.23%) 
 
 Corneal Transplant     
  Yes 109 (1.1%) 8 (2.3%) 101 (1.0%) 0.026 
  No 9,988 (98.9%) 341 (97.7%) 9,648 (99.0%)  
 Iris     
  Yes 1,517 (15.0%) 35 (10.0%) 1,482 (15.2%) 0.008 
  No 8,580 (85.0%) 314 (90.0%) 8,266 (84.8%)  
 Laser angle surgery     
  Yes 4,916 (48.7%) 182 (52.2%) 4,734 (48.6%) 0.19 
  No 5,181 (51.3%) 167 (47.8%) 5,014 (51.4%)  
 Photocoagulation     
  Yes 620 (6.1%) 13 (3.7%) 607 (6.2%) 0.06 
  No 9,477 (95.9%) 336 (94.3%) 9,141 (93.8%)  
 Interventions for retinal disease     
  Yes 497 (4.9%) 13 (3.7%) 484 (5.0%) 0.29 
  No 9,600 (95.1%) 336 (96.2%) 9,264 (95.0%)  
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range; CAI, 
carbonic anhydrase inhibitor; PGA, prostaglandin analogue; NSAIDs, non-steroidal anti-inflammatory drugs. 
†Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of data cells 
containing fewer than 5 patients. 
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Table 2-1 continued. Cohort Characteristics (Overall, Secondary Surgical Intervention and No 
Outcome)*  
Variable Entire Cohort 
n=10,097 
Secondary 
Intervention 
n=349 
No Outcome 
N=9,748 P Value 
Glaucoma Medication History (1 year)     
 Beta-Blocker      
  Yes 5,379 (53.3%) 191 (54.7%) 5,188 (53.2%) 0.58 
  No 4,718 (46.7%) 158 (43.3%) 4,560 (46.8%)  
  Mean ±SD days of meds/patient 136.3 ± 105.9 130.3 ± 108.2 136.5 ± 105.8 0.42 
 CAI      
  Yes 2,253 (22.3%) 74 (21.3%) 2,179 (22.4%) 0.61 
  No 7,844 (77.7%) 275 (78.7%) 7,569 (77.6%)  
  Mean ±SD days of meds/patient 124.4 ±111.6 117.0 ± 124.0 123.7 ± 111.1 0.65 
 Miotics      
  Yes 2,595 (25.7%) 90 (25.8%) 2,505 (25.7%) 0.97 
  No 7,502 (74.3%) 259 (74.2%) 7,243 (74.3%)  
  Mean days ±SD of meds/patient 108.0 ± 108.0 105.1 ± 113.4 108.1 ± 107.8 0.80 
 PGA      
  Yes 8,987 (89.0%) 323 (92.5%) 8,664 (88.9%) 0.03 
  No 1,110 (11.0%) 26 (7.5%) 1,084 (11.1%)  
  Mean ±SD days of medspatient 159.4 ± 107.3 153.4 ± 102.6 159.7 ± 107.5 0.32 
 Sympathomimetics      
  Yes 4,538 (44.9%) 172 (49.3%) 4,366 (44.8%) 0.14 
  No 5,559 (55.1%) 177 (50.7%) 5,382 (55.2%)  
  Mean ±SD days of meds/patient 131.6 ± 108.1 124.4 ± 93.0 131.8 ± 108.6 0.47 
Other Ophthalmic Medications (30 days)     
 Antibiotic      
  Yes 851 (8.4%) 46 (13.2%) 805 (8.3%) 0.001 
  No 9,246 (91.6%) 303 (86.8%) 8,943 (91.7%)  
 Corticosteroid      
  Yes 4,519 (44.8%) 169 (48.4%) 4,350 (44.6%) 0.16 
  No 5,578 (55.2%) 180 (51.6%) 5,398 (55.4%)  
 Aminoglycoside      
  Yes 135 (1.3%) 15 (4.3%) 120 (1.2%) <0.001 
  No 9,962 (98.7%) 334 (95.7%) 9,628 (98.8%)  
 Mydriatic      
  Yes 426 (4.2%) 33 (9.5%) 393 (4.0%) <0.001 
  No 9,671 (95.8%) 316 (90.5%) 9,355 (96.0%)  
 NSAIDs      
  Yes 1,767 (17.5%) 36 (10.3%) 1,731 (17.8%) <0.001 
  No 8,330 (82.5%) 313 (89.7%) 8,017 (82.2%)  
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range; CAI, 
carbonic anhydrase inhibitor; PGA, prostaglandin analogue; NSAIDs, non-steroidal anti-inflammatory drugs. 
†Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of data cells 
containing fewer than 5 patients. 
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2.3.1 Type of Primary Filtration Surgery 
Most primary filtration surgeries were solo procedures, with 6,947 (68.80%) 
patients undergoing primary filtration surgery without cataract extraction or 
implantation of an indwelling drainage device (IDD). Filtration surgery was 
combined with cataract extraction in 1,745 (17.28%) patients. An IDD was used 
in approximately 860 (8.52%) cases, and approximately 550 (5.45%) cases were 
combined with cataract extraction and implantation of an IDD. Of these initial 
cases, 2,510 (25.8%) patients had their second eye undergo primary filtration 
surgery. Of these, 1,698 (67.7%) were solo-procedures, 504 (20.1%) were 
combined with cataract extraction, 134 (5.3%) involved an IDD and 174 (6.9%) 
cases were combined with an IDD and cataract extraction. 
2.3.2 Primary Outcome 
Secondary surgical intervention was required for 349 patients (3.46%) a median 
[IQR] of 21 [9-56] days following the initial filtering surgery. Life table is presented 
in Table 2-2. For these patients, 303 conjunctival manipulations occurred, 
approximately 5 implanted drainage devices were removed, and 72 revision 
filtration surgeries were performed (certain patients experienced multiple 
secondary surgical interventions within the 1-year follow-up period).  
Table 2-2: Life table of primary outcome – unilateral cohort†  
Time 
Interval 
(days) 
Filtering 
procedure 
(solo-procedure) 
Filtering Surgery 
+IDD 
Filtering Surgery 
+cataract 
extraction 
Filtering Surgery 
+IDD, +cataract 
extraction 
N 
Outcome N at Risk 
N 
Outcome N at Risk 
N 
Outcome N at Risk 
N 
Outcome N at Risk 
0-182 270 5427 20 740 27 1354 ≤5 427 
182-365 20 4825 ≤5 681 ≤5 1184 ≤5 357 
†Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of 
data cells containing fewer than 5 patients 
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Solo-filtration surgeries had a secondary surgical intervention rate of 1.43 per 
10,000 person-days. With use of an IDD, the rate was approximately 1.00 per 
10,000 person-days (vs solo-filtration, p = 0.0.035). When filtering surgery was 
combined with cataract extraction the rate was 0.61 per 10,000 person-days (vs 
solo-filtration, p < 0.0001). Patients who underwent filtration surgery combined 
with cataract extraction and an IDD experienced secondary surgical interventions 
at a rate of less than 0.25 per 10,000 patient-days (vs solo-filtration, p < 0.0001). 
In the sequential-bilateral filtration surgery cohort, following patients for an 
additional 365-days after primary intervention on the contralateral eye revealed 
higher rates of secondary surgical intervention compared to patients with 
monocular surgical interventions (Table 2-3). Secondary surgical intervention 
was undertaken in 367 patients and had an incidence rate of 7.44 per 10,000 
person-days, which was higher than that of the unilateral surgery cohort – 1.08 
per 10,000 person-days (p < 0.0001). Considering a per-eye event rate equal to 
half that observed in the sequential-bilateral cohort, there was additional risk 
observed on a per-eye basis. 
  
 39 
 
 T
a
b
le
 2
-3
: 
P
ri
m
a
ry
 o
u
tc
o
m
e
 b
y
 c
o
h
o
rt
 a
n
d
 t
y
p
e
 o
f 
fi
lt
ra
ti
o
n
 s
u
rg
e
ry
 
T
y
p
e
 o
f 
P
ri
m
a
ry
 S
u
rg
e
ry
 
 
U
n
ila
te
ra
l 
C
o
h
o
rt
 
 
 
S
e
q
u
e
n
ti
a
l 
B
ila
te
ra
l 
C
o
h
o
rt
 
 
 
N
 
O
u
tc
o
m
e
s
 
P
e
rs
o
n
-d
a
y
s
 
o
f 
fo
llo
w
 u
p
 
E
v
e
n
t 
R
a
te
* 
N
 
O
u
tc
o
m
e
s
 
P
e
rs
o
n
-d
a
y
s
 
o
f 
fo
llo
w
 u
p
 
E
v
e
n
t 
R
a
te
* 
P
 v
a
lu
e
**
 
F
ilt
e
ri
n
g
 p
ro
c
e
d
u
re
 
(s
o
lo
-p
ro
c
e
d
u
re
) 
2
9
0
 
2
,0
2
8
,4
2
5
 
1
.4
3
 
2
3
5
 
3
3
8
,0
5
0
 
6
.9
5
 
<
0
.0
0
0
1
 
F
ilt
e
ri
n
g
 s
u
rg
e
ry
  
+
 I
D
D
†
 
≤
3
0
 
2
7
2
,9
7
1
 
≤
1
.0
0
 
5
9
 
1
7
,0
9
9
 
3
4
.5
0
 
<
0
.0
0
0
1
 
F
ilt
e
ri
n
g
 s
u
rg
e
ry
  
+
 c
a
ta
ra
c
t 
e
x
tr
a
c
ti
o
n
 
3
1
 
5
0
7
,5
9
4
 
0
.6
1
 
6
0
 
1
0
2
,8
1
2
 
5
.8
4
 
<
0
.0
0
0
1
 
F
ilt
e
ri
n
g
 s
u
rg
e
ry
  
+
 c
a
ta
ra
c
t 
e
x
tr
a
c
ti
o
n
  
+
 I
D
D
†
 
≤
5
 
1
5
7
,3
9
7
 
≤
0
.2
5
 
1
3
 
3
5
,4
3
2
 
3
.6
7
 
<
0
.0
0
0
1
 
T
o
ta
l 
3
2
1
 
2
,9
6
6
,3
8
7
 
1
.0
8
 
3
6
7
 
4
9
3
,3
9
3
 
7
.4
4
 
<
0
.0
0
0
1
 
*E
v
e
n
t 
ra
te
 p
e
r 
1
0
,0
0
0
 p
e
rs
o
n
-d
a
y
s
; 
**
p
-v
a
lu
e
 w
a
s
 d
e
ri
v
e
d
 u
s
in
g
 a
 p
o
is
o
n
 r
e
g
re
s
s
io
n
 m
o
d
e
l 
to
 c
o
m
p
a
re
 i
n
c
id
e
n
c
e
 r
a
te
s
 i
n
 
u
n
ila
te
ra
l 
a
n
d
 b
ila
te
ra
l 
g
ro
u
p
s
; 
†
In
s
ti
tu
te
 f
o
r 
C
lin
ic
a
l 
a
n
d
 E
v
a
lu
a
ti
v
e
 S
c
ie
n
c
e
s
 (
IC
E
S
) 
p
ri
v
a
c
y
 p
o
lic
ie
s
 p
re
c
lu
d
e
 t
h
e
 p
u
b
lic
a
ti
o
n
 
o
f 
d
a
ta
 c
e
lls
 c
o
n
ta
in
in
g
 f
e
w
e
r 
th
a
n
 5
 p
a
ti
e
n
ts
 
 
 
 
  
 40 
 
2.3.3 Covariables 
Patient demographics, medical comorbidities, ophthalmic surgical history, eye 
drop medication history and eye drop preservative exposure are listed in Table 
2-1 for the complete cohort (n=10,097), those who required secondary surgical 
intervention (n=349) and those who did not experience an outcome within the first 
post-operative year (n=9,748). 
Analysis of patients who underwent unilateral glaucoma filtration surgery 
revealed that the initial type of filtration surgery was significantly associated with 
secondary surgical intervention rates. Surgeries that included an IDD, 
phacoemulsification, or both had decreased risks compared with solo-filtration 
procedures without an IDD (HR=0.58 (p=0.013), HR=0.33 (p < 0.0001), and 
HR=0.087 (p = 0.0001) respectively).  In the adjusted multivariable Cox 
proportional hazards model, several factors in a patient’s medical history were 
identified to have a significant association with secondary surgical intervention 
(Table 2-4). Patients under the age of 75 were more likely to undergo secondary 
surgical intervention than those over 75 years of age (HR=1.35, p=0.005). A 
history of iris surgery (laser iridotomy, iridectomy) was associated with a reduced 
risk of secondary surgical intervention (HR=0.70, p=0.04). Filling a prescription 
for aminoglycoside or mydriatic eye drops within the month preceding filtration 
surgery was associated with an increased risk of secondary surgical intervention, 
HR=3.19 (p < 0.0001) and HR=2.32 (p=0.0002) respectively. Hazard functions 
that violated the proportionality assumption, and are variable over time, are 
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displayed in Figure 2-2 for the unilateral cohort and in Figure 2-3 for the bi-lateral 
cohort. 
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Figure 2-3: Hazard functions that violated the proportionality assumption are 
displayed for the cohort of patients who had filtration surgery on both eyes. Iris: 
prior surgeries on the iris. 
Figure 2-2 Hazard functions that violated the proportionality assumption are 
displayed for the unilateral cohort. The proportional hazards assumption was 
evaluated using Schoenfeld residuals, interaction with time covariables, and 
log-negative-log plots of the survival function. 
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Within the sequential-bilateral surgery cohort, several covariables were 
significantly associated with the rate of secondary surgical intervention (Table 
2-4). Surgeries involving an IDD were associated with higher rates of secondary 
surgical intervention (HR=3.24, p < 0.0001), whereas surgeries combined with 
cataract extraction and an IDD were associated with reduced risk (HR=0.56, p < 
0.04). History of corneal transplant was associated with more frequent secondary 
surgical interventions (HR=4.77, p < 0.0001) as was perioperative exposure to 
mydriatic eye drops (HR=4.03, p < 0.0001). Hazard functions that violated the 
proportionality assumption (surgeries of the iris and aminoglycoside exposure), 
and vary over time, are displayed in Figure 2-3. 
The competing risk of death was considered not to have confounded results 
(Appendix H), as the cause-specific hazard ratios were almost equivalent to the 
subdistribution hazard ratios - due to the rarity of the competing risk event 
(death).156 Further, the cumulative incidence function for death was not significant 
(p=0.7403) across all types of initial filtration surgeries. Therefore, immortality 
bias was not a major concern. 
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2.3.4 Benzalkonium Chloride Exposure Cohort 
Patient demographics, medical comorbidities, ophthalmic surgical history, eye 
drop medication history and eye drop preservative exposure are listed in Table 
2-5 for the BAK-cohort (n=8,676), those who required secondary surgical 
intervention (n=315) and those who did not experience an outcome within the first 
post-operative year (n=8,361). Within the BAK-cohort, only 48 patients were 
exclusively prescribed preservative free medications within the 365 days prior to 
surgery. None of these patients experienced an outcome within the follow-up 
period. However, cumulative 365-day BAK exposure preceding surgery was not 
associated with secondary surgical intervention, with patients requiring secondary 
surgical intervention exposed to a median [IQR] of 11 [5-23] vs. 12 [5-26] ml for 
patients who did not (p = 0.64). 
Significant covariables were unchanged from the main study cohort except in the 
case of PGA exposure. The group of patients who filled a prescription for PGA 
eye drops within the year preceding primary filtration surgery experienced a post-
operative secondary intervention rate of 3.6% (p=0.031). However, in the BAK 
cohort a history of PGA had no significant association with secondary intervention 
(p=0.066). 
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Table 2-5: BAK Exposure Cohort Characteristics (Overall, Secondary Surgical 
Intervention and No Outcome)* 
Variable 
BAK Cohort 
n=8,676 
Secondary 
Intervention 
n=315 
No Outcome 
N=8,361 
P 
value 
Demographics     
 Age      
  Mean ± SD 76.7 ± 6.5 75.7 ± 6.4 76.7 ± 6.4  
  66-69.9 3,474 (40%) 150 (47.6%) 3,324 (39.8%) 0.005 
  70-74.9 5,202 (60%) 165 (52.4%) 5,037 (60.2%)  
 Sex      
  Male (%) 3,654 (42.1%) 130 (41.3%) 3,524 (42.2%) 0.76 
  Female (%) 5,022 (57.9%) 185 (58.7%) 4,837 (57.8%)  
 Year of Primary Filtration Surgery 
  2003-2004 1,202 (13.9%) 44 (14.0%) 1,158 (13.9%) 0.14 
  2005-2006 1,712 (19.7%) 67 (21.3%) 1,645 (19.7%)  
  2007-2008 1,601 (18.5%) 75 (23.8%) 1,526 (18.3%)  
  2009-2010 1,613 (18.6%) 52 (16.5%) 1,561 (18.7%)  
  2011-2012 1,449 (16.7%) 41 (13.0%) 1,408 (16.8%)  
  2013-2014 957 (11.0%) 30 (9.5%) 927 (11.1%)  
  2015 142 (1.6%) 6 (1.9%) 136 (1.6%)  
 Income Quintile      
  1st (lowest) 1,740 (20.1%) 50 (15.8%) 1,690 (20.2%) 0.20 
  2nd 1,772 (20.4%) 76 (24.1%) 1,696 (20.3%)  
  3rd 1,719 (19.8%) 67 (21.3%) 1,652 (19.8%)  
  4th  1,612 (18.6%) 61 (19.4%) 1,551 (18.6%)  
  5th (highest) 1,833 (21.1%) 61 (19.4%) 1,772 (21.1%)  
 Charlson Comorbidity Index     
  Mean ± SD 0.64 ± 1.2 0.68 ± 1.1 0.64 ± 1.2 0.58 
  0 5,940 (68.5%) 205 (65.0%) 5,735 (68.6%) 0.54 
  1 1,166 (13.4%) 46 (14.6%) 1,120 (13.4%)  
  2 1,001 (11.5%) 43 (13.7%) 958 (11.5%)  
  ≥3 569 (6.6%) 21 (6.7%) 548 (6.5%)  
 Diabetes      
  Yes 1,713 (19.7%) 57 (18.1%) 1,656 (19.8%) 0.45 
  No 6,963 (80.3%) 258 (81.9%) 6,705 (80.2%)  
 Hypertension      
  Yes 5,173 (59.6%) 190 (60.3%) 4,983 (59.6%) 0.79 
  No 3,503 (40.4%) 125 (39.7%) 3,378 (40.4%)  
 Asthma      
  Yes 1,023 (11.8%) 43 (13.6%) 980 (11.7%) 0.29 
  No 7,653 (88.2%) 272 (86.4%) 7,381 (88.3%)  
 Stroke      
  Yes 612 (7.1%) 28 (8.9%) 584 (7.0%) 0.19 
  No 8,064 (92.9%) 287 (91.1%) 7,777 (93.0%)  
 Sleep Apnea      
  Yes 344 (3.9%) 8 (2.5%) 336 (4.0%) 0.19 
  No 8,332 (96.0%) 307 (97.5%) 8,025 (96.0%)  
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range. 
†Institute for Clinical and Evaluative Sciences (ICES) privacy policies preclude the publication of data cells 
containing fewer than 5 patients. 
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Table 2-5 continued. BAK Exposure Cohort Characteristics (Overall, Secondary Surgical Intervention and 
No Outcome)*  
Variable 
BAK Cohort 
n=8,676 
Secondary 
Intervention 
n=315 
No Outcome 
N=8,361 
P 
value 
Prior Ocular Surgery (5 years)     
  Yes 6,247 (72.0%) 226 (71.7%) 6,021 (72.0%) 0.92 
  No 2,429 (28.0%) 89 (28.3%) 2,340 (28.0%)  
Prior Conjunctival Disrupting Surgery (5 years)    
  Yes 458 (5.3%) 19 (6.0%) 439 (5.3%) 0.54 
  No 8,218 (94.7%) 296 (94.0%) 7,922 (94.7%)  
 Scleral      
  †Yes ≤55 ≤5  51 (0.6%) 0.51 
  †No ≥8,621 ≥310 8,310 (99.4%)  
 Vitreous       
  Yes 383 (4.4%) 16 (5.1%) 367 (4.4%) 0.56 
  No 8,293 (95.6%)  299 (94.9%) 7,994 (95.6%)  
 Retinal      
  †Yes ≤85 ≤5  82 (1.0%) 0.54 
  †No ≥8,591 ≥310 8,279 (99.0%)  
 Conjunctival      
   †Yes ≤20 ≤5  18 (0.2%) 0.70 
   †No ≥8,656 ≥310 8,343 (99.8%)  
Prior Conjunctival Sparing Surgery (5 years)    
  Yes 6,216 (71.7%) 225 (71.4%) 5,991 (71.7%) 0.93 
  No 2,460 (28.3%) 90 (28.6%) 2,370 (28.3%)  
 Lens      
  Yes 2,234 (25.8%) 87 (27.6%) 2,147 (25.7%) 0.44 
  No 6,442 (74.2%)  228 (72.4%) 6,214 (74.3%)  
 Corneal Transplant     
  Yes 97 (1.1%) 8 (2.5%) 89 (1.1%) 0.02 
  No 8,579 (98.9%)  307 (97.5%) 8,272 (98.9%)  
 Iris      
  Yes 1,318 (15.2%) 32 (10.2%) 1,286 (15.4%) 0.01 
  No 7,358 (84.8%) 283 (89.8%) 7,075 (84.6%)  
 Laser angle surgery     
  Yes 4,232 (48.8%) 163 (51.7%) 4,069 (48.7%) 0.28 
  No 4,444 (51.2%)  152 (48.3%) 4,292 (51.3%)  
 Photocoagulati
on 
     
  Yes 544 (6.3%) 12 (3.8%) 532 (6.4%) 0.07 
  No 8,132 (93.7%) 303 (96.2%) 7,829 (93.6%)  
 Interventions for retinal disease     
  Yes 427 (4.9%) 12 (3.8%) 415 (5.0%) 0.35 
  No 8,249 (95.1%) 303 (96.2%) 7,946 (95.0%)  
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile range; 
CAI, carbonic anhydrase inhibitor; PGA, prostaglandin analogue; NSAIDs, non-steroidal anti-inflammatory 
drugs; BAK, benzalkonium chloride. 
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Table 2-5 continued. BAK Exposure Cohort Characteristics (Overall, Secondary Surgical Intervention and 
No Outcome)*  
Variable 
BAK Cohort 
n=8,676 
Secondary 
Intervention 
n=315 
No Outcome 
N=8,361 
P 
value 
Glaucoma Medication History (1 year)    
 Antibiotic      
  Yes 716 (8.23%) 38 (12.1%) 678 (8.1%) 0.01 
  No 7,960 (91.7%) 277 (87.9%) 7,683 (91.9%)  
 Corticosteroid      
  Yes 3,951 (45.5%) 154 (48.9%) 3,797 (45.4%) 0.22 
  No 4,725 (54.5%)  161 (51.1%) 4,564 (54.6%)  
 Aminoglycoside     
  Yes 119 (1.4%) 13 (4.1%) 106 (1.3%) < 
0.001 
  No 8,557 (98.6%) 302 (95.9%) 8,255 (98.7%)  
 Mydriatic      
  Yes 373 (4.3%) 30 (9.5%) 343 (4.1%) < 
0.001 
  No 8,303 (95.7%) 285 (90.5%) 8,018 (95.9%)  
 NSAIDs      
  Yes 1,580 (18.2%) 34 (10.8%) 1,546 (18.5%) < 
0.001 
  No 7,096 (81.8%) 281 (89.2%) 6,815 (81.5%)  
BAK Exposure (1 year)     
 BAK Containing Drops     
  Yes 8,628 (99.5%) 315 (100%) 8,628 (99.5%) 0.02 
  No 48 (0.5%) 0 (0%) 48 (0.5%)  
 Cumulative BAK Load (percentile)   
  1st to 25th 2,166 (25.0%) 73 (23.2%) 2,093 (25.0%) 0.64 
  25th to 50th 1,956 (22.5%) 82 (26.0%) 1,874 (22.4%)  
  50th to 75th  2,042 (23.5%) 82 (26.0%) 1,960 (23.5%)  
  75th to 100th percentile 2,512 (29.0%) 78 (24.8%) 2,434 (29.1%)  
*Data are expressed as n (%) unless otherwise indicated. SD, standard deviation; IQR, inter-quartile 
range; CAI, carbonic anhydrase inhibitor; PGA, prostaglandin analogue; NSAIDs, non-steroidal anti-
inflammatory drugs; BAK, benzalkonium chloride. 
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2.4 Discussion 
This large administrative data study of more than 10,000 cases identified the 
proportion of filtration surgery patients that required secondary surgical 
intervention (3.46%) within the first year of follow-up. The rate was higher in solo 
filtration surgery procedures, while combined surgeries (IDD, cataract extraction) 
experienced reduced rates of secondary surgical intervention. The rate was 
unchanged between men and women, however older age was associated with 
reduced rates of secondary surgical intervention. No significant differences were 
found in annual rates from 2003 to 2015 and there was no significant association 
with socioeconomic status. Overall, prior intraocular surgery had minimal 
association with secondary surgical intervention rates. Age, prior iris surgery as 
well as perioperative aminoglycoside and mydriatic exposure were all significant 
variables in the adjusted Cox multivariate model.  
The sequential-bilateral cohort revealed a dramatically increased rate of 
secondary surgical intervention, with several different covariables reaching 
significance compared to the unilateral cohort. The difference in risk may be due 
to patients requiring sequential-bilateral interventions having potentially more 
advanced glaucoma, and thus placing them at a higher risk for secondary 
surgical intervention – even when considered on a risk-per-eye basis.157  
Analysis of the BAK-cohort revealed no major changes in significant covariables 
from the main cohort. BAK exposure had no effect on secondary surgical 
intervention rates. No trends were evident for any other types of prior ocular 
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surgeries, any of the systemic comorbidities assessed nor any specific class of 
glaucoma medication, save the prostaglandin analogs which showed a significant 
association with secondary surgical intervention in the main study cohort. 
This population-based analysis is strengthened by the nature of the public 
healthcare system in Ontario. Filtration surgery, as well as all risk factors 
discussed, are insured services and for physicians to be reimbursed for their 
services, billing records must be submitted to the Ontario Health Insurance Plan.  
Patient records are continuous, even patients who have switched surgeons within 
Ontario are captured in our datasets. The number of patients that are lost to 
follow-up is low. Only if a patient elects to pay out-of-pocket for surgery in another 
province, country or in an independent surgical center would that data not be 
captured. Finally, our analysis of BAK exposure as a risk factor used a 
cumulative 365-day pre-operative exposure, which allowed us to model it as a 
continuous outcome in order to maximize the chance of detecting a significant 
effect on surgical failure rates. However, all data relies on the accuracy and 
reliability of billing practices and medical records coding. Further, ODB only 
tracks prescriptions filled by patients greater than 65 years old, necessitating 
exclusion of patients under the age of 66 from our study in order to obtain and 
analyze prescription information. Medically treated surgical failures were not 
captured – only secondary surgical interventions. Further limitations to these data 
should also be clarified. We could not determine the type of IDD used in 
combined procedures, patient compliance with prescribed medications, receipt of 
 50 
 
non-recorded “sample” medications from physician offices, nor could we 
determine any risk factors for IOP-related outcomes. 
It is our understanding that, to date, this study is the largest to investigate rates of 
secondary surgical intervention within the first post-operative year after glaucoma 
filtration surgery, considering single eye interventions and sequential-bilateral 
interventions separately. The observed rate within the present study’s unilateral 
cohort was similar to those reported previously, ranging from three to eight 
percent in unilateral interventions.131–133,158 Patients who underwent glaucoma 
surgery in the contralateral eye were more than twice as likely to experience 
secondary surgical interventions. In agreement with these data, Mietz and 
colleagues previously analyzed 138 trabeculectomy patients and found that 
additional interventions occurred more frequently in the second operated eye.159 
The work of Iwasaki et. al. further supports this trend and found that as the length 
of time between surgery on the first and second eye increased, so did the risk of 
failure.160 
Our unilateral cohort showed significantly lower secondary surgical intervention 
rates when undergoing glaucoma procedures combined with cataract extraction 
and/or an IDD. This is in contrast to previous reports indicating similar safety 
profiles for both filtration surgery and phaco-filtration surgery – however it is 
possible that our larger sample size has allowed us to statistically elucidate this 
association.161,162 As Ontario does not yet have device-specific billing codes, data 
specifying the type of IDD used were unavailable. Thus, the IDD procedures 
captured within this study were likely a heterogeneous mixture of various shunt 
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devices including both traditional as well as micro-invasive glaucoma surgical 
(MIGS) drainage devices. As MIGS devices are currently only indicated to be 
combined with phacoemulsification, patients receiving these devices would likely 
have been captured in the cataract extraction w/IDD group. However, this 
precludes attributing any of the observed risk factors to a specific type of IDD. 
Data must be interpreted within the context of its collection however, and the 
included heterogeneity may allow for greater generalizability (i.e. what risk is 
attributable to a foreign body in the eye vs no foreign body and is it associated 
with secondary surgical intervention). 
In patients who underwent glaucoma surgery on their second eye, combined 
procedures were also protective, except for the insertion of an IDD alone. In this 
IDD group, a much larger hazard was associated with IDDs than observed in the 
unilateral cohort. The severity of glaucomatous disease is likely greater in 
patients who had surgeries in both eyes, and perhaps these IDDs were more 
likely to be traditional valves and shunts, not novel MIGS devices, which could 
help to explain these findings. Nevertheless, care should be taken when inserting 
any foreign body into an eye with advanced disease. 
In the present study, older age significantly reduced the risk of secondary surgical 
intervention in the unilateral cohort, however the significance was lost if patients 
underwent sequential-bilateral procedures. Several studies have reported similar 
results for unilateral procedures.134,139 Previous intraocular surgery has been well 
explored as a risk factor for filtration failure.135,139 Broadway and Chang found 
that fibroblast and inflammatory cell numbers were increased in the conjunctiva of 
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patients with a positive history, providing a potential physiological mechanism for 
this risk factor.71,72 However, data from the present study did not reveal any clear 
association between prior ocular surgery and rates of secondary surgical 
intervention in the real world setting. No significant effect was observed for prior 
conjunctival disrupting surgeries, nor for conjunctival sparing surgeries, save for 
the protective effect of prior surgery on the iris in the unilateral cohort and prior 
corneal transplant in the sequential-bilateral cohort. 
Exposure to topical antiglaucoma medications and the preservative 
benzalkonium chloride (BAK) has been associated with filtration surgery 
failure.68,70–72 Our results indicated that neither the type, save prostaglandin 
analogs in the main study cohort, nor the amount of dispensed glaucoma 
medications in the year prior to surgery were significantly associated with 
secondary surgical intervention rates. Neither was cumulative BAK exposure. 
Previous work has supported BAK exposure as a risk factor for early failure, 
however it was also noted that significance was independent of the number of 
BAK containing medications used.68 As just 48 patients received prescriptions for 
exclusively preservative free medications during the study period, and none of 
these patients experienced an outcome during the observation period, it remains 
possible that the complete absence of BAK exposure does result in a lower risk 
of secondary surgical intervention. 
Prescriptions for certain topical ocular medications, filled within 30 days prior to 
surgery, were significantly associated with secondary surgical intervention. 
Topical NSAIDs were significantly associated with decreased rates of secondary 
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surgical intervention in the unilateral cohort, however significance was lost within 
the sequential-bilateral cohort. Interestingly, dexamethasone was not significantly 
associated with intervention rates. Previously, a randomized clinical trial 
investigated the potential benefit of pre-operative topical NSAIDs versus steroids 
before trabeculectomy.163 Patients were treated with either drug 4 times daily for 
one month before surgery and both drugs were found to significantly reduce 
needling rates. These findings were also mirrored in a study involving Ahmed 
glaucoma valves.90 These results together with the incidence of steroid induced 
IOP spikes97 suggests NSAIDs could serve as preferential adjunctive medications 
to these surgical procedures. 
Filling a prescription for an antibiotic, particularly aminoglycosides, prior to 
surgery was significantly associated with increased rates of secondary surgical 
intervention in the unilateral cohort. One in nine patients who received a 
prescription for aminoglycosides required a secondary surgical intervention. 
Aminoglycosides are known to be toxic in the ear and induce toxicity and scarring 
in the kidney.164,165 However, it is unclear if this study’s observation is a 
consequence of these drugs acting on subconjunctival tissues, or if the infection 
being treated by these medications may be negatively influencing surgical 
outcomes. An ocular infection and accompanied inflammation just prior to 
filtration surgery could prime the conjunctiva for aggressive post-surgical wound 
healing. These novel findings warrant further investigation. 
In conclusion, the rate of secondary surgical intervention within the first post-
operative year after glaucoma filtering surgery is modest within the Ontario. 
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Approximately a quarter of patients undergo sequential-bilateral filtering 
procedures, and secondary surgical interventions occur much more frequently in 
this group of patients – even on a per-eye basis. Surgeries involving IDDs, 
combination with cataract surgery or both experienced fewer surgical 
interventions in the unilateral cohort. Surgeries combined with both an IDD and 
cataract extraction experienced fewer secondary surgical interventions in the 
sequential-bilateral cohort, whereas surgeries with IDDs alone experienced 
secondary surgical interventions more frequently. Further investigation into the 
effects of mydriatic and aminoglycoside use prior to surgery should be 
undertaken and caution may be warranted when patients undergoing filtration 
surgery have experienced recent ocular infections. Exploring the potential 
physiological basis of these associations could provide novel strategies for 
perioperative wound management and guide the development of novel adjuvant 
therapies. Results indicate that filtration surgery combined with an IDD and/or 
phacoemulsification may be considered as a primary surgical intervention and 
patients undergoing sequential-bilateral glaucoma procedures should be 
counseled regarding their greatly increased surgical risk. 
 55 
 
Chapter 3  
3 Differential Effects of Dexamethasone and 
Indomethacin: Implications for Glaucoma Surgery2 
 
 
In the previous chapter, surprisingly, perioperative exposure to NSAIDs was 
found to be more strongly associated with GFS success than were 
corticosteroids. Due to the favorable actions of RMs during wound healing, and 
the fact that much of RM biosynthesis is abrogated by corticosteroids, we 
hypothesized that NSAIDs may better impede post-operative wound healing 
phenomena than corticosteroids. 
In Chapter 3, these ideas are pursued in vitro, comparing the effects of steroidal 
vs. NSAID anti-inflammatory exposure on wound healing phenomena elicited by 
primary human subconjunctival fibroblasts within a 3D collagen culture system. 
  
                                                 
2
 Parts of this chapter have been published: Armstrong, J.J., Denstedt, J., Trelford, C.B, Li, E. and Hutnik, 
C.M.L. Differential effects of dexamethasone and indomethacin on Tenon’s capsule fibroblasts: 
Implications for glaucoma surgery. Experimental Eye Research. 2019; 182(Jan); 65 
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3.1 Introduction 
Antimetabolites dramatically increase glaucoma surgery success rates, but may 
be associated with complications relating to overly suppressed wound healing - 
i.e. bleb leakage, blebitis, endophthalmitis, bleb dysesthesia and hypotony.92,166–
168 The use of perioperative, anti-inflammatory drops permits further control of 
inflammation-driven wound healing. This strategy allows the surgeon to adjust 
dosing in response to changing bleb morphology over the post-operative period, 
a clinical luxury absent when relying on anti-metabolites as the sole modality of 
wound modulation.169 To this end, topical corticosteroids are commonly used to 
control inflammation-driven scarring after glaucoma surgery. Typically, they are 
applied peri-operatively, oftentimes for several weeks or months, before89and/or 
after glaucoma surgery.170 This includes trabeculectomy, phacotrabeculectomy, 
traditional tube shunt or many of the novel micro-invasive glaucoma surgical 
(MIGS) devices or procedures. However, steroids are associated with adverse 
events such as cataract development, elevation of intraocular pressure (IOP) and 
increased infection risk.96–103 These risks add to the unpredictability of post-
operative wound healing and fuel the search for viable alternatives to control 
post-operative inflammation and scarring. 
Several clinical trials have compared topical NSAIDs to topical steroids for 
perioperative inflammation control in glaucoma surgery.90,163,171–173 A recent 
meta-analysis synthesized the results from several of these smaller trials and 
determined that there was insufficient evidence to recommend one modality of 
inflammation control over the other.174 When examining the individual studies of 
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this meta-analysis, most found topical NSAIDs to produce equivalent IOP 
outcomes to those attained with topical steroids.90,163,171,175 However, in a 
randomized trial of 42 patients undergoing phacotrabeculectomy, patients 
receiving post-operative topical diclofenac required fewer glaucoma medications 
after surgery compared to those who received topical dexamethasone.175 Another 
study reported a reduced likelihood of post-operative needling in a group of 54 
patients who received topical ketorolac before trabeculectomy compared to the 
group receiving topical fluorometholone.163 A further two studies found that 
NSAIDs after Ahmed glaucoma valve insertion lead to significantly lower post-
operative IOPs – albeit with a higher risk of wound healing related complications 
such as hypotony and bleb leak.90,173 Finally, we recently conducted a 
retrospective analysis of over 10,000 glaucoma surgery patients and found that 
those who filled a prescription during the perioperative period for a topical NSAID 
experienced significantly fewer interventions directed against bleb failure 
compared to patients who did not fill a prescription for an NSAID during the 
perioperative period.67 These clinical findings suggest that NSAIDs and steroids 
exert differential effects on the quality of subconjunctival wound healing when 
given perioperatively for glaucoma surgery. 
Steroids mitigate inflammation by blocking transcription of phospholipase A2176 
as well as the activity of the cyclooxygenase and lipoxygenase biosynthetic 
pathways, thereby suppressing the production of lipid-derived autacoids – of 
which the prostaglandins and leukotrienes are the best known pro-inflammatory 
examples.177,178 However, steroids also abrogate synthesis of another two 
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classes of lipid-derived autacoids, synthesized by the lipoxygenase enzymes and 
known to actively resolve inflammation – the specialized pro-resolving mediators 
(SPMs) and the lipoxins.17,179 Non-steroidal anti-inflammatory drugs (NSAIDs) are 
known to be very effective at reducing blood aqueous barrier breakdown and 
preventing cystoid macular edema after cataract surgery through inhibition of 
cyclooxygenase activity and prostaglandin synthesis.180–182 NSAIDs do not 
significantly inhibit phospholipase A2 nor the lipoxygenase enzymes. This subtle 
difference in mechanism of action leaves the endogenous enzymatic machinery 
responsible for the resolution of inflammation intact – not the case after treatment 
with steroidal anti-inflammatories.  
NSAIDs are not in routine use after glaucoma filtration surgery, and their effects 
relative to steroidal treatment on critical post-operative wound healing 
phenomena remain unknown. Two dimensional monolayer cell culture 
experiments have demonstrated the anti-proliferative effects of several NSAIDs 
to be greater than that of dexamethasone on human ocular fibroblasts.95,183 
However, their effects on ocular fibroblast mediated wound healing activity have 
yet to be compared within a three-dimensional collagen-based culture system. 
Such a culture system permits the study of cell-matrix interactions, allowing one 
to study the influence of experimental treatment on cell-mediated tissue 
contraction and matrix remodeling 
Successful filtering surgery depends on the incomplete healing of the surgical 
wound and establishment of a controlled, chronic wound within the 
subconjunctival or superciliary tissues.3,4 Therefore, it is of critical importance to 
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understand how these two classes of anti-inflammatory drug effect the wound 
healing functions of human ocular fibroblasts. The purpose of this study was to 
compare cell-mediated collagen contraction and remodeling in a three-
dimensional collagen-based culture system.184 Through macroscopic and 
microscopic assessment of the human Tenon’s capsule fibroblast (HTCF) 
containing collagen matrices that are produced by this culture method, we 
present in vitro evidence, complementary to previous in vivo trials, for the 
differential effects of these drugs on collagen remodeling and wound healing 
phenomena orchestrated by HTCFs. 
3.2 Methods 
3.2.1 Isolation and Culture of HTCFs 
This study followed the tenants of the Declaration of Helsinki and was approved 
by the office of Human Research Ethics at Western University (REB# 106783). 
Primary HTCF cell lines were derived from 2-4 mm3 surgically resected segments 
of Tenon’s capsule. After the acquisition of informed consent, tissue specimens 
were obtained from male and female glaucoma patients undergoing primary 
trabeculectomy at St. Josephs Hospital, London, Canada. The samples were 
obtained by ophthalmic surgeons who removed segments of Tenon’s capsule 
and placed them into primary culture growth media containing Dulbecco modified 
Eagle's minimal essential medium (DMEM), 10% Fetal Bovine Serum (FBS), 1% 
penicillin/streptomycin, and 1% amphotericin, all from Sigma-Aldrich (Oakville, 
Canada). After, specimens were placed in fibronectin (Sigma-Aldrich) coated 6-
well culture plates, submerged in primary culture media, and subcultured upon 
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confluency for further use. Cell cultures were used for experimentation prior to 
passage five. Table 3-1 provides a summary of donor characteristics for the 
HTCF cell lines used in experiments. 
 
Table 3-1: Donor information for the HTCF cell lines used for experimentation 
Patient no. Age/Sex 
Glaucoma 
Diagnosis 
Surgery 
Glaucoma Medications  
(at time of surgery) 
1 69/F POAG Trabeculectomy Bimatoprost, Dorzolamide-timolol 
2 78/M POAG Trabeculectomy Brimonidine, Timolol, Latanoprost 
3 71/M POAG Seton Implant Bimatoprost, Brimonidine, Timolol 
4* 63/F OAG Seton Implant Timolol, Metoprolol 
5 83/F POAG Trabeculectomy Bimatoprost, Dorzolamide-timolol 
6#,* 71/F OAG Trabeculectomy Timolol, Metoprolol 
#Histologically processed sections not available for fluorescent microscopy experiments; *Protein 
samples not available for western blot experiments; POAG: primary open-angle glaucoma; OAG: 
open-angle glaucoma 
 
 
3.2.2 Collagen Contraction Assay 
The delayed release fibroblast populated collagen lattice model,185 based on the 
model first proposed by Bell,186 was used to assess the effects of 
dexamethasone and indomethacin on HTCF-mediated gel contraction. In brief, 
HTCFs were mixed within an extracellular matrix (ECM) mixture containing 400μl 
of type I collagen (1.8mg/ml; A1048301, Gibco), 80μl of neutralizing solution 
(equal parts Waymouth media (Sigma-Aldrich) and 0.275M NaOH) and 20μl of 
HTCF conditioned media (concentrated to 25x to obtain a 1x final concentration 
within the 500μl construct volume) in order to achieve a final cell density of 2.5 x 
105 cells/mL within the solution. Cell free collagen lattices were prepared 
identically, albeit without the inclusion of HTCFs, as negative control. The 
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solution was pipetted gently to ensure homogenous distribution of HTCFs while 
avoiding the production of air bubbles, then 500μl were pipetted into each well of 
a 24-well tray. Collagen constructs were allowed to polymerize at 37°C and 5% 
CO2 for 45 minutes before adding low serum culture media containing DMEM, 
2% Fetal Bovine Serum (FBS), 1% penicillin/streptomycin. 
 After incubation at 37°C and 5% CO2 for 72 hours, a sterile spatula was used to 
detach each collagen construct from the edges of the culture well. Plates were 
then immediately scanned on a flatbed laser scanner (Scanjet 8200, Hewlett-
Packard) to record baseline area, and then every subsequent 24 hours for 7 
days. The surface area of each collagen construct was measured using 
ImageJ187 and standardized against the baseline surface area measurement to 
express changes in area as a percentage of original surface area. 
3.2.3 Anti-Inflammatory Treatment Protocol 
After release of collagen constructs from the sides of the culture wells, the media 
was removed twice daily (8am and 6pm) and replaced with one of the three 
treatment solutions for a duration of 15 minutes. This schedule continued from 
time of release for 7 days at which point the experiment concluded. 
Dexamethasone (0.05, 0.1 and 0.2% wt/vol in DMEM with dimethyl sulfoxide 
(DMSO: D2650, Sigma-Aldrich) 0.1% vol/vol), indomethacin (0.03, 0.1, 0.3 
%wt/vol in DMEM with 0.1% DMSO) and vehicle control (DMSO, 0.1% vol/vol in 
DMEM) treatment solutions were prepared from purified form (dexamethasone: 
D4902; indomethacin: I8280, both from Sigma-Aldrich) and then filtered through a 
0.2μm syringe filter to remove particulate and sterilize. These concentrations of 
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indomethacin and dexamethasone were chosen to mirror doses in clinically 
available topical preparations. After each treatment, the collagen constructs were 
washed with PBS to remove any remaining treatment solution and fresh culture 
media was added. 
3.2.4 Extracellular Matrix Remodeling 
Upon conclusion of the contraction assay, collagen constructs were fixed in 4% 
paraformaldehyde overnight. After fixation, collagen constructs were dehydrated 
in ethanol, embedded in paraffin blocks, sectioned (5µM) and mounted on glass 
microscope slides using standard methods. For histological staining, sections 
were deparaffinized and hydrated using standard protocols. Sections were 
stained with picrosirius red. Briefly, a solution of 0.1% Sirius red (Sigma-Aldrich) 
in saturated picric acid (Sigma-Aldrich) was applied for 60 min, followed by 2 x 
0.5% acetic acid washes. Collagen birefringence, used to determine collagen 
fibrillar hue,188 was assessed by circularly polarized light microscopy of picrosirius 
red stained sections. Images were taken with an Abrio quantitative birefringence 
imaging system (Hinds Instruments, Portland, Oregon) mounted on an Olympus 
BX-51 microscope (Olympus Corporation, Tokyo, Japan). Specifically, a constant 
light intensity, a fixed 45° angle to the polarizing filter, a 20x objective and the 
same analyzer were used to facilitate consistent comparisons between each 
sample. 
When viewed under polarized light, the color of the collagen fibers stained with 
picrosirius red depends upon fiber thickness and spatial orientation; with the color 
changing from blue to yellow to orange to red as fiber thickness and density 
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increase.189,190 This method has been used previously in rabbit experimental 
filtration surgery to examine subconjunctival fibrosis, and red/orange staining was 
associated with bleb dysfunction.105 Using ImageJ, this property was leveraged to 
determine the relative proportions of different color fibers within the collagen 
constructs. This quantitative method has been previously described by Rich and 
Whittaker.191 In short, relative color content of the images is obtained by 
separating the digital images into their hue, saturation and value components. 
The hue component contains information on the color of each pixel within the 
image. Every pixel can have one of 256 possible colors. To identify the red, 
orange, yellow and blue pixels within a given image the following hue definitions 
were used within ImageJ: red 2-9 and 230-256, orange 10-38, yellow 39-51 and 
blue 52-128.191 The number of pixels within each hue range is calculated and 
expressed as a proportion of the total number of pixels within each field 
representing collagen. Ten random frames using a 20x objective were taken per 
tissue section, with three tissue sections imaged per patient cell line and 
treatment group. 
3.2.5 Fluorescent Microscopy 
Collagen constructs were cast with equal cell density, therefore there should be 
equal variance in cell density between treatment groups after the 7-day 
incubation period. This was assessed through fluorescent microscopy. Briefly, 
deparaffinized and hydrated sections were permeabilized for 30 minutes with 1% 
Triton X-100 (Sigma-Aldrich) in PBS (Sigma-Aldrich). Slides were then stained 
with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for 10 minutes and 
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imaged with a laser-scanning confocal microscope (A1R HD; Nikon Instruments 
Inc., Tokyo, Japan). Relative cell density was determined by cell (nucleus) count 
standardized to area of collagen autofluorescence (in pixels) within each section 
and measured using ImageJ. Ten random frames were taken with the 40x 
objective per tissue section, with three tissue sections imaged per patient cell line 
and treatment group. The laser intensity settings were kept consistent between 
slides to facilitate consistent comparison between replicates. 
Expression of the contractile protein alpha smooth muscle actin (αSMA) by 
HTCFs within collagen constructs was assessed through immunohistochemistry. 
Deparaffinized and hydrated sections were permeabilized for 30 minutes with 1% 
Triton X-100 in PBS. After blocking of nonspecific sites with 1% BSA in PBS, 
sections were incubated for 40 minutes with Alexa Fluor 488–conjugated primary 
antibody against αSMA (Abcam, ab202295). Finally, slides were stained with 
DAPI for 10 minutes. For each tissue section, ImageJ was used to measure the 
total area staining positive for αSMA. This value was then normalized to the total 
number of nuclei counted within that same frame and compared between 
treatment groups. Since fibroblasts and myofibroblasts are mononuclear this 
approximates the αSMA expression per cell. Ten random frames were taken with 
the 40x objective per tissue section, with three tissue sections imaged per patient 
cell line and treatment group. The laser intensity settings were kept consistent 
between slides to facilitate consistent comparison between replicates. 
Thresholding of images to minimize background autofluorescence of the collagen 
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matrix was accomplished using identical cut off values for each laser channel and 
image analyzed prior to analysis. 
3.2.6 Cell Culture and Western Blot 
HTCFs were grown in 6-well culture plates in DMEM with 10% FBS at 37°C and 
5% CO2 until 80-90% confluent. The cultures were then starved of serum for 
24hrs, after which they were treated with vehicle (DMEM), TGFβ1 (2ng/ml, 
Sigma-Aldrich) or TGFβ1 co-incubated with one of the experimental anti-
inflammatory treatment solutions. After 48hrs incubation, western blot was used 
to assess relative protein expression between the experimental treatment groups. 
Briefly, cells were lysed in lysis buffer (PhosphoSafe Extraction Reagent, 
Novagen) containing a protease inhibitor cocktail (P2714, Sigma-Aldrich) and the 
crude protein lysate (10μg) was resolved using a Novex WedgeWell 4-20% tris-
glycine gel (Invitrogen). Using an iBlot Gel Transfer Device (IB1001, Invitrogen), 
the separated protein was transferred to a nitrocellulose membrane (IB301001, 
iBlot Transfer Stack, Invitrogen) which was then blocked with 5% (w/v) bovine 
serum albumin (Sigma- Aldrich) in Tris buffered saline (TBST) for 1 hour at room 
temperature. The membranes were incubated overnight at 4°C with primary 
antibody diluted in TBST containing 5% BSA (w/vol). Primary antibodies used 
were as follows: collagen 1 (ab138492, Abcam), αSMA (ab5694, Abcam) and 
GAPDH (Santa Cruz Biotechnology, Inc.). After incubation with primary 
antibodies, the blots were washed and hybridized with 1:3000 (v/v) dilutions of 
goat anti-rabbit IgG conjugated with horseradish peroxidase (Santa Cruz 
Biotechnology, Inc.). Visualization was accomplished by applying WesternBright 
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Quantum chemiluminescent reagent (Advansta, Inc.), with GAPDH used as a 
protein loading control. Imaging and relative densiometric quantification was 
accomplished using a ChemiDoc MP System (Bio-Rad Laboratories, Inc.) 
connected to Image Lab (Version 6, Bio-Rad Laboratories, Inc.). 
3.2.7 Statistical Analysis 
All data are presented as means ± SEM. For reporting purposes, all experimental 
replicates using multiple cell lines are denoted using ‘N = x’, and the number of 
experimental repeats performed using each cell line will be denoted using ‘n = y’. 
Collagen contraction assay data were subject to two-way analysis of variance 
followed by, if necessary, the Tukey-Kramer test with use of statistical and 
graphing software Prism 7 (Version 7.03, GraphPad Software Inc.). For collagen 
remodelling assay data, the relative area of collagen stained blue, yellow, orange 
or red, under different treatment conditions were assessed by one-way ANOVA 
with Dunnett’s multiple comparisons post hoc test with a single pooled variance, if 
necessary. The same methods were used for western blot and fluorescent 
microscopy data. For all experiments, a P value of less than 0.05 was considered 
statistically significant.  
3.3 Results 
3.3.1 Collagen Contraction Assay 
An in vitro assay utilizing HTCFs seeded within delayed-release collagen 
matrices was employed to measure the effects of drug exposures on HTCF 
mediated collagen contraction. Compared to vehicle control, exposure to all 
tested indomethacin and dexamethasone treatment solutions (except dex 0.05% 
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at all timepoints) significantly inhibited collagen contraction over the seven-day 
incubation period (Table 3-2). Tukey-Kramer multiple comparisons test indicated 
that 0.3% wt/vol. indomethacin inhibited HTCF mediated collagen contraction to a 
significantly greater degree than 0.05% wt/vol. dexamethasone at all timepoints 
(Figure 3-1, N = 6, n = 6, p<0.05). Indomethacin 0.1% wt/vol. also inhibited 
contraction to a significantly greater degree than 0.05% wt/vol. dexamethasone at 
all timepoints (N = 6, n = 6, p<0.05) except on day six where the P value was 
0.07. 
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Figure 3-1: Scan of HTCF-collagen matrices at experiment conclusion and graph 
illustrating the effects of indomethacin (blue lines: 0.03, 0.1, 0.3% w/vol.) or 
dexamethasone (red lines: 0.05, 0.1, 0.2% w/vol.) on the contraction of HTCF-
populated collagen lattices compared to vehicle treated (black line). A Tukey-
Kramer multiple comparisons test demonstrated that indomethacin dosed at 0.3% 
and 0.1% had a significantly greater inhibitory effect on contraction than 0.05% 
dexamethasone at the indicated time points. Data shown are mean ± SEM (N = 
6, n=6, #indicates significance level for Indo 0.3% vs. Dex 0.05%, ^indicates 
significance level for Indo 0.1% vs. Dex 0.05%). 
 
3.3.2 Extracellular Matrix Remodeling 
Picrosirius red staining was used in combination with circularly polarized light as 
a highly sensitive means to visualize collagen fibers. Fibrillar hue was used to 
assess structural changes induced by HTCFs in the collagen matrix compared to 
cell free matrices (Figure 3-2). Cell free matrices, incubated for seven days under 
identical experimental conditions, contained significantly greater proportions of 
blue staining compared to constructs containing HTCFs, which revealed a 
predominance of densely packed, mature red/orange staining collagen fibers 
(Figure 3-2). These changes are inferred to be cell mediated, structural changes 
to the collagen matrix. 
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Figure 3-2: Picrosirius red and polarized light microscopy enabled assessment of 
cell-mediated collagen remodeling. Collagen matrices were prepared with and 
without HTCFs then cultured under normal conditions for two weeks, fixed, 
sectioned and stained with picrosirius red. HTCF remodeling activity on the 
collagen matrix is revealed by comparing cell free matrices, which stain uniformly 
blue, to those cultured with HTCFs. Those cultured with HTCFs exhibit regions 
staining yellow, orange and red where cell-mediated matrix modifications are self-
evident. This remodeling activity was semi-quantitatively assessed in the 
presence of steroidal (dexamethasone) and non-steroidal (indomethacin) anti-
inflammatory drugs by comparing the mean relative color content of each image 
within a treatment group and using one-way ANOVA with Dunnett’s Multiple 
comparisons test (N = 6, n = 3, five random high powered frames at 20x 
magnification imaged per tissue section; **p<0.03, ***p<0.01, ****p<0.001 vs. 
HTCF+VC experimental group). 
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The effects of anti-inflammatory exposure on this remodeling activity was 
assessed (Figure 3-2). Sections of dexamethasone treated constructs displayed a 
similar fibrillar hue composition at all treatment doses compared to vehicle 
treated sections (N = 6, n = 3, p>0.05). Indomethacin treated sections exhibited 
significantly reduced red staining compared to vehicle treated sections and 
sections treated with any dose of dexamethasone. Indomethacin treated sections 
exhibited significantly greater areas of blue/yellow staining collagen fibrils 
compared to vehicle and dexamethasone treated sections. 
3.3.3 Fluorescent Microscopy 
The number of DAPI stained nuclei per unit area of collagen matrix was 
calculated to evaluate the final number of HTCFs within the collagen constructs 
after seven days of experimental conditions. The effects of anti-inflammatory 
treatment on final cell number are illustrated in Figure 3-3. Dexamethasone had 
no significant effect compared to vehicle control on the density of HTCFs within 
the collagen matrix at any concentration. The two highest concentrations of 
indomethacin (0.1 and 0.3%) significantly reduced the number of HTCFs per unit 
area of matrix after seven days of experimental conditions compared to vehicle 
control. Expression of αSMA by HTCFs within the collagen constructs was 
assessed using immunohistochemistry. Those treated with 0.2% dexamethasone 
as well as those incubated with 0.1 and 0.3% indomethacin showed significantly 
reduced αSMA staining per nuclei compared to vehicle control (Figure 3-3). 
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Figure 3-3 Representative confocal laser scanning microscope images for each 
treatment group. Cellular density was calculated as the number of nuclei (blue) 
standardized to collagen matrix area (background collagen autofluorescence – 
isolated by thresholding) within each given frame. Only indomethacin significantly 
affected cellular density relative to vehicle control (N = 5, n = 3, *p<0.05, 
**p<0.01). αSMA expression (green) within HTCF collagen constructs was 
calculated as the area of αSMA staining (green) standardized to the number of 
nuclei stained with DAPI (blue) within each given frame. Dexamethasone 0.2% 
and indomethacin 0.1 and 0.3% significantly reduced the area of αSMA staining 
per nuclei compared to vehicle control (N = 5, n = 3, *p<0.05, **p<0.01, 
****p<0.0001). 
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3.3.4 Western Blot 
Western blot analysis of crude protein lysate revealed that, after 48hrs of culture, 
indomethacin significantly impaired TGFβ1-induced collagen 1 and αSMA 
expression such that it resembled the expression level of TGFβ1 naïve cells at all 
concentrations tested (Figure 3-4, N = 4, *p<0.05, **p<0.01). Dexamethasone 
exhibited a dose dependent impairment of TGFβ1-induced collagen 1 expression, 
however this trend only reached statistical significance relative to the TGFβ1 
control group at the highest concentration tested. The inhibition of αSMA 
observed with dexamethasone was statistically significant in the 0.1 and 0.2% 
(w/vol) treatment groups (Figure 3-4, N = 4, *p<0.05, **p<0.01, ***p<0.001). 
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3.4 Discussion 
Tissues undergo repair in three stages: inflammation, proliferation and 
remodeling. Normal tissue repair requires an orderly and efficient transition 
between these stages and events that disrupt these transitions, such as pre-
existing chronic inflammation due to a patient’s medication burden or the novel 
interaction of aqueous humor with soft tissues at the surgical site, can cause 
scarring and fibrosis. This complication is responsible for the majority of 
glaucoma filtration surgery failures. Pharmacologic suppression of the 
inflammatory response and modulation of fibroblast activity are thus essential to 
the success rate of glaucoma filtering surgery. 
Myofibroblast mediated tissue contraction is believed to contribute to bleb 
encapsulation and a loss of patency in the surgical fistula that connects the AC to 
the drainage structure, both of which can limit the structure’s outflow 
capacity.3,4,192 Histological specimens of Tenon’s capsule obtained from failed 
trabeculectomy blebs have been compared to control specimens obtained from 
patients in surgically naïve eyes undergoing filtration surgery, retinal 
reattachment or cataract surgery.193 These control sections demonstrate loose 
connective tissue with few cellular infiltrates, and few cells positive for αSMA.  In 
contrast, sections from failed filtration structures tend to demonstrate αSMA 
positive cell-rich mesenchymal proliferations containing densely packed collagen 
fibrils which stain predominantly red/orange with picrosirius red.105,115,117,192–194 
The intent of the presented in vitro model was to mimic the in vivo exposure 
patient subconjunctival tissues might experience after topical application of 
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steroid (dexamethasone) or NSAID (indomethacin) post-operatively.  Collagen 
constructs were immersed in treatment solutions twice daily for 15 minutes after 
detachment of collagen constructs from culture wells, similar to the topical 
application of medications after surgical tissue manipulation. Both 
dexamethasone and indomethacin significantly inhibited HTCF-mediated 
collagen contraction compared to control, with indomethacin exhibiting 
significantly greater inhibition than dexamethasone at the extremes of the doses 
assessed. Expression of the myofibroblast marker and contractile protein, αSMA, 
is necessary for cell mediated tissue contraction to occur.112,195 
Immunohistochemical staining demonstrated that both drugs had an inhibitory 
effect on the expression of αSMA, however this effect was again slightly greater 
with higher doses of indomethacin compared to dexamethasone. The effects of 
treatment solutions on TGFβ1-induced αSMA expression was also assessed 
through western blot. These results were corroborative of the trends seen in the 
immunohistochemical experiments. These findings suggest that both drugs may 
function in vivo to prevent decreases in outflow capacity due to the contraction of 
tissues at or around the filtration site, however at the level of the fibroblast, 
NSAIDs may better impair collagen contraction and associated biomarkers. 
Picrosirius red staining revealed that only indomethacin significantly mitigated 
HTCF-mediated collagen remodeling. Western blot after monolayer cell culture 
revealed significant inhibition of TGFβ1-induced collagen 1 expression at all 
tested indomethacin concentrations and certain dexamethasone concentrations. 
The observed trend in collagen 1 expression is supportive of the trend seen in the 
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picrosirius collagen remodeling assay. Indomethacin’s effects on collagen 
remodeling may further be explained by the observation that treatment with 
indomethacin significantly reduced the number of cells within collagen constructs 
at experimental conclusion leaving fewer to remodel the matrix relative to the 
control and dexamethasone groups. These observations are further strengthened 
by previous monolayer cell culture experiments comparing the antiproliferative 
effects of NSAIDs to that of steroids. NSAIDs showed comparable, or better, anti-
proliferative effects on ocular fibroblasts than did steroids.95 Another possible 
explanation comes from the work of Sakaki et al, who cultured human gingival 
fibroblasts and found that indomethacin reduced expression of matrix 
metalloproteinases (MMPs).196 MMPs play an important role in extracellular 
matrix remodeling and tissue repair, and MMP inhibitors have previously reduced 
scarring outcomes in an in vitro model similar to the one presented here.125 
Further, dexamethasone was previously demonstrated to decrease 
glycosaminoglycan synthesis in cultured fibroblasts.197,198 Glycosaminoglycans 
increase the hydration capacity of collagen matrixes, permitting looser 
arrangement of fibers,199 thus providing further explanation for the denser 
matrices produced by HTCFs when exposed to dexamethasone above that 
provided by our collagen 1 western blot results. Further work is necessary to 
characterize the cellular mechanisms underpinning the significant differential 
effect these anti-inflammatory modalities exert on HTCF-mediated collagen 
remodeling. 
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In the present study, the combined anti-contractile and anti-remodeling effects of 
indomethacin, in addition to its effects on cellular density, collagen 1 and αSMA 
expression, suggest a capacity to mitigate many of the histopathological findings 
associated with failed filtration blebs. Several previous glaucoma surgical trials 
have compared perioperative treatment with NSAIDs to steroids and assessed 
the impact on surgical outcomes.90,163,173,175,200 Patients treated post-operatively 
with NSAIDs exhibited a clinical tendency to do better than those treated with 
steroidal anti-inflammatory modalities in terms of the number of post-operative 
glaucoma medications required, final IOP and bleb morphology.175 Favorable 
bleb morphology with NSAID treatment in a clinical setting may be analogous to 
the in vitro effects NSAIDs exhibited on HTCF-mediated collagen contraction and 
remodeling in the present study. 
Two previous studies evaluated NSAID versus steroid treatment after Ahmed 
valve implantation and found a more favorable post-op IOP reduction with NSAID 
treatment.90,173 However, complications relating to inadequate healing (such as 
wound leak, hypotony, conjunctival retractions, etc.) were observed at higher 
rates in the NSAID arm of one study.90 These findings support the conclusion that 
indomethacin may better impede collagen remodeling orchestrated by HTCFs. 
Remodeling, however, is an essential aspect of healthy wound healing and 
critical, to a degree, in order to prevent bleb leaks, infection and hypotony. This 
highlights the importance of modulating the existing positive and negative wound 
healing stimuli that may influence the activity of HTCFs and, ultimately, surgical 
outcomes. The glaucoma surgeon and patient will benefit from the understanding 
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that NSAIDs and steroids are both effective at mitigating wound healing during 
the post-operative phase. However, understanding the subtle differences in 
efficacy and cellular mechanisms of action will allow for greater control of the 
maturing bleb in vivo, allowing for finer adjustments to bleb maturation in 
response to post-operative clinical observations. 
Most of our current understanding of cellular functions such as migration, 
differentiation and reaction to extra-cellular forces has been derived from 
studying cells in two-dimensional monolayer cultures.184 In vivo, wound healing 
and pathological scarring processes are a complex interaction between cells and 
the extracellular matrix – the outcome of which is largely dependent on the 
immediate microenvironment. The presented 3D collagen-based culture model 
enables assessment of cell-mediated changes in collagen architecture as well as 
differences in markers of cellular phenotype.201 It also accounts for the three-
dimensional cell-matrix interactions and signal transduction pathways, present in 
vivo, that are unaccounted for in two-dimensional monolayer culture models.184 
Our conclusions are strengthened by the complementary nature of the 
macroscopic collagen contraction assay and the microscopic assessment of 
collagen architecture as well as cellular morphology and protein expression. 
A limitation of this in vitro model is the absence of inflammatory cells and immune 
system. The infiltration of immune cells is thought to contribute to the failure of 
glaucoma filtration surgery.71 It is highly likely that the anti-inflammatory 
properties of steroids and NSAIDs act to limit the effects of these cells in vivo as 
well, which in turn might diminish any negative impact on local fibroblast activity. 
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Future studies could be undertaken incorporating inflammatory cells within a co-
culture system to investigate the impact these drugs have on HTCF wound 
healing activities in the presence of immune cells.  
3.5 Conclusions 
In conclusion, both steroidal and non-steroidal anti-inflammatory treatment can 
influence HTCF-mediated collagen contraction and αSMA expression. 
Indomethacin alone was observed to mitigate HTCF-mediated changes in 
collagen remodeling. This may be the result of different intracellular secondary 
messengers being stimulated by the two drugs or a difference in relative potency 
at the clinically available concentrations tested. These findings support the use of 
this in vitro model to help understand observations from clinical trials involving ab 
externo glaucoma surgery. Further, this model may be useful to investigate the 
effects of other wound modulating agents, as well as the influence of surgically 
implanted minimally invasive glaucoma (MIGS) devices. Given the rapidity and 
frequency by which MIGS devices are emerging, this may be useful in providing 
evidence to help optimize the success rates of implanted devices and peri-
operative wound management practices. 
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Chapter 4  
4 Acetylsalicylic Acid Mitigates Cytokine Induced 
Myofibroblast Transdifferentiation and Activity within 
Human Ocular Fibroblasts 
 
 
Given the significant inhibitory effects on wound healing phenomena that are 
observed with competitive COX inhibition, acetylsalicylic acid (ASA) and its 
unique covalent inhibition of COX enzymes and PG production struck me as 
potentially more powerful than what could be achieved with competitive inhibition. 
Delving deeper, I learned of the relatively recent finding that ASA-acetylated 
COX2 remains functional in situ – with the acetyl-COX2 enzyme now capable of 
producing RMs from PUFA precursors, but not PGs. The ability to quickly and 
simply acetylate this enzymatic engine of inflammation propagation into an 
engine of resolving mediator production has the potential to be an immuno-
resolvent intervention. Chapter 5 pursues this idea and examines the effects of 
ASA on RM generation, and the effects these ASA-triggered RMs exert on the in 
vitro wound healing phenomena of subconjunctival fibroblasts. 
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4.1 Introduction 
Glaucoma represents a group of conditions involving progressive damage to the 
optic nerve and subsequent vision loss. Glaucoma is one of the leading causes of 
irreversible blindness, affecting over 70 million people across the world.202 There 
is currently no cure, and the only known modifiable risk factor is the reduction of 
intraocular pressure (IOP). Patients are prescribed medications to control their 
intraocular pressure. However, due to physiological tolerance to the medications, 
as well as poor treatment compliance, patients may undergo trabeculectomy.203 
Trabeculectomy, also known as filtration surgery, involves the creation of a 
pocket under the conjunctiva called a filtering bleb. Excess aqueous humor 
drains into this bleb, thus lowering the intraocular pressure. Filtration surgery may 
be considered the gold standard surgical intervention for refractory glaucoma 
patients.202 However, the surgical failure rate is high: with a 10% failure rate per 
year and up to a 50% failure rate in 5 years. This rate may be due to a 
fibroproliferative response in the trabecular meshwork, the fistula between the 
anterior chamber and the bleb, and/or the Tenon’s capsule, leading to 
subconjunctival scarring after surgery and increased resistance to aqueous 
outflow.3,4  
The Tenon’s capsule is a collagen rich layer of connective tissue that lies under 
the conjunctiva. This region contains fibroblasts; cells that transdifferentiate into 
myofibroblasts,1 which function in wound healing by producing extracellular 
matrix and contractile force.32,204 Under normal physiological conditions, the 
Tenon’s capsule does not encounter aqueous humor. However, after filtration 
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surgery, there is an influx of aqueous humor to this region of the eye. Numerous 
cytokines are present in the aqueous humor, such as transforming growth factor 
beta 1 (TGFβ1) and TGFβ2,86,205 tumor necrosis factor-alpha (TNFα), interferon-
gamma (IFN-γ), and interleukin-1b (IL-1β).85,206,207 These inflammatory and 
wound healing molecules function at the level of the fibroblast to promote wound 
healing process, both directly and vicariously through immune cell recruitment. 
These processes are required to some degree to avoid bleb leaks. However, if 
the inflammatory phase of the wound healing response fails to resolve and re-
establish homeostasis in the eye, chronic inflammation ensues.16,20,202 The TGFβ 
isoforms are well-established as one of the main drivers of scarring after 
glaucoma surgery.208–210 Myofibroblasts within the subconjunctival and Tenon’s 
capsule tissues of failing glaucoma surgeries display excess proliferation, wound 
contraction, and extracellular matrix protein production.1,4,211 These cellular 
processes ultimately result in subconjunctival scar formation, increased 
resistance to aqueous outflow and failure of IOP control. 
Within the pro-inflammatory microenvironment of the filtration bleb, phospholipids 
in the plasma membrane of HTCFs are converted to arachidonic acid by 
phospholipase.12 Cyclooxygenase (COX) enzymes convert arachidonic acid into 
pro-inflammatory mediators such as prostaglandins, which can recruit 
inflammatory cells and subsequently vicariously activate local fibroblasts such 
that they express fibrosis associated proteins such as alpha-smooth muscle actin 
(α-SMA) and matrix metalloproteinases (MMPs).33,34 α-SMA is a structural protein 
involved in scar contraction during the wound healing process. MMPs encompass 
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a group of enzymes that degrade extracellular matrix and are involved in collagen 
remodeling in wound healing.212 Previous work has demonstrated the 
involvement of MMP9 in fibrosis after glaucoma surgery125,127,213 and MMP9 is 
also upregulated during inflammatory processes.214 A healthy wound healing 
response involves the build-up of pro-inflammatory mediators within the 
fibroblast,16,215 which triggers the activity of lipoxygenases (LOX).35,216 The LOX 
enzymes are the group enzymes whose actions produce most pro-resolving lipid 
mediators, which then function to ultimately resolve inflammatory 
processes.17,20,22 
Anti-scarring agents in current use after glaucoma surgery include mitomycin C 
— an antimetabolite that inhibits cell proliferation217 — and corticosteroids —
broad-acting anti-inflammatory agents.65,218,219 However, these options have had 
limited success. Mitomycin C may increase patients’ risk of developing 
cataracts220, infection and hypotony.100,221 It is dosed empirically and has a very 
narrow therapeutic range. As well, the use of corticosteroids have many adverse 
effects, such as, dramatically increasing intraocular pressure in a subset of 
patients, infection and cataract.69,97,222 Therefore, the efficacy of other agents 
needs to be explored.  
As an alternative, nonsteroidal anti-inflammatory drugs (NSAIDs) have shown 
promise in a large retrospective study,67 in vitro223 and in a recent meta-analysis 
of several small clinical trials.174 Acetylsalicylic acid (ASA), is unique among all 
NSAIDs in that it does not competitively inhibit the COX2 enzyme. Instead, it 
acetylates COX2 at Ser516 and changes its function.224,225 The acetylated COX2 
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enzyme no longer produces prostaglandins, but instead produces pro-resolving 
lipid mediators akin to those produced by the LOX enzymes. Examples of ASA-
triggered lipid mediators include: 5R-hydroxyeicosatetraenoic acid (HETE), 
15(R)-HETE226–228, 18-hydroxyeicosapentaenoic acid (HEPE)229 and 17R-
hydroxy docosahexaenoic acid (OHDHA).6,230–232 Thus, ASA facilitates the 
transition within cells from the pro-inflammatory biolipid synthesis pathway to the 
pro-resolving biolipid synthesis pathway by triggering the production of pro-
resolving lipid mediators from COX2 at the same time as mitigating PG synthesis 
from the same enzyme. The downstream effects of ASA on TGFβ1-induced 
myofibroblastic changes in human Tenon’s capsule fibroblasts are unknown. In 
this study, we hypothesize that ASA will decrease TGFβ1-induced cell metabolic 
activity and protein expression in HTCFs through the induction of pro-resolving 
lipid mediators. 
4.2 Materials and Methods 
4.2.1 Isolation and Culture of Human Tenon’s Capsule Fibroblasts 
This study was approved by the Human Research Ethics board at Western 
University (REB# 106783). Human Tenon’s capsule tissue, 2-4 mm3 in size, were 
resected from patients at St. Joseph’s Hospital, London, Canada. Specimens 
were placed in a 1.5 mL microtube containing Dulbecco’s Modified Eagle Medium 
(DMEM) with 10% (v/v) Fetal Bovine Serum (FBS) and 1% (v/v) Penicillin and 
Streptomycin (PS), then placed into culture plates coated with fibronectin (Sigma-
Aldrich, USA) at 37℃, 5% CO2. Cells from outgrowth were passaged prior to 
reaching 80% confluence and all experiments were conducted with cells that 
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were passaged fewer than 5 times. Donor information for the cell lines used in 
experimentation are listed in Table 3-1. 
HTCFs were cultured in separate 75 cm2 flask in DMEM with 10% FBS and 1% 
PS (Gibco, Thermo Fisher Scientific, Canada). For all experiments, cells were 
seeded at 105 cells/mL in 10% FBS-1% PS DMEM for 24 h or until 80% 
confluence was reached. Next, cells were serum-starved for 24h. Vehicle control 
HTCFs were treated with 0% FBS-1% PS DMEM and positive control HTCFs 
was treated with 2 ng/mL of TGFβ1 (Thermo Fisher Scientific, Canada) in 0% 
FBS-1% PS DMEM. To assess the effects of ASA (Thermo Fisher Scientific, 
Canada) on HTCFs under non-inflammatory conditions, 3200 µg/mL ASA was 
fully dissolved for 15 minutes in 0% FBS DMEM at 37℃, then serially diluted by a 
factor of 2 to the lowest concentration of 100 µg/mL ASA, obtaining a total of 
seven ASA concentrations. To assess the effects of ASA on TGFβ1-induced 
HTCFs, cells were treated with the same set of ASA concentrations co-incubated 
with 2 ng/mL of TGFβ1. Plates were incubated for 48 h at 37℃ and 5% CO2 prior 
to conducting MTT/LDH assays, western blot, and immunohistochemistry.  
4.2.2 Lipid Mediator Secretion Assay 
Relative quantification of secreted pro-inflammatory and pro-resolving lipid 
mediators was achieved using liquid chromatography tandem mass spectrometry 
(LC-MS/MS). Specifically, we focused our analyses on the COX2 derived lipid 
mediators, kPGF1a and PGE2; as well as the acetyl-COX2 derived mediators, 5-
HETE, 15-HETE, 17-OHDHA and 18-HEPE; and their PUFA precursors, AA, 
DHA and EPA. Known quantities of deuterated internal standards of the analyzed 
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the lipid mediators were added to each sample to enable relative quantification 
between samples (Item Numbers: #10007737, #320110, #314010, #11182, 
#315210, #319030, #390030, #10006410, #10006199, #334230, and 
#10008040, Cayman Chemical). This is a well-established method to determine 
the relative activity of lipid biosynthetic pathways 233,234. In brief, the ratios of the 
integrated areas of the chromatographic peaks corresponding to each analyte 
and the integrated areas of the peaks corresponding to each analyte’s internal 
standard (with known absolute quantity) are used to determine the relative 
quantity of each analyte in a given sample. After supernatant sample collection, 
250μl of methanol containing 100pg of each deuterated internal standard was 
added. Samples were then vigorously vortexed and centrifuged at 10,000g for 
10min before loading onto solid-phase extraction cartridges (Strata-X 33um 
Polymeric Reversed Phase, 10mg, Phenomenex 8B-S100-AAK), that were 
previously activated with 2ml methanol and rinsed with 2ml water. Samples were 
diluted upon loading so that the final concentration of methanol was between 10 
and 15% of total volume. After washing with 5ml water, extracts were eluted with 
1ml methanol. Solvent was then evaporated under vacuum in a SpeedVac 
centrifuge, and the extract was resuspended in 100μl acetonitrile/water 60:40 
(v/v). An aliquot of 20μl was injected into the LC-MS/MS system for analysis. A 
Sciex ExionLC Integrated System was used with a 0.3ml/min flow rate, initial 
mobile phase of 10% water / 0.1% formic acid followed by 100% acetonitrile / 
0.1% formic acid on a Kinetex 2.6um C18 100 Å 100x2.1mm, Phenomax column 
(OOD-4462-AN). A Sciex Triple Quad 6500+ mass spectrometer with multiple 
reaction monitoring was used in negative ion mode. The chromatographic profile 
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of the ion count for each m/z transition was monitored, and the area under the 
peaks (ion intensity vs elution time) was integrated using commercial software 
(MultiQuant, Sciex). Total cellular protein concentration was used for 
normalization of the supernatant samples. 
4.2.3 Collagen Contraction Assay 
The delayed release fibroblast populated collagen lattice model,185 based on the 
model first proposed by Bell,186 was used to assess the effects of experimental 
treatments on cell-mediated gel contraction. In brief, HTCFs were mixed within an 
extracellular matrix (ECM) mixture containing 80% type I collagen (1.8mg/ml; 
A1048301, Gibco), 16% neutralizing solution (equal parts Waymouth media 
(Sigma-Aldrich) and 0.275M NaOH) and 20μl of ocular fibroblast conditioned 
media (concentrated to 25x to obtain a 1x final concentration within the 500μl 
construct volume) in order to achieve a final cell density of 2.5 x 105 cells/mL 
within the solution. Cell free collagen lattices were prepared identically, albeit 
without the inclusion of ocular fibroblasts, as negative control. The solution was 
pipetted gently to ensure homogenous distribution of ocular fibroblasts while 
avoiding the production of air bubbles, then 500μl were pipetted into each well of 
a 24-well tray. Collagen constructs were allowed to polymerize at 37°C and 5% 
CO2 for 45 minutes before adding low serum culture media containing DMEM, 
2% Fetal Bovine Serum (FBS), 1% penicillin/streptomycin. 
After incubation at 37°C and 5% CO2 for 72 hours, a sterile spatula was used to 
detach each collagen construct from the edges of the culture well. Plates were 
then immediately scanned on a flat bed laser scanner (Scanjet 8200, Hewlett-
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Packard) to record baseline area, and then periodically for the duration of the 
experiment. The surface area of each collagen construct was measured using 
ImageJ187 and standardized against the baseline surface area measurement to 
express changes in area as a percentage of original surface area. 
4.2.4 Collagen Remodeling Assay 
Upon conclusion of the contraction assay, collagen constructs were fixed in 4% 
paraformaldehyde overnight. After fixation, collagen constructs were dehydrated 
in ethanol, embedded in paraffin blocks, sectioned (5µM) and mounted on glass 
microscope slides using standard methods. For histological staining, sections 
were deparaffinized and hydrated using standard protocols. Sections were 
stained with picrosirius red. Briefly, a solution of 0.1% Sirius red (Sigma-Aldrich) 
in saturated picric acid (Sigma-Aldrich) was applied for 60 min, followed by 2 x 
0.5% acetic acid washes. Collagen birefringence, used to determine collagen 
fibrillar hue,188 was assessed by circularly polarized light microscopy of picrosirius 
red stained sections. Images were taken with an Abrio quantitative birefringence 
imaging system (Hinds Instruments, Portland, Oregon) mounted on an Olympus 
BX-51 microscope (Olympus Corporation, Tokyo, Japan). Specifically, a constant 
light intensity, a fixed 45° angle to the polarizing filter, a 20x objective and the 
same analyzer were used to facilitate consistent comparisons between each 
sample. 
When viewed under polarized light, the color of the collagen fibers stained with 
picrosirius red depends upon fiber thickness and spatial orientation; with the color 
changing from blue to yellow to orange to red as fiber thickness and density 
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increase.189,190 This method has been used previously in rabbit experimental 
filtration surgery to examine subconjunctival fibrosis, and red/orange staining was 
associated with bleb dysfunction.105 Using ImageJ, this property was leveraged to 
determine the relative proportions of different color fibers within the collagen 
constructs. This quantitative method has been previously described by Rich and 
Whittaker.191 In short, relative color content of the images is obtained by 
separating the digital images into their hue, saturation and value components. 
The hue component contains information on the color of each pixel within the 
image. Every pixel can have one of 256 possible colors. To identify the red, 
orange, yellow and blue pixels within a given image the following hue definitions 
were used within ImageJ: red 2-9 and 230-256, orange 10-38, yellow 39-51 and 
blue 52-128.191 The number of pixels within each hue range is calculated and 
expressed as a proportion of the total number of pixels within each field 
representing collagen. Ten random frames using a 20x objective were taken per 
tissue section, with three tissue sections imaged per patient cell line and 
treatment group. 
4.2.5 Cellular Metabolic Activity Assay 
To determine the effects of ASA on HTCF cell metabolic activity, MTT assays 
(Sigma-Aldrich, USA) were conducted in 24-well plates. Supernatant from each 
well was collected in individual microtubes for the LDH assay. Then, 0.5 mg/mL 
MTT working solution in 0% FBS-1% PS DMEM was added per well, followed by 
incubation for 3 h at 37℃, 5% CO2. Afterwards, the MTT solution was removed 
and 500 µL of dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Canada) was added to 
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each well. Plates were mixed for 30s on an orbital shaker, then analyzed using a 
spectrophotometer at 575 nm. Optical densities (ODs) were corrected for 
background OD from the DMSO, outliers were removed, and the mean corrected 
optical densities of triplicate values were calculated. Cell metabolic activity was 
calculated using the following equation: 
Metabolic activity (%) = 
mean corrected OD570 of experimental condition
mean corrected OD 570 of negative control
 x 100% 
4.2.6 Cytotoxicity Assay 
Cytotoxicity was assessed using a Pierce LDH Cytotoxicity Assay Kit 
(ThermoFisher, Canada). For this colorimetric assay, DMEM culture media 
without phenol red (Gibco, Thermo Fisher Scientific, Canada) was used. In 
addition to the previously indicated experimental treatment groups, HTCFs were 
treated with 10% (v/v) TritonX-100 (Sigma-Aldrich, USA) diluted in 0% FBS-1% 
PS DMEM for 1 h and 48hr, as a positive necrotic cell death control. After 
experimental conclusion, supernatants were collected and the samples 
immediately centrifuged for 10 minutes at 1,800g and 4℃. Next, each sample 
was plated in duplicate in a 96-well plate with LDH standards. Output was 
measured by spectrophotometer at dual filter 490 nm and 655 nm. Optical 
densities were corrected for background, and the mean corrected optical 
densities of the sample duplicates were calculated. Percentage of cell death was 
calculated using the following equation:  
Cytotoxicity (%) = 
mean corrected OD490/655 of experimental condition
mean corrected OD490/655 of negative control
 x 100% 
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4.2.7 Western Blot 
Once the effects of acetylsalicylic acid on TGFβ1-induced cell metabolic activity 
were determined, ASA concentration at 100 µg/mL, 400 µg/mL, 1600 µg/mL and 
3200 µg/mL were selected to assess the effects of ASA on TGFβ1-induced 
protein levels. HTCFs were seeded in 6 well-plates at 105 cells/mL, then co-
treated with 2 ng/mL TGFβ1 and the selected ASA concentrations for 48 h at 
37℃, 5% CO2. Afterwards, total protein was extracted with lysis buffer 
(PhosphoSafe Extraction Reagent, Novagen) containing a protease inhibitor 
cocktail (P2714, Sigma-Aldrich) and a cell scraper (Pierce, Thermo Fisher 
Scientific, Canada). Crude protein lysate (10 µg), determined using a Micro BCA 
Protein Assay Kit (Thermo Fisher Scientific, USA), was separated using a 10% 
acrylamide gel, alongside a SeeBlue Pre-stained Protein Standard (Thermo 
Fisher Scientific, Canada). After gel electrophoresis, proteins were transferred to 
a nitrocellulose membrane using an iBlot Gel Transfer Device (IB1001, 
Invitrogen). Membranes were blocked in 5% (w/v) bovine serum albumin (BSA) 
(Sigma- Aldrich, USA) dissolved in 10% (v/v) tris buffered saline (TBST) (Thermo 
Fisher Scientific, Canada) for 1 h at room temperature, then incubated in primary 
antibody overnight at 4℃, followed by incubation in secondary antibody 
conjugated with horseradish peroxidase for 1 h at room temperature on a 
benchtop shaker. Membranes were washed three times, 5 minutes each, with 
10% TBST before and after the addition of each antibody. For analysis of alpha-
smooth muscle actin (α-SMA) protein levels, membranes were incubated in 2 
µL/mL rabbit anti-alpha smooth muscle actin antibody (ab5694, Abcam, Canada) 
in 3% BSA solution, washed, then incubated in 0.66 µL/mL secondary goat anti-
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rabbit antibody (Bio-Rad Laboratories, Canada) in 3% BSA. For analysis of 
matrix metalloproteinase-9 (MMP-9) protein levels, the same procedure was 
followed but using rabbit anti-MMP9 antibody (ab38898, Abcam, Canada). All 
membranes were also incubated with 2 µL/mL mouse anti-glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) antibody (ab8245, Abcam, Canada) in 3% 
BSA, followed by incubated in 0.66 µL/mL secondary anti-mouse antibody (Bio-
Rad Laboratories, Canada) both for 1 h at room temperature on a benchtop 
shaker. Membranes were visualized by applying WesternBright Quantum 
chemiluminescent reagent (Advansta, Inc.), with GAPDH used as a protein 
loading control. Imaging and relative densiometric quantification was 
accomplished using a ChemiDoc MP System (Bio-Rad Laboratories, Inc.) 
connected to Image Lab (Version 6, Bio-Rad Laboratories, Inc.).  
4.2.8 Immunohistochemistry 
In order to examine the effects of ASA on TGFβ1-induced myofibroblast 
morphology and α-SMA levels, HTCFs were seeded in 24-well plates, each 
containing a 13 mm glass coverslip. Cells were treated in duplicate and analyzed 
after incubation for 48h in the same treatment conditions as indicated for the 
western blot experiments. Cells were washed with PBS two times, fixed and 
permeabilized with 4% formaldehyde for 15 minutes, then washed again with 
PBS two times. Cells were then incubated in 5% BSA dissolved in PBS for 1 h at 
room temperature, followed by incubation with rabbit anti-α-SMA antibody at a 
1:200 (v/v) dilution in 5% BSA for 1 h at room temperature. Cells were washed 3 
times with PBS, 5 minutes each, then incubated in secondary goat anti-rabbit IgG 
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(Alexa Fluor 555 Dye, Abcam, Canada) for 1 h, F-actin Staining Kit in Blue 
Fluorescence (ab112124, Abcam, Canada) for 30 minute, then stained with 
Hoechst solution (Thermo Fisher Scientific, Canada) for 15 minutes. Cells were 
washed with PBS two times and dH2O two times prior to imaging using 
fluorescence microscopy at 60x objective. Images were analyzed using ImageJ 
by comparing, within each treatment group, the total area of α-SMA to the 
number of nuclei. Ten random frames were taken with the 40x objective per 
replicate, with three replicates imaged per treatment group within each patient 
cell line. The laser intensity settings were kept consistent between samples to 
facilitate consistent comparisons. 
4.2.9 Exogenous Lipid Mediator Assay 
The pro-resolving capabilities of ASA-triggered lipid mediators on TGFβ1-induced 
HTCFs were assessed by western blot. HTCFs were seeded in 6-well plates at 
105 cells/ml, serum-starved for 24 h, then treated with 2ng/mL TGFβ1 alone or 
co-incubated with one of: 5(R)-HETE, 11(R)-HETE, 15(R)-HETE, and 17(R)-
OHDHA (Cayman Chemicals, USA) at concentrations of 10, 100, and 1000 
ng/ml. After 48 h incubation, total protein was collected, and samples were 
analyzed by western blot using the procedure described above. To include a non-
ASA-triggered lipid mediator negative control, 11-HETE was used due to its 
derivation from cytochrome P450 in vivo. 
4.2.10 Statistical Analysis 
Data from all experiments are presented as mean ± SD. Experimental replicates 
are denoted as ‘N=x’ and technical replicates performed within each cell line are 
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denoted as ‘n=y’. Data collected from multiple treatment groups over time were 
assessed by two-way repeated measures ANOVA with Dunnett’s multiple 
comparison post hoc test. Data from the exogenous lipid mediator western blot 
were assessed by one-way ANOVA with Tukey’s multiple comparisons post hoc 
test. A p-value of less than 0.05 was considered statistically significant.  
4.3 Results 
4.3.1 Acetylsalicylic acid reduces prostaglandin production and 
induces resolving mediator production in HTCFs 
First, we assessed the ability of ASA to illicit ASA-triggered lipid mediators within 
inflammation activated ocular fibroblasts. Cells induced with growth factors found 
within the aqueous humor (AHGFs - 1ng/ml each: TGFβ1, TNFα, INFɣ and IL-1β) 
exhibited high levels of prostaglandin production. Any dose of ASA exposure 
resulted in the near complete abrogation of PG production (Figure 4-1A and B). 
The relative production of ASA-triggered mediators 5-HETE, 15-HETE and 18-
HEPE was significantly increased after ASA exposure in a dose dependent 
manner, up to 48hrs after exposure Figure 4-1C-E). No 17-OHDHA was detected 
in any sample analyzed. 
Error! Reference source not found.F summarizes the relative biosynthetic activity 
of COX2 vs. acetyl-COX2 enzymes. The mean relative production of COX2 
products (PGE2 and kPGF1a) was calculated, and from this figure the mean 
relative production of acetyl-COX2 products (5-HETE, 15-HETE and 18-HEPE) 
was subtracted. This way a value of zero would indicate equal relative 
biosynthetic activity between acetyl-COX2 and COX2 enzymes; positive values 
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would indicate COX2 dominated biosynthesis of lipid mediators; and negative 
values would indicate acetyl-COX2 dominated lipid mediator biosynthesis. 
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Figure 4-1 Relative AHGF-induced LM secretion was determined by supernatant 
sampling and LC-MS/MS analysis at the indicated timepoints after exposure of 
AHGF-induced ocular fibroblasts to the indicated experimental treatment. A-B) 
COX2 prostaglandin products: kPGF1a and PGE2. C-E) Acetyl-COX2 RM 
products: 5-HETE, 15-HETE and 18-HEPE. F) Displays the differential mean 
relative secretion between pro-inflammatory mediators (PGE2 and kPGF1a) and 
pro-resolving mediators (5-HETE, 15-HETE, 18-HEPE). A value of zero indicates 
equal relative biosynthetic activity between acetyl-COX2 and COX2; positive 
values indicate COX2 dominated biosynthesis of lipid mediators; and negative 
values indicate acetyl-COX2 dominated lipid mediator biosynthesis. A-F) Two-
way ANOVA with Dunnett’s post hoc test: *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
 
 98 
 
4.3.2 Acetylsalicylic acid inhibits HTCF-mediated collagen 
contraction and remodeling 
 
Cell-mediated collagen contraction was assessed in the presence of increasing 
concentrations of ASA (Figure 4-2). Compared to vehicle treated replicates, ASA 
elicited a significant and dose dependent inhibition of ocular fibroblast-mediated 
contraction over a period of four days. Contraction was almost completely 
inhibited at 1600μg/ml ASA. 
  
A) 
VC 
ASA400 
ASA800 
ASA1600 
4h 24h 48h 72h 96h 
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Picrosirius red staining was used in combination with circularly polarized light as 
a highly sensitive means to visualize collagen fiber morphology. Fibrillar hue was 
used to assess structural changes induced by ocular fibroblasts in the collagen 
matrix compared to cell free matrices (Figure 4-3). Cell free matrices, incubated 
for seven days under identical experimental conditions, contained significantly 
greater proportions of blue staining compared to constructs containing HTCFs, 
which revealed a predominance of densely packed, mature red/orange staining 
collagen fibers (Figure 4-3). These changes are inferred to be cell mediated, 
structural changes to the collagen matrix. Exposure to 1600μg/ml ASA 
significantly inhibited the observed cell-mediated remodeling activity of ocular 
fibroblasts.  
Figure 4-2 A) Representative scans of the same four contracting HTCF-
populated collagen lattices with the indicated treatments, the first 96hrs after 
detachment from culture wells. B) Graph illustrating the effects of ASA (400, 
800 and 1600 µg/ml in DMEM) on the contraction of HTCF-populated collagen 
lattices compared to vehicle treated. Data shown are mean ± SEM (N = 6, n=6). 
Two-way ANOVA with Dunnett’s post hoc test: *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
B) 
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Figure 4-3 Picrosirius red and polarized light microscopy enabled assessment 
of cell-mediated collagen remodeling. Collagen matrices were prepared with 
and without HTCFs then cultured under normal conditions for two weeks, fixed, 
sectioned and stained with picrosirius red. HTCF remodeling activity on the 
collagen matrix is revealed by comparing cell free matrices, which stain 
uniformly blue, to those cultured with HTCFs. Those cultured with HTCFs 
exhibit regions staining yellow, orange and red where cell-mediated matrix 
modifications are self-evident. This remodeling activity was semi-quantitatively 
assessed over 7 days in the presence of 1600μg/ml ASA in DMEM. One-way 
ANOVA with Tukey’s post hoc test: N=3, n=3, frames=10; **p<0.01, 
***p<0.001. 
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4.3.3 Acetylsalicylic acid decreases TGFβ1 induced HTCF 
metabolic activity without increasing necrotic cell death 
High levels of PG production are often associated with increased cellular 
metabolic activity. Thus, to better understand the mechanisms underlying ASA’s 
effects on in vitro wound healing phenomena, we examined the effects of ASA on 
TGFβ1-induced HTCF cell metabolic activity. TGFβ1 increased HTCF cell 
metabolic activity compared to un-induced fibroblasts (Figure4-4A). TGFβ1-
induced fibroblasts, treated with increasing concentrations of ASA, exhibited a 
dose-dependent decrease in metabolic activity. In contrast, ASA had minimal 
effects on HTCF metabolic activity in the absence of TGFβ1. A notable exception 
in both cases was ASA at 3200 µg/mL — where metabolic activity was lower than 
all other samples for both groups. Potentially reflecting an interference with 
COX1’s homeostatic functions. Importantly, ASA at 1600 µg/mL returned TGFβ1-
induced metabolic activity to that of the baseline, no-TGFβ1 control. Thus, ASA 
produced a significant and dose-dependent decrease in TGFβ1-induced HTCF 
metabolic activity.  
Next, we assessed whether ASA was exerting its effects — in particular at higher 
concentrations — through cytotoxic mechanisms. We conducted an LDH assay 
using supernatant from HTCFs (N=4, n=3) treated with the same conditions as 
the MTT assay. HTCFs were also treated with 10% TritonX-100 for 1 h and 48 h 
as a positive cell death control. For HTCFs treated both in the presence and 
absence of TGFβ1, there was no difference in cell death – even at the highest 
dose assessed (Figure4-4B). When compared to cells treated with vehicle and 
those treated with TritonX-100, ASA treatments caused no significant increase in 
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cell death. These results suggest that ASA decreases TGFβ1-induced metabolic 
activity in HTCFs through a non-cytotoxic mechanism. 
  
Figure 4-4 ASA decreases, A) cell metabolic activity, without significantly 
impacting, B) cell death. HTCFs were co-cultured in triplicate in 24-well plates at 
1 x 105 cells/mL with TGFβ1 and ASA at 100-3200 µg/mL for 48 h at 37℃ in 5% 
CO2. Cell metabolic activity (N=6, n=3) and cell death (N=4, n=3) were measured 
by MTT and LDH assays, respectively. TritonX-100 at 10% concentration was 
used to assess maximal cell death. Results are presented as mean ± SD. Mean 
and SD values were obtained at OD595 for MTT and OD490/655 for LDH. Readings 
were corrected for background optical density, outliers were removed, and 
treatment group ODs were normalized to the vehicle control OD. ASA, 
acetylsalicylic acid; OD, optical density; VC, vehicle control. One-way ANOVA 
with Tuckey’s post hoc test are indicated *p < 0.05, ***p < 0.001, ****p < 0.0001 
B) 
A) 
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4.3.4 Acetylsalicylic acid decreases TGFβ1-induced 
fibroproliferation-associated proteins 
We assessed the effects of ASA on downstream protein expression within 
TGFβ1-induced HTCFs by western blot. HTCFs (N=3-4, n=1) were co-treated 
with TGFβ1 and ASA at 100, 400 and 1600 µg/mL for 48h. Relative levels of 
myofibroblast-associated proteins—αSMA and MMP9—were measured and 
normalized to GAPDH. HTCFs treated with TGFβ1 displayed an increase in 
αSMA and MMP9 protein levels compared with that of the no-TGFβ1 vehicle 
control (Figure 4-5A and B). A reduction in the levels of both proteins was 
observed after treatment with increasing concentrations of ASA, suggesting that 
ASA decreases the levels of TGFβ1-induced myofibroblast-associated proteins. 
  
A) 
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To supplement the western blot findings, we conducted immunohistochemistry to 
examine the effects of ASA on cell morphology and α-SMA levels. HTCFs treated 
with TGFβ1 exhibited an expanded cell shape with a noticeable increase in linear 
actin filaments when compared to vehicle control (Figure4-6A). After treatment 
with increasing concentrations of ASA, there was an observable reduction in this 
expanded and linear cell morphology. Furthermore, semi-quantitative analysis of 
α-SMA within this assay revealed increased expression after treatment with 
TGFβ1 when compared to vehicle control (Figure4-6B). A significant and dose 
dependent reduction in α-SMA expression was observed with ASA exposure. 
These findings follow a similar trend with those of the western blots, suggesting 
that ASA represses myofibroblast-associated proteins induced by TGFβ1. 
B) 
Figure 4-5 ASA decreases TGFβ1-induced protein levels. HTCFs (N=4) were co-
cultured in 6-well plates at 105 cells/mL with TGFβ1 and ASA for 48 h at 37℃ in 
5% CO2. Relative protein levels were measured by western blot. A) Results of 
densiometric analysis are presented as mean ± SD normalized to GAPDH with 
one-way ANOVA with Tuckey’s post hoc test are indicated *p < 0.05, ***p < 
0.001, ****p < 0.0001. B) Images of representative blots for each protein. ASA, 
acetylsalicylic acid; α-SMA, alpha-smooth muscle actin; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; VC, vehicle control. 
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B) 
Figure 4-6 ASA decreases TGFβ1-induced myofibroblastic changes. HTCFs 
(N=3, n=2) were co-cultured in 24-well plates at 105 cells/mL with TGFβ1 and 
ASA for 48 h at 37℃ in 5% CO2. A) Area of α-SMA was obtained through 
ImageJ analysis and normalized to nuclei number. α-SMA levels are 
presented as mean ± SD. Results from a one-way ANOVA with Tukey’s post 
hoc test are indicated:  *p < 0.05, ***p < 0.001, ****p < 0.0001. B) α-SMA (red) 
and F-actin (green) expression were assessed by immunohistochemistry ASA, 
acetylsalicylic acid; α-SMA, alpha-smooth muscle actin; VC, vehicle control. 
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4.3.5 Acetylsalicylic acid triggered lipid mediators decrease TGFβ1 
induced alpha-smooth muscle actin expression 
We assessed whether exogenous treatment of ASA-triggered lipid mediators 
would yield the same effect as treatment with ASA on TGFβ1-induced HTCFs. 
We conducted western blots to assess relative levels of the myofibroblast-
associated protein, α-SMA, after lipid mediator treatment. HTCFs (N=7, n=1) 
were co-treated for 48 h with TGFβ1 and lipid mediator 5(R)-HETE, 11(R)-HETE, 
15(R)-HETE, and 17(R)-OHDHA at concentrations 10, 100, and 1000 ng/mL. 
HTCFs treated with TGFβ1 alone displayed a significant increase in α-SMA level 
compared to vehicle control (Figure 4-7). A significant reduction in α-SMA was 
observed after treatment with 5(R)-HETE, 15(R)-HETE and 17(R)-OHDHA at 100 
and 1000 ng/ml, however, no significant difference was observed after treatment 
with 11(R)-HETE. These findings suggest that the downstream lipid mediators 
triggered by ASA can, themselves, repress myofibroblast-associated proteins.  
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Figure 4-7 Exogenous lipid mediators decrease TGFβ1-induced α-SMA levels. 
HTCFs (N=6, n=2) were co-cultured in 6-well plates at 105 cells/mL with TGFβ1 
and lipid mediators: 5R-hydroxyeicosatetraenoic acid (HETE), 11(R)-HETE, 
15(R)-HETE and 17(R)-hydroxy docosahexaenoic acid (17-OHDHA) for 48 h at 
the indicated concentrations (nM). α-SMA levels were measured by western blot. 
Results are normalized to GAPDH and presented as mean ± SD. Dotted line 
represents α-SMA densitometry after treatment with TGFβ1 alone. One-way 
ANOVA with Tukey’s post hoc test *p < 0.05, ***p < 0.001, ****p < 0.0001. 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; VC, vehicle control. 
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4.4 Discussion 
We have demonstrated, for the first time, that inflammation and wound healing 
cytokines found within the aqueous humor illicit high levels of PG production 
within HTCFs. PG production and the associated heightened metabolic activity 
can be mitigated by ASA exposure, at the same time as inducing the production 
of ASA-triggered resolving mediators. Both ASA and the exogenous applications 
of ASA-triggered lipid mediators were found to repress TGFβ1-induced cellular 
metabolic activity and protein expression in human Tenon’s capsule fibroblasts, 
suggesting that this signaling system is capable of impeding the propagation of 
both inflammatory and fibroproliferative processes. Indeed, results from the cell-
mediated collagen contraction and remodeling assays demonstrate ASA’s ability 
to impair cell mediated wound healing phenomena in vitro. 
TGFβ1, as well as its other two isoforms, are present in aqueous humor235 and 
are implicated in post-surgical scarring by inducing the transdifferentiation of 
fibroblasts into myofibroblasts.1,4 Based on the MTT results, ASA seems to 
reverse the effects of TGFβ1 in a dose-dependent manner by decreasing TGFβ1-
induced cell metabolic activity. This finding is most prominently observed at ASA 
concentration 1600 µg/mL, where TGFβ1-induced metabolic activity returns to 
the baseline control level. Previous studies have observed a similar decline in 
metabolic activity either after treatment at a single ASA concentration on non-
human fibroblasts,236,237 or after treatment at multiple concentrations of ASA on 
non-fibroblast cell lines.238–241 Therefore, to our knowledge, our study is the first 
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to elucidate a dose-response to ASA in TGFβ1-induced human Tenon’s capsule 
fibroblasts.  
Furthermore, in the LDH assay, no notable increase in necrotic cell death was 
observed, even at increasing ASA concentrations. This finding indicates that the 
ASA concentrations tested are not cytotoxic to the fibroblasts, which aligns with 
work from other research groups that have demonstrated the protective effects of 
ASA against inflammation induced cellular damage.242–244 Together, the MTT and 
LDH results suggest that ASA may be inactivating—rather than killing—TGFβ1-
induced fibroblasts, which subsequently lowers their metabolic activity level to 
that of the pre-inflammation-induced state. On theoretical grounds, these results 
may translate to a desirable outcome in vivo by decreasing fibroblast scarring 
activity after glaucoma filtration surgery without inducing lethal effects on healthy 
tissues. 
We have also examined the downstream effects of ASA on expression of TGFβ1-
induced proteins, such as α-SMA and MMP-9. Western blot analysis 
demonstrates that ASA represses the levels of both scarring associated proteins, 
suggesting that ASA may mitigate the scar-forming potential these TGFβ1-
induced fibroblasts. Immunohistochemistry imaging confirmed these findings and 
further demonstrates the ability of ASA to resolve the linear actin contractile fibers 
induced by TGFβ1. These results are strengthened by the work from other 
research groups, which have found a similar reduction in fibrosis-associated 
proteins expression after ASA treatment in human236 and mouse237 fibroblasts, as 
well as in other cell types.238–241 ASA’s ability to represses TGFβ1-induced 
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proteins that are implicated in fibrosis suggests that ASA may mitigate the ability 
of these cells to form scar tissue in vivo after filtration surgery. 
After exogenous treatment of ASA-triggered lipid mediators, we have observed a 
decrease in α-SMA levels within TGFβ1-induced HTCFs. This suggests that 
downstream lipid mediators generated by ASA may have a role in transducing 
the intracellular effects of ASA exposure. These findings align with those of 
previous studies, which have demonstrated the ability of 5(R)- and 15 (R)-HETE 
to reduce fibrosis in mice,35 and 17(R)-OHDHA was also found to be involved in 
resolution in humans.230,231,245 We observed no effect with treatment of 11(R)-
HETE across the three concentrations tested. This was encouraging as it is not 
considered an ASA-triggered lipid mediator, but the oxygenation product of 
cytochrome P450 enzymes acting upon arachidonic acid.6 
A limitation in this study is that the effects of ASA were assessed on a single cell 
type. The chronic inflammatory micro-environment implicated in scarring after 
filtration surgery involves the interaction of many different cell types, such as 
immune cells, which cannot be completely recreated with the exogenous 
inflammatory cytokine application.70,71 Therefore, future research may explore the 
lipid mediator modulating effects of ASA within a fibroblast-immune cell co-culture 
system.  
In conclusion, we have shown that ASA and its associated lipid mediators shift 
lipid mediator production from pro-inflammatory to pro-resolving, inhibit in vitro 
wound healing phenomena. Data support that these findings are likely due to a 
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reversal of TGFβ1-induced metabolic activity and protein expression in HTCFs 
with exposure to ASA/ASA-triggered lipid mediators. These findings expand our 
understanding of the mechanism of ASA as an anti-inflammatory and anti-
scarring agent in TGFβ1-induced HTCFs and provide the foundation for future in 
vivo research, which may potentially explore the effects of topical ASA application 
for ophthalmic pathologies. With the well-established safety profile of ASA in 
human patients, translation of these findings may be rapid. 
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Chapter 5  
5 Acetylation of COX2: An Immuno-resolving and Anti-
Cicatrizing Ocular Intervention3 
 
 
Building on the promising results of Chapter 5, this chapter sought to further 
modulate the production of LMs. Theoretically, after ASA acetylation, all 
enzymatic machinery downstream of PLA2 – acetyl-COX2 and the endogenous 
LOX enzymes – will act on PUFA precursors to generate RMs. This would 
suggest that agonizing the activity of PLA2 under these conditions would 
theoretically lead to increased PUFA precursor generation for downstream 
processing into RMs. In Chapter 6, to test this hypothesis, we used ASA and a 
second, more COX2 specific acetylating molecule to induce COX acetylation in 
the presence of two separate PLA2 agonists. The effects of these interventions 
on the in vitro wound healing phenomena of subconjunctival fibroblasts are 
presented. 
  
                                                 
3
 Parts of this chapter have been patented: Armstrong, J.J. and Hutnik, C.M.L. 2018. Compositions and 
methods for treating ocular inflammation and ocular scarring. U.S. Provisional Patent Application No. 
62/677,284, filed May 2018. Provisional status until May 2019. 
Submission for peer reviewed publication will follow patent approval. 
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5.1 Introduction 
Inflammation driven myofibroblast transdifferentiation and activity is at the heart 
of much currently unanswered ocular morbidity. Glaucoma filtration surgery, 
corneal stromal injury, posterior capsule opacification after cataract surgery, 
proliferative vitreoretinopathy and the sub-macular scarring associated with age-
related macular degeneration are some major contributors to ocular morbidity 
with myofibroblast transdifferentiation at the core of the pathology.1 More broadly, 
estimates implicate fibroproliferative disease in 45% of morbidity and mortality at 
a systemic level in the developed world246 – it is unsurprising that the eye mirrors 
the rest of the body in unanswered contributors to mortality. Recent changes in 
our understanding of inflammation and, more importantly, its endogenously 
controlled resolution necessitate a reimagining of treatments for inflammation 
driven scarring. 
Over the past twenty years, our understanding of inflammation and its resolution 
has shifted. Long have the prostaglandin family of lipid mediators, derived from 
cyclooxygenase 2 (COX2), been tied with the cardinal signs of inflammation. 
More recently, however, we have come to understand the subsidence of these 
cardinal signs, or the resolution of inflammation, to be an active process that is 
endogenously controlled by the pro-resolving superfamily of lipid mediators.16 
These resolving mediators (RMs) are produced mainly from the actions of 
lipoxygenase (LOX) enzymes on the polyunsaturated fatty acid (PUFA) 
precursors arachidonic acid (AA), eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA).10 The actions of RMs on inflammatory cells have 
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been well established (i.e. inhibiting tissue infiltration of polymorphonuclear 
(PNM) cells, promoting phagocytosis of cellular and wound debris, and 
decreasing the antibiotic requirements for bacterial clearance) and their 
cumulative effects are understood to decrease the duration and impact of 
inflammation-induced cellular activity.28,247 
Fibroblasts have been considered by some to be early sentinels of the immune 
system, capable of both mounting and modulating inflammatory processes.30 
Further, the process of fibroproliferation itself could be considered an appropriate 
innate immune response to contain certain infectious organisms that can evade 
immune cell killing. If myofibroblasts were to be modelled as inflammation-
activated fibroblasts, one would expect high levels of endogenous prostaglandin 
production to be observed within the myofibroblast phenotype. It would then 
follow that, if RM secretion was promoted and resolution triggered, myofibroblasts 
may abrogate their fibroproliferative activity. In fact, much recent work has 
demonstrated the anti-fibrotic properties of RMs when stimulated endogenously 
through overexpression of lipoxygenase enzymes,35 or when applied 
exogenously as individual lipid mediators.21,36,37,248 
Therapeutically, the endogenous stimulation of RMs can be accomplished 
through a specific in situ acetylation of COX2. Acetylation at specific residues 
induces a change in enzymatic function and repurposes COX2 from an 
endogenous producer of pro-inflammatory prostaglandins, to one that resembles 
a LOX enzyme in function and produces RMs. Recently, an enzyme endogenous 
to murine neurons was found to acetylate murine COX2 at Ser565. The authors 
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noted that acetylation of COX2 by this enzyme impaired PG production, enabled 
production of RMs and induced resolution of dysfunctional microglial 
inflammation within the Alzheimer’s disease model they employed.249 These 
findings illustrate a naturally occurring example of COX2 repurposing. 
Acetylsalicylic acid (ASA) was long thought to inactivate COX2 through 
acetylation of Ser516,250 however we now understand this modification to not 
only inhibit prostaglandin production, but to also enable RM generation through 
the acetylated enzyme.10,224,251–253 This property of ASA has been measured in 
enzymatic assays,224 cell-based systems228 as well as in human subjects taking 
ASA in a randomized controlled trial.226 
Prior to understanding the potential immuno-resolving impact of generating RMs 
from acetylated COX2, several COX2 specific acetylators were developed as 
potential inhibitors of prostaglandin production.225 However, little is known 
regarding the potential of more specific COX2 acetylators to trigger the 
production of LMs akin to ASA. As COX1 function is abrogated completely by 
acetylation, one would hypothesize that a more specific COX2 acetylator would 
lead to more acetyl groups being attached to COX2 enzymes relative to COX1 
enzymes and therefore illicit greater RM production than a non-specific COX2 
acetylator such as ASA. This would be especially true in the setting of high levels 
of inflammation induced COX2. From this we hypothesized that acetylating COX2 
in a pro-inflammatory and wound healing microenvironment would lead to 
increased generation of RMs relative to prostaglandins and decreased in vitro 
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cell-mediated wound healing phenomena through the impairment of 
myofibroblast transdifferentiation and activity. 
5.2 Materials and Methods 
5.2.1 COX2 Acetylating Agents and PLA2 Agonists 
To our knowledge, the most specific COX2 Ser516 acetylating agent identified to 
date is o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS),225,254 which was purchased 
from Santa-Cruz Biotechnology (Catalog #sc-200668). ASA was purchased from 
Sigma Aldrich (A5376). Both melittin (M4171) and gentamicin (G1391) were 
purchased from Sigma-Aldrich. Molecular structures with key moieties are 
displayed in Figure 5-1. Structures of COX1 and COX2 are shown in Figure 5-2. 
Figure 5-1 A) depicts 
the molecular structure 
of ASA. B) depicts the 
molecular structure of 
APHS. C) summarizes 
how the molecular 
moieties of ASA/APHS 
have been shown to 
interact with the active 
site of COX1/2. 
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Figure 5-2: A) displays a schematic representation of COX1 and COX2. The 
location of Ser530 and Ser516 are indicated in bold (the residues acetylated by 
ASA and APHS on COX 1 and 2, respectively). Other key residues are indicated 
for schematic orientation. Important differences to note are the larger overall size 
of COX2 vs COX1 (72 kDA vs 68 kDa) and the hydrophobic side pocket on 
COX2 absent in COX1. B) displays the same schematic representations of COX1 
and COX2, with ASA superimposed over the active site of COX1 and APHS 
superimposed over the active site of COX2. The longer, hydrophobic tail of APHS 
leverages the overall larger enzymatic structure and side pocket unique to COX2 
in order to attain 60x greater affinity to COX2 compared to ASA. ASA has 
approximately 20x greater specificity to COX1 vs. COX2. 
 119 
 
5.2.2 Inflammatory and Wound Healing Cytokines 
Ocular tissues respond to injury or insult by eliciting the cellular programs defined 
grossly as inflammation and wound healing. Specific factors, found within the 
aqueous humor and surgical sites of ophthalmic patients, are thought to drive 
inflammatory and fibroproliferative responses observed in ocular tissues.84–88 To 
model these in vitro, we used physiologically relevant mixtures (1ng/ml each) of 
inflammatory and wound healing cytokines IL-1β (SRP6169), TNFα (SRP2102), 
INFɣ (MSST0040) and TGFβ1 (T7039), all from Sigma-Aldrich.  
5.2.3 Isolation and Culture of Tenon’s Capsule Fibroblasts 
This study followed the tenants of the Declaration of Helsinki and was approved 
by the office of Human Research Ethics at Western University (REB# 106783). 
Primary ocular fibroblast cell lines were derived from 2-4 mm3 surgically resected 
segments of Tenon’s capsule. After the acquisition of informed consent, tissue 
specimens were obtained from male and female glaucoma patients undergoing 
primary trabeculectomy at St. Josephs’ Hospital, London, Canada. The samples 
were obtained by ophthalmic surgeons who removed segments of Tenon’s 
capsule and placed them into primary culture growth media containing Dulbecco 
modified Eagle's minimal essential medium (DMEM), 10% Fetal Bovine Serum 
(FBS), 1% penicillin/streptomycin, and 1% amphotericin, all from Sigma-Aldrich 
(Oakville, Canada). After, specimens were placed in fibronectin (Sigma-Aldrich) 
coated 6-well culture plates, submerged in primary culture media, and 
subcultured upon confluency for further use. Cell cultures were used for 
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experimentation prior to passage five. Table 3-1 provides a summary of donor 
characteristics for the ocular fibroblast cell lines used in experiments. 
5.2.4 Stimulated Lipid Mediator of Inflammation / Resolution 
Secretion Assays 
Relative quantification of secreted pro-inflammatory and pro-resolving lipid 
mediators was achieved using liquid chromatography tandem mass spectrometry 
(LC-MS/MS). Specifically, we focused our analyses on the COX2 derived lipid 
mediators, kPGF1a and PGE2; as well as the acetyl-COX2 derived mediators, 5-
HETE, 15-HETE, 17-OHDHA and 18-HEPE; and their PUFA precursors, AA, 
DHA and EPA. Known quantities of deuterated internal standards of the analyzed 
the lipid mediators were added to each sample to enable relative quantification 
between samples (Item Numbers: #10007737, #320110, #314010, #11182, 
#315210, #319030, #390030, #10006410, #10006199, #334230, and 
#10008040, Cayman Chemical). This is a well-established method to determine 
the relative activity of lipid biosynthetic pathways.233,234 In brief, the ratios of the 
integrated areas of the chromatographic peaks corresponding to each analyte 
and the integrated areas of the peaks corresponding to each analyte’s internal 
standard (with known absolute quantity) are used to determine the relative 
quantity of each analyte in a given sample. After supernatant sample collection, 
250ul of methanol containing 100pg of each deuterated internal standard was 
added. Samples were then vigorously vortexed and centrifuged at 10,000g for 
10min before loading onto solid-phase extraction cartridges (Strata-X 33um 
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Polymeric Reversed Phase, 10mg, Phenomenex 8B-S100-AAK), that were 
previously activated with 2ml methanol and rinsed with 2ml water. Samples were 
diluted upon loading so that the final concentration of methanol was between 10 
and 15% of total volume. After washing with 5ml water, extracts were eluted with 
1ml methanol. Solvent was then evaporated under vacuum in a SpeedVac 
centrifuge, and the extract was resuspended in 100μl acetonitrile/water 60:40 
(v/v). An aliquot of 20μl was injected into the LC-MS/MS system for analysis. A 
Sciex ExionLC Integrated System was used with a 0.3ml/min flow rate, initial 
mobile phase of 10% water / 0.1% formic acid followed by 100% acetonitrile / 
0.1% formic acid on a Kinetex 2.6um C18 100 Å 100x2.1mm, Phenomax column 
(OOD-4462-AN). A Sciex Triple Quad 6500+ mass spectrometer with multiple 
reaction monitoring was used in negative ion mode. The chromatographic profile 
of the ion count for each m/z transition was monitored, and the area under the 
peaks (ion intensity vs elution time) was integrated using commercial software 
(MultiQuant, Sciex). Total cellular protein concentration was used for 
normalization of the supernatant samples. 
5.2.5 Collagen Contraction Assays 
The delayed release fibroblast populated collagen lattice model,185 based on the 
model first proposed by Bell,186 was used to assess the effects of experimental 
treatments on ocular fibroblast-mediated gel contraction. In brief, ocular 
fibroblasts were mixed within an extracellular matrix (ECM) mixture containing 
80% type I collagen (1.8mg/ml; A1048301, Gibco), 16% neutralizing solution 
(equal parts Waymouth media (Sigma-Aldrich) and 0.275M NaOH) and 4% 
 122 
 
vol./vol. ocular fibroblast conditioned media (concentrated to 25x to obtain a 1x 
final concentration within the 500μl construct volume) in order to achieve a final 
cell density of 2.5 x 105 cells/mL within the solution. Cell free collagen lattices 
were prepared identically, albeit without the inclusion of ocular fibroblasts, as 
negative control. The solution was pipetted gently to ensure homogenous 
distribution of ocular fibroblasts while avoiding the production of air bubbles, then 
500μl were pipetted into each well of a 24-well tray. Collagen constructs were 
allowed to polymerize at 37°C and 5% CO2 for 45 minutes before adding low 
serum culture media containing DMEM, 2% Fetal Bovine Serum (FBS), 1% 
penicillin/streptomycin. 
After incubation at 37°C and 5% CO2 for 72 hours, a sterile spatula was used to 
detach each collagen construct from the edges of the culture well. Plates were 
then immediately scanned on a flatbed laser scanner (Scanjet 8200, Hewlett-
Packard) to record baseline area, and then periodically for the duration of the 
experiment. The surface area of each collagen construct was measured using 
ImageJ187 and standardized against the baseline surface area measurement to 
express changes in area as a percentage of original surface area. 
5.2.6 Collagen Remodeling Assays 
To assess collagen remodeling unconfounded by cell-mediated contraction, 
collagen constructs were left attached to culture wells for the duration of the 
experiment. At experimental conclusion (12 days incubation), collagen constructs 
were fixed in 4% paraformaldehyde for 3h. After fixation, they were dehydrated in 
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ethanol, embedded in paraffin blocks, sectioned (5µM) and mounted on glass 
microscope slides using standard methods. Sections were deparaffinized and 
hydrated using standard protocols. Sections were then stained with picrosirius 
red. Briefly, a solution of 0.1% Sirius red in saturated picric acid was applied for 
60 min, followed by 2 x 0.5% acetic acid washes. Collagen birefringence, used to 
determine collagen fibrillar hue,188 was assessed by circularly polarized light 
microscopy of picrosirius red stained sections. Images were taken with an Abrio 
quantitative birefringence imaging system (Hinds Instruments) mounted on an 
Olympus BX-51 microscope. Specifically, a constant light intensity, a 45° angle to 
the polarizing filter and the same analyzer were used to facilitate comparisons 
between each sample. 
When viewed under polarized light, the color of the collagen fibers stained with 
picrosirius red depends upon fiber thickness, spatial orientation and packing 
density; with the color changing from blue to yellow to orange to red as fiber 
maturity, thickness and density increase.189,190 This method has been used 
previously in rabbit experimental filtration surgery to examine subconjunctival 
fibrosis, and blue(green)/yellow staining was associated with improved bleb 
function.105 Using ImageJ, this property was leveraged to determine the relative 
proportions of different color fibers within the stained collagen constructs. This 
quantitative method has been previously described,191 and is employed within the 
current experiment to assess changes in collagen architecture due to the 
remodelling activity of ocular fibroblasts. In short, relative color content of the 
images is obtained by separating the digital images into their hue, saturation and 
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value components. The hue component contains information on the color of each 
pixel within the image. Every pixel can have one of 256 possible colors. To 
identify the relative proportions of red, orange, yellow and blue pixels within a 
given image, a propriety script was written and run using the following hue 
definitions within ImageJ: red 2-9 and 230-256, orange 10-38, yellow 39-51 and 
green 52-128. The number of pixels within each hue range is calculated and 
expressed as a proportion of the total number of pixels. 
5.2.7 Fluorescent Microscopy 
Expression of the contractile protein alpha smooth muscle actin (α-SMA), the 
myofibroblastic phenotype marker,255 by ocular fibroblasts within collagen 
constructs was assessed through immunohistochemistry. Deparaffinized and 
hydrated sections were permeabilized for 30 minutes with 1% Triton X-100 in 
PBS. After blocking of nonspecific sites with 1% BSA in PBS, sections were 
incubated for 40 minutes with Alexa Fluor 568–conjugated primary antibody 
against α-SMA (Abcam, CAT. NO: ab202295). Finally, slides were stained with 
4,6-diamidino-2-phenylindole for 10 minutes. For each tissue section, the area 
positive for α-SMA staining was measured in ImageJ and then divided by the 
number of nuclei counted within that same frame, this number was then 
compared between treatment groups. Ten random frames were taken per tissue 
section, with five tissue sections imaged per patient cell line and treatment group. 
Cellular proliferation was assessed through immunohistochemistry. Briefly, 
deparaffinized and hydrated sections were permeabilized for 30 minutes with 1% 
 125 
 
Triton X-100 in PBS. After blocking of nonspecific sites with 1% BSA in PBS, 
sections were incubated for 40 minutes with Alexa Fluor 568–conjugated primary 
antibody against Ki-67 (Abcam, CAT. NO: ab197234) a marker of active cellular 
proliferation.256 Slides were then stained with 4,6-diamidino-2-phenylindole for 10 
minutes and imaged with a laser-scanning confocal microscope (A1R HD; Nikon 
Instruments Inc., Tokyo, Japan). Cells were counted by nuclei using ImageJ, and 
the proportion expressing Ki-67 was taken as an estimate of relative cellular 
proliferation between treatment groups. Ten random frames were taken per 
tissue section, with five tissue sections imaged per patient cell line and treatment 
group. 
Collagen constructs were cast with equal cell density, therefore there should be 
equal variance in cell density between treatment groups after the experimental 
incubation period. This was assessed through fluorescent microscopy. Briefly, 
deparaffinized and hydrated sections were permeabilized for 30 minutes with 1% 
Triton X-100 (Sigma-Aldrich) in PBS (Sigma-Aldrich). Slides were then stained 
with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for 10 minutes and 
imaged with a laser-scanning confocal microscope (A1R HD; Nikon Instruments 
Inc., Tokyo, Japan). Relative cell density was determined by cell (nucleus) count 
standardized to area of collagen autofluorescence (in pixels) within each section 
and measured using ImageJ. Ten random frames were taken with the 40x 
objective per tissue section, with three tissue sections imaged per patient cell line 
and treatment group. The laser intensity settings were kept consistent between 
slides to facilitate consistent comparison between replicates. 
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5.2.8 LIVE/DEAD Cytotoxicity Assays 
To assess the relative cellular viability between different experimental conditions, 
an in situ fluorescence-based LIVE/DEAD assay was used. This is a well 
reported method for estimating the cytotoxicity of an intervention. In brief, two 
florescent dyes, fluorescein diacetate and propidium iodide, are added to the 
culture media surrounding the collagen constructs. Fluorescein diacetate is 
converted into a blue fluorescent molecule by esterases within living cells. 
Propidium iodide (red) cannot pass through a viable cell’s membrane, however it 
can penetrate disordered areas of dead cell membranes and then intercalates 
with the nuclear DNA. After a 5min incubation with the staining solution, collagen 
constructs were washed with PBS and immediately imaged on a laser-scanning 
confocal microscope (A1R HD; Nikon Instruments Inc., Tokyo, Japan). Ten 
random frames were taken with the 20x objective per tissue section, with three 
tissue sections imaged per patient cell line and treatment group. The laser 
intensity settings were kept consistent between samples to facilitate consistent 
comparison between replicates. 
Using imageJ, blue signals were counted as living cells and totalled within every 
frame. The same was done for red signals, and these were counted as dead 
cells. The ratio of living (blue) to total (blue+red) cells was recorded. 
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5.2.9 Cell Culture and Western Blot 
Ocular fibroblasts were grown in 6-well culture plates in DMEM with 10% FBS at 
37°C and 5% CO2 until 80-90% confluent. The cultures were then starved of 
serum for 24hrs, after which they were switched to experimental treatment media. 
For experiments involving inhibition of PPARɣ, we used the small molecule 
inhibitor GW9662 (Item Number: #70785, Cayman Chemical) at a concentration 
of 1uM.  
After 48hrs incubation with the indicated experimental treatment, western blot 
was used to assess relative protein expression between the experimental 
treatment groups. Briefly, cells were lysed in lysis buffer (PhosphoSafe Extraction 
Reagent, Novagen) containing a protease inhibitor cocktail (P2714, Sigma-
Aldrich) and the crude protein lysate (10μg) was resolved using a Novex 
WedgeWell 4-20% tris-glycine gel (Invitrogen). Using an iBlot Gel Transfer 
Device (IB1001, Invitrogen), the separated protein was transferred to a 
nitrocellulose membrane (IB301001, iBlot Transfer Stack, Invitrogen) which was 
then blocked with 5% (w/v) bovine serum albumin (Sigma- Aldrich) in Tris 
buffered saline (TBST) for 1 hour at room temperature. The membranes were 
incubated overnight at 4°C with primary antibody diluted in TBST containing 5% 
BSA (w/vol). Primary antibodies used were as follows: collagen 1 (ab138492, 
Abcam), αSMA (ab5694, Abcam), MMP9 (ab38898, Abcam), PPARɣ (sc-7273, 
SantaCruz Biotechnology), SMAD2/3 (ab63672, Abcam), pSMAD2/3 (ab63399, 
Abcam) and GAPDH (sc-47724, Santa Cruz Biotechnology, Inc.). After incubation 
with primary antibodies, the blots were washed and hybridized with 1:3000 (v/v) 
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dilutions of goat anti-rabbit or anti-mouse IgG conjugated with horseradish 
peroxidase (Santa Cruz Biotechnology, Inc.). Visualization was accomplished by 
applying WesternBright Quantum chemiluminescent reagent (Advansta, Inc.), 
with GAPDH used as a protein loading control. Imaging and relative densiometric 
quantification was accomplished using a ChemiDoc MP System (Bio-Rad 
Laboratories, Inc.) connected to Image Lab (Version 6, Bio-Rad Laboratories, 
Inc.). 
5.2.10 Statistical Analysis 
For reporting purposes, “N” denotes the number of biological replicates within an 
experiment and “n” denotes the number of technical replicates performed of each 
biological replicate. Comparisons between two groups were accomplished with 
Student’s t test. When more than two groups were compared to each other at a 
single time point, a one-way analysis of variance was used, followed by Tukey’s 
post hoc test if necessary. In cases where more than two groups were compared 
to each other at multiple time points, a two-way analysis of variance was used, 
followed by Dunnett’s multiple comparisons post hoc test with a single pooled 
variance if necessary. All statistical analyses were performed using Prism 8 
(Version 8.01, GraphPad Software Inc.) statistical software. Values for *p < 0.05, 
**p < 0.01, ***p < 0.001, and ****p < 0.0001 were considered significant. 
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5.3 Results and Discussion 
5.3.1 Within inflammation induced fibroblasts, melittin increases 
the production of acetyl-COX2 products relative to COX2 
products after ASA exposure 
Relatively small amounts of acetyl-COX2 products have been measured in vivo 
after ASA-induced COX2 acetylation in humans.226 This led us to hypothesize 
that the acetylated COX2 enzyme may be limited in its production of acetyl-COX2 
products, potentially by the competitive inhibitory activity of the co-localized 
salicylate ion – the byproduct of ASA’s de-acetylation. In an effort to displace the 
salicylate ion from the active site of acetyl-COX2, we employed an extremely 
potent phospholipase A2 agonist to increase the availability of PUFA precursors 
for downstream processing through COX2 or acetyl-COX2. Melittin, isolated from 
wasp venom, directly increases the activity of PLA2 and is responsible for the 
swelling associated with their sting. It was previously measured to profoundly 
increase the production of AA by PLA2 in cell based systems.257,258 
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To assess the impact of COX2 Ser516 acetylation on inflammation induced 
ocular fibroblasts, they were pre-incubated with inflammatory and wound healing 
cytokines (Inf. Cytokines: 1ng/ml each of IL-1β, TNFα, INFɣ and TGFβ1) for 12 
hours before being treated with vehicle, ASA alone or ASA+Melittin (a potent 
phospholipase A2 agonist). Melittin significantly increased the relative abundance 
of precursor PUFA’s compared to both vehicle and ASA only treated ocular 
fibroblasts, by 200 to 400 fold (Figure 5-3A-C). ASA alone impaired the secretion 
of PG products kPGF1a (Figure5-3D) and PGE2 (Figure5-3E), however no 
significant increases were observed in acetyl-COX2 derived products, 5-HETE 
(Figure5-3F), 15-HETE (Figure5-3G), 17-OHDHA (Figure5-3H) and 18-HEPE 
(Figure5-3I). When melittin was combined with ASA, significant increases were 
observed in all lipid mediators analyzed (Figure5-3D-I). While the relative PG 
secretion was increased by approximately 2 to 20-fold, the relative RM secretion 
was increased by 3 to 400-fold – depending on the mediator analyzed. This 
suggested that a small fraction of un-acetylated COX2 was still present at the 
concentration of ASA assayed, however, a much greater proportion of the 
acetylated enzyme was likely present which accounts for the dramatic relative 
difference observed in COX2 vs. acetyl-COX2 product secretion. 
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Figure 5-3 Relative inf. cytokine-induced LM secretion was determined by 
supernatant sampling and LC-MS/MS analysis at the indicated timepoints after 
exposure of inf. cytokine induced ocular fibroblasts to the indicated experimental 
treatment. A-C) PUFA precursors: AA, EPA and DHA. D-E) COX2 prostaglandin 
products: kPGF1a and PGE2. F-I) Acetyl-COX2 RM products: 5-HETE, 15-
HETE, 18-HEPE and 17-OHDHA. A-I) Two-way ANOVA with Dunnett’s post hoc 
test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 5-4 summarizes the relative biosynthetic activity of acetyl-COX2 vs. COX2 
enzymes. The mean relative production of COX2 products (PGE2 and kPGF1a) 
was calculated and from this figure the mean relative production of acetyl-COX2 
products (5-HETE, 15-HETE, 17-OHDHA and 18-HEPE) was subtracted. This 
way a value of zero would indicate equal relative biosynthetic activity between 
acetyl-COX2 and COX2 enzymes; positive values would indicate COX2 
dominated biosynthesis of lipid mediators; and negative values would indicate 
acetyl-COX2 dominated lipid mediator biosynthesis. Under induced inflammatory 
conditions, ASA slightly reduces the proportion of COX2 derived products relative 
to acetyl-COX2 products, and that the addition of melittin causes a profound shift 
toward acetyl-COX2 dominated lipid mediator production - by several orders of 
magnitude (Figure5-4A). 
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Figure 5-4 Lipid mediator secretion is shifted from a pro-inflammatory to a pro-
resolving profile. Graphs display the differential mean relative secretion between 
pro-inflammatory mediators (PGE2 and kPGF1a) and pro-resolving mediators (5-
HETE, 15-HETE, 18-HEPE and 17OH-DHA). A value of zero indicates equal 
relative biosynthetic activity between acetyl-COX2 and COX2; positive values 
indicate COX2 dominated biosynthesis of lipid mediators; and negative values 
indicate acetyl-COX2 dominated lipid mediator biosynthesis. Supernatant was 
sampled from cultured ocular fibroblasts after co-incubation with inf. cytokines 
and one of: A) ASA ± melittin (µg/ml, N=3), B and C) ASA ± gentamicin (µg/ml, 
N=4), or D) APHS ± gentamicin (µg/ml, N=4) at the indicated timepoints. The 
vehicle control was serum free DMEM and did not contain inf. cytokines. 
Differential mean relative secretion: ((PGE2 + kPGF1a) / 2) – ((5-HETE + 15-
HETE + 18-HETE + 17-OHDHA)/4). Two-way ANOVA with Dunnett’s post hoc: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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5.3.2 Less potent PLA2 agonist and more specific COX2 Ser516 
acetylating agent exert similar modulatory effects on lipid 
mediator production 
Previous authors have modelled lipid derived signaling molecules similar to 
neurotransmitters in that, theoretically, modulation of signaling activity should be 
preferred to its abrogation.259 The concept of modulating the production of LMs to 
avoid the negative consequences of inflammation on patient tissues is not new. 
The competitive NSAID drugs partially block COX2, eliciting a dampening of PG 
production and therefore mitigating their impact. However, altering enzymatic 
activity in order to stimulate PUFA precursor production at the same time as 
redirecting the bulk of the downstream, now acetylated, COX2 enzymatic activity 
toward RM production is a novel approach, and has the potential to function as 
an immuno-resolvent intervention. Immuno-resolvents are theoretically preferable 
to immuno-suppressive modalities. Thus, we wished to determine if additional 
molecules with similar effects on COX2 and PLA2 could recreate the modulatory 
effects observed in the previous LM secretion experiment with ASA and melittin.  
The second LM secretion experiment we conducted involved the gentler PLA2 
agonist, gentamicin,260 and the more potent COX2 Ser516 acetylating agent, 
APHS. APHS possesses the same COX2 Ser516 acetylating function as ASA, 
and, due to its larger lipophilic structure, it was shown to be approximately 20x 
more specificity for COX2 over COX1.254 For reference, ASA has previously been 
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measured to have approximately 10 to 20 times greater specificity for COX1 over 
COX2.261,262 
Gentamicin had a small stimulatory effect on the relative secretion of PUFA 
precursors AA, EPA and DHA when compared to the inf. cytokines induction 
group (Figure 5-5A-C). Both ASA and APHS were able to significantly reduce the 
secretion of PG products kPGF1a (Figure 5-5D-F) and PGE2 (Figure 5-5G-I). 
The addition of gentamicin to any experimental treatment group had no effect on 
PG synthesis (Figure 5-5D-I). These results confirmed the ability of both COX2 
Ser516 acetylating agents to prevent PG synthesis within ocular fibroblasts. 
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When examining the secretion of RMs, we noticed ASA had a small stimulatory 
effect on 5-HETE (Figure 5-6A), 15-HETE (Figure 5-6D) and 18-HEPE (Figure 
5-6G) secretion in the presence of inf. cytokines, relative to inf. cytokines alone. 
However, the significant effects observed were transient and small. APHS alone 
had a profoundly significant stimulatory effect on the relative secretion of 5-HETE 
(Figure 5-6C), which peaked at 6hrs and returned to inf. cytokine treated only 
levels by 24hrs. APHS alone also had profound stimulatory effects on 15-HETE 
(Figure 5-6F) and 18-HEPE (Figure 5-6I) secretion under inflammatory 
conditions, relative to inf. cytokine treatment alone, and remained significant past 
48hrs post-treatment. Finally, when ASA or APHS were combined with 
gentamicin, significant and lasting increases in 5-HETE (Figure 5-6B and C), 15-
HETE (Figure 5-6E and D) and 18-HEPE (Figure 5-6H and I) in were observed in 
the presence of inf. cytokines, relative to either ASA or APHS alone in the 
presence of inf. cytokines. To our knowledge this is the first characterization of 
acetyl-COX2 products being triggered by APHS exposure under inflammatory 
conditions. 
  
Figure 5-5 Relative inf. cytokine-induced LM secretion was determined by 
supernatant sampling and LC-MS/MS analysis at the indicated timepoints after 
exposure of inf. cytokine induced ocular fibroblasts to the indicated experimental 
treatment. A-C) PUFA precursors: AA, EPA and DHA. D-I) COX2 prostaglandin 
products: kPGF1a and PGE2. A-I) Two-way ANOVA with Dunnett’s post hoc test: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 5-4B, C and D illustrate the summary effects of ASA, APHS and 
gentamicin on the relative secretion of COX2 vs acetyl-COX2 products. ASA and 
APHS alone were both able to disrupt COX2 activity and induce a significant and 
dose dependent shift toward acetyl-COX2 dominated LM production. When 
gentamicin was combined with ASA or APHS, significantly greater acetyl-COX2 
activity was observed relative to ASA or APHS alone in the presence of inf. 
cytokines. These results support ASA and APHS having similar modulatory 
effects on the production of pro-inflammatory and pro-resolving lipid mediators. 
Results also demonstrate that both melittin and gentamicin can augment the pro-
resolving effects of COX2 acetylating molecules.  
5.3.3 COX2 acetylation inhibits in vitro wound healing, PLA2 
agonist increases effect 
Cell-mediated extracellular matrix contraction is a hallmark of in vivo wound 
healing. We assessed the effects of lipid mediator modulation using ASA and 
gentamicin on cell-mediated collagen contraction. A collagen contraction assay 
with a double dose response for each drug was used to determine the optimal 
concentrations for inhibition of cell-mediated contraction. Gentamicin did not have 
a significant effect on cell-mediated collagen contraction at any tested 
Figure 5-6: Relative inf. cytokine-induced LM secretion was determined by 
supernatant sampling and LC-MS/MS analysis at the indicated timepoints after 
exposure of inf. cytokine induced ocular fibroblasts to the indicated experimental 
treatment. A-C) PUFA precursors: AA, EPA and DHA. D-I) Acetyl-COX2 RM 
products: 5-HETE, 15-HETE and 18-HEPE. A-I) Two-way ANOVA with Dunnett’s 
post hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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concentration (Figure 5-7A). Alone, ASA significantly impaired cell-mediated 
collagen contraction in a dose dependent manner (Figure 5-7B). Gentamicin was 
not able to increase the effect of low dose ASA on cell-mediated collagen 
contraction (Figure 5-7C); however, significantly greater inhibitory effects on cell-
mediated contraction were seen when gentamicin was combined with higher 
doses of ASA (Figure 5-7D and E).  
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Figure 5-7 Effects of ASA and gentamicin on ocular-fibroblast mediated collagen 
contraction. A) Gentamicin alone had no significant effect relative to vehicle 
control on the area of collagen expressed as a proportion of baseline area at any 
timepoint. B) ASA alone had a dose dependent inhibitory effect. C) The effects of 
500 µg/ml ASA were not significant, and not potentiated significantly by 
gentamicin, although a trend was evident. D) The effects of 1000 µg/ml ASA 
were significantly inhibitory, and gentamicin significantly increased the observed 
inhibition. E) The effects of 1500 µg/ml ASA were significantly inhibitory, and 
gentamicin significantly increased the inhibition observe. A-E) Two-way ANOVA 
with Dunnett’s post hoc test: N=3, n=2; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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Two-drug dose-optimization is illustrated in Figure 5-8A. Complete inhibition of 
cell-mediated collagen contraction was achieved with 2000 μg/ml of ASA and 
1000μg/ml gentamicin (Figure 5-8B). Cell-mediated collagen remodeling was also 
assessed under the indicated treatment conditions (Figure 5-8C). Cell free 
collagen matrices stained a uniform blue with picrosirius red staining, indicating a 
homogeneous and loosely packed collagen fibril arrangement. When ocular 
fibroblasts were cultured within the collagen matrices, areas of red, orange and 
yellow staining became apparent, which are regions of high collagen fibril density 
and are inferred to indicate the local occurrence of cell-mediated collagen 
remodeling. ASA alone was able to decrease the relative proportion of red, 
orange and yellow stained collagen fibrils within matrices containing ocular 
fibroblasts, implying an impairment of cell-mediated matrix remodeling. When 
gentamicin was combined with ASA, an even greater inhibition of cell-mediated 
matrix remodeling was observed relative to both ASA alone and vehicle control. 
Matrices and the contained cells were fixed and stained immunohistochemically 
to evaluate cellularity (Figure 5-8D) as well as the expression of myofibroblastic 
and proliferative biomarkers, αSMA (Figure 5-8E) and Ki-67 (Figure 5-8F) 
respectively. Combined, ASA and gentamicin treatment had an inhibitory effect 
on cellularity, as measured by the number of nuclei per unit area of collagen 
section. Combined, ASA and gentamicin were able to significantly reduce the 
amount of αSMA staining per nuclei relative to vehicle control. Finally, the 
combination treatment was able to significantly decrease the proportion of cells 
expressing Ki-67 within the collagen matrix relative to vehicle control. These data 
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suggest that the LM modulating composition, ASA and gentamicin, causes an 
impairment of the wound healing related functions and biomarkers of ocular 
fibroblasts. 
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Figure 5-8 ASA ± gentamicin can modulate the unstimulated in vitro wound 
healing functions of ocular fibroblasts. A) Graph representing the effects of ASA 
and gentamicin (µg/ml) on the ocular fibroblast-mediated contraction of collagen 
matrices. Bars depict mean ± SD area (as a proportion of baseline area) of 
collagen remaining after 96hrs of contraction (N=3, n=3). B) Temporal effects of 
ASA ± gentamicin (µg/ml) on cell-mediated collagen contraction over a period of 
96hrs. Two-way ANOVA with Dunnett’s post hoc test (N=6, n=3; *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001). C) The effects of ASA and gentamicin 
(ug/ml) on ocular fibroblast-mediated collagen remodelling after 12 days 
incubation. Picrosirius red stain: collagen fibril density increases as color 
changes from blue to yellow to orange to red. One-way ANOVA with Tukey’s 
post hoc test: N=3, n=3, frames=10; *p<0.05, **p<0.01, ***p<0.001. D) After 12 
days of culture, effects of ASA combined with gentamicin (µg/ml) on the number 
of fibroblasts per unit area of collagen matrix (N=3, n=3, frames=10. E) ASA and 
gentamicin (µg/ml) reduced the amount of area positive for αSMA per nuclei 
within the collagen matrix (N=3, n=3, frames=10), and F) the proportion of nuclei 
that stained positive for the proliferative biomarker, Ki-67, was also reduced 
(N=3, n=3, frames=10). D-F) Student’s t test: **p<0.01, ***p<0.001, ****p<0.0001. 
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5.3.4 COX2 acetylation w/PLA2 agonist can overcome TGFβ1 
induced collagen contraction 
To assess how robust the inhibition of cell-mediated collagen contraction 
observed with COX2 acetylation was, we added 2ng/ml TGFβ1 to the culture 
media of actively contracting collagen constructs at the experiment’s midpoint 
(Figure 5-9A). During the two days prior to TGFβ1 stimulation, a dose dependent 
inhibition of contraction was observed for both concentrations of ASA assessed. 
Further, gentamicin was able to significantly augment these effects. After TGFβ1 
stimulation, contraction was accelerated greatly in the control groups, however 
less so in the ASA treated groups. In fact, after TGFβ1 stimulation, the dose 
dependent, ASA-induced impairment of contraction became more apparent and, 
the effect continued to be significantly augmented by gentamicin. Cellular viability 
was assessed within the collagen constructs by incubating them in FDA and PI to 
label living and dead cells, respectively, and then imaging on a confocal laser 
scanning microscope (Figure 5-9B and C). When the ratio of living cells to total 
cells was compared across treatment groups, there were no significant 
differences observed between any of the groups assessed. This suggests the 
observed treatment effects stem from a modulation of cellular activity as opposed 
to the by-product of a cytotoxic effect. 
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5.3.5 Inhibition of Inf. Cytokine-induced wound healing with COX2 
acetylation and PLA2 agonist is comparable to that of 
mitomycin C in vitro 
To model the ocular scarring in vitro, we assessed cell-mediated collagen 
contraction in the presence of inf. cytokines and compared the inhibitory actions 
of COX2 acetylation to that of a short duration exposure to MMC – the current 
clinical gold standard for reducing sub-conjunctival scarring (Figure 5-10A). Inf. 
cytokines significantly stimulated cell-mediated collagen contraction relative to 
vehicle control, supporting these growth factors’ contribution to the pathological 
changes observed in the subconjunctiva after glaucoma surgery. On its own, 
ASA was able to significantly inhibit inf. cytokine-induced collagen contraction 
(Figure 5-10A). The effect size, however, was significantly smaller than that of a 
four-minute MMC application immediately prior to the initiation of contraction. 
When gentamicin was combined with ASA, the effect size increased significantly 
Figure 5-9 The effects of ASA and gentamicin can overcome TGFb1-induced 
cell-mediated collagen contraction without suppressing cellular viability. A) Un-
induced contraction was assessed for the first 48hrs with the indicated 
experimental treatments, after 48hrs of experimental conditions, 2ng/ml was 
added to the culture media to assess the lasting ability of experimental 
treatments to impede TGFb1-induced contraction. No further experimental 
treatments were added at this point. Results of two-way repeated measures 
ANOVA with Dunnett’s post hoc test. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 for 1500ASA+750G vs. 1500ASA. B) Relative cellular viability was 
compared at the conclusion of the contraction assay by in situ LIVE/DEAD 
staining. One-way ANOVA showed no significant differences between groups 
(N=3, n=3, frames=10). C) Representative LIVE/DEAD fluorescent micrographs 
for the indicated treatment groups. 
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and was statistically indistinguishable from that of a 4-minute exposure to MMC 
prior to contraction (Figure 5-10A and D). Cellular viability was assessed within 
the collagen constructs to assess the contribution of cytotoxicity to the observed 
effects on cell-mediated collagen contraction (Figure 5-10B and C). Relative to 
vehicle control, exposure to all tested durations of MMC exposure significantly 
decreased the proportion of living to total cells – confirming MMC’s cytotoxic 
mechanism of action. No significant differences in cellular viability were observed 
relative to vehicle control with exposure to either ASA alone or in combination 
with gentamicin. 
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D) 
Figure 5-10 ASA ± gentamicin (µg/ml) can modulate inf. cytokine induced in vitro 
wound healing functions of ocular fibroblasts without increased cell death. A) Inf. 
cytokines potentiate ocular fibroblast-mediated collagen contraction relative to 
vehicle control. Proportion of baseline area remaining at the indicated timepoints is 
reported for the indicated experimental groups (N=5, n=3). B) After 96hrs of 
contraction, relative cytotoxicity of exposures was assessed by LIVE/DEAD 
staining of collagen matrices and comparing the proportion of living (blue) to total 
cells (blue + red) within the collagen matrices (N=4, n=3, frames=10). C) 
Representative LIVE/DEAD images of the indicated treatment groups. D) 
Representative scans of collagen matrices exposed to the indicated treatments 
and allowed to contract for 96hrs. A) Two-way ANOVA with Dunnett’s post hoc 
test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. B) One-way ANOVA with 
Tukey’s post hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 155 
 
APHS impaired cell-mediated collagen contraction in a dose dependent manner, 
and the effect was significantly augmented by gentamicin at all tested dose 
(Figure 5-11A). At the highest dose, APHS alone was significantly more effective 
at impairing contraction than a 4-minute exposure to MMC, however the effect 
was transient and lost significance after 48hrs. The combination of APHS and 
gentamicin, at the highest dose, was significantly more effective than a four-
minute exposure to MMC at impairing inf. cytokine-induced collagen contraction. 
Figure 5-11B displays representative scans of contracted collagen matrices 
clearly displaying the described effects. 
 
A)  
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Relative cellular viability was again compared between experimental treatments 
(Figure 5-12A and B). Relative to the inf. cytokine control, APHS alone or in 
combination with gentamicin did not have a significant effect on cellular viability. 
Together, these results suggest that the modulation of lipid mediators with COX2 
Ser516 acetylating agents is associated with a modulation of fibroblast function. 
The effect of MMC appears to be mediated through cytotoxic means, whereas 
the effects of COX2 acetylating agents do not seem to be mediated through 
cytotoxic means. 
Figure 5-11 APHS, ASA ± gentamicin (µg/ml) can modulate inf. cytokine induced in 
vitro wound healing functions of ocular fibroblasts without increased cell death. A)  
effects of APHS ± gentamicin on the inf. cytokine-induce ocular fibroblast-mediated 
contraction of collagen matrices relative to a 4 minute exposure to MMC (N=4, n=3). 
B) Representative scans of collagen matrices exposed to the indicated treatments 
and allowed to contract for 96hrs. A) Two-way ANOVA with Dunnett’s post hoc test: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. C) One-way ANOVA with Tukey’s post 
hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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A) 
B) 
Figure 5-12 A) Effects of APHS ± gentamicin (µg/ml) on the cellular viability 
(N=3, n=6, frames=10). B) Representative LIVE/DEAD images of the indicated 
treatment groups. A) One-way ANOVA with Tukey’s post hoc test: *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
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5.3.6 COX2 acetylation inhibits inf. cytokine-induced myofibroblast 
metabolic activity and pathognomonic protein expression 
We wished to investigate the effects of COX2 acetylation on the fibroblast and 
myofibroblast phenotype as a means to better understand the mechanism 
responsible for modified function within collagen-based culture. First, we 
assessed the effect of ASA and APHS on the metabolic activity of TGFβ-induced 
myofibroblasts and control ocular fibroblasts (Figure 5-13A and B). Both COX2  
  
Figure 5-13 Effects of A) ASA, or B) APHS (µg/ml) on the TGFb1 (2ng/ml)-
induced metabolic activity ocular fibroblasts. A-B) Results from MTT assays 
48hrs after the indicated treatments, the optical density of the experimental 
groups was normalized to the vehicle control group. One-way ANOVA with 
Tukey’s post hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
A) 
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acetylating agents had a relatively small effect on the metabolic activity of the 
non-induced fibroblasts, until the extreme of the dose range tested. TGFβ1 had a 
significant stimulatory effect on fibroblast metabolic activity. When TGFβ1 was 
co-incubated with either COX2 acetylating agent, a significant reduction in 
metabolic activity was noted, with return to non-TGFβ stimulated levels in a dose 
dependent manner. 
The protein alpha smooth muscle actin (αSMA) is pathognomonic of the 
myofibroblast phenotype and essential for contraction of the extracellular matrix 
to occur. Matrix metalloproteinase nine (MMP9) is essential for invasion and 
remodeling of the extracellular matrix. Using monolayer cell culture and western 
blot, we found that inf. cytokines induced differentiation of ocular fibroblasts into 
myofibroblasts, exhibiting increased expression of both αSMA and MMP9 relative 
to non-induced fibroblasts (Figure 5-14A and B). The inf. cytokines-induced 
expression of αSMA and MMP9 expression was significantly reversed ASA in a 
dose dependent manner (Figure 5-14A). APHS, at the concentration assessed 
(10μg/ml), has approximately equal COX2 acetylating power as 500μg/ml ASA 
(1/60th as many moles, with approx. 60x COX2 specificity). It was also able to 
significantly inhibit the observed inf. cytokine-induced expression of αSMA 
(Figure 5-14B). These results support the impairment of myofibroblast 
transdifferentiation by both COX2 acetylating agents. 
The effects of adding the PLA2 agonist, gentamicin, was assayed using the same 
methodology (Figure 5-15A-C). Gentamicin alone had no significant effect on the 
inf. cytokine-induced expression of collagen 1 and αSMA. Both ASA and  
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APHS were able to impair the cytokine induced expression of collagen 1 and 
αSMA on their own. The effects of both COX2 acetylating agents on inf. cytokine-
induced collagen 1 and αSMA expression were significantly potentiated by their 
co-incubation with gentamicin. 
  
A) 
B) 
 
Figure 5-14 Assessment of inf. Cytokine induced αSMA and/or MMP9 expression 
by western blot of ocular fibroblast total protein lysate after 48hrs of culture with 
the indicated exposures (µg/ml). Results from a one-way ANOVA with Tukey’s 
post hoc test are shown. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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5.3.7 COX2 acetylation results in differential regulation of 
transcription factors PPARɣ and SMAD2/3 
Previous work has demonstrated the ability of ASA to suppress MMP9 
expression in mouse celiac macrophages.239 These authors’ conclusions 
implicated activation of PPARɣ as mechanistic rationale for the ASA-induced 
changes in protein expression. Conceptually, these findings are supported by our 
findings that the production of endogenous PPARɣ ligands, such as 15-HETE,263 
can be generated by the acetylated COX2 enzyme. Another study reported the 
effects of troglitazone, a potent synthetic PAPRy agonist, on collagen synthesis in 
human hypertrophic scar fibroblasts.264 These authors found that agonizing 
PPARɣ led to impaired collagen expression and demonstrated this to occur 
through induction of miR-145, which itself causes inhibition of SMAD3. We 
hypothesized that the same intracellular mechanisms were responsible for the 
effects observed within ocular fibroblasts after exposure to ASA and APHS. We 
expected to see differential regulation of PPARɣ and SMAD2/3 after COX2 
acetylation (Figure 5-16).  
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Figure 5-16 Schematic representation of the hypothesized mechanism leveraged 
for the modulation of lipid mediator production. 
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We first investigated the ability of ASA and APHS to influence PPARɣ after inf. 
cytokine-stimulation. Inf. cytokines significantly inhibited PPARɣ expression 
relative to vehicle control (Figure 5-17A and B). ASA was able to rescue inf. 
cytokine-induced PPARɣ expression in a dose dependent manner, exceeding the 
relative expression levels of the vehicle control group (Figure 5-17A). The effects 
of APHS alone on PPARɣ expression were inhibitory relative to vehicle control, 
however when APHS was co-incubated with inf. cytokine-induced fibroblasts, a 
significant increase in PPARɣ expression level was observed relative to both inf. 
cytokine control and vehicle control groups (Figure 5-17B). This finding in 
particular supports the requirement for COX2’s induction before the therapeutic 
effects of its acetylation can be observed. 
 
Figure 5-17 Effects of A) ASA and B) APHS (µg/ml) on the transcription factors 
PPARy. Expression of PPARy relative to GAPDH was assessed by western blot 
of ocular fibroblast total protein lysate after 48 hours of culture with the indicated 
exposures (N=5). A-B) One-way ANOVA with Tukey’s post hoc multiple 
comparisons test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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To investigate the occurrence of a corresponding SMAD2/3 downregulation, we 
analyzed the relative expression of both phosphorylated SMAD2/3 and total 
SMAD2/3 (Figure 5-18). Inf. cytokines induced high levels of SMAD2/3 
expression and phosphorylation relative to vehicle control. Gentamicin had no 
effect on the inf. cytokine-induced phosphorylation or expression of SMAD2/3. 
ASA and APHS were able to significantly repress both the inf. cytokine-induced 
phosphorylation and expression of SMAD2/3, and gentamicin was able to 
significantly augment the effects of both COX2 acetylating agents. The ratio of 
 
Figure 5-18 APHS, ASA ± gentamicin’s (µg/ml) effects on the transcription factor 
SMAD2/3 total expression and phosphorylation state. Expression of phosphorylated 
SMAD2/3, total SMAD2/3 and the ratio of phosphorylated to total SMAD2/3 relative 
to GAPDH after 48hrs of culture with the indicated exposures (N=5). One-way 
ANOVA with Tukey’s post hoc multiple comparisons test: *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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activated (phosphorylated) to total SMAD2/3 was returned to vehicle control 
expression levels from inf. cytokine-induced levels with the application of 
1000μg/ml ASA and 500μg/ml gentamicin or 12μg/ml APHS and 250μg/ml 
gentamicin. 
To confirm PPARɣ’s involvement in the effects observed, we co-incubated the 
COX2 acetylating agents with a PPARɣ inhibitor, GW9662 (1 µM). When either 
ASA or APHS were co-incubated with GW9662, no significant inhibition of inf. 
cytokine-induced αSMA expression within ocular fibroblasts was noted (Figure 5-
19A and B). These findings support PPARɣ’s role in mediating the effects of 
COX2 acetylating agents on myofibroblast transdifferentiation. 
 
  
Figure 5-19 PPARy inhibition (GW9662, 1 µM) attenuates the effects seen with 
COX2 Ser516 acetylating agents. A) Densiometric analysis of multiple (N=4) 
western blots. One-way ANOVA with Tukey’s post hoc test: ***p<0.001. B) 
Representative western blot of total protein lysate from ocular fibroblasts 48hrs 
after the indicated exposures. ASA (µg/ml); APHS (µg/ml). 
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5.4 Conclusions 
The presented evidence suggests that, within inflammation activated ocular 
fibroblasts, the modulation COX2 and PLA2 enzymatic function and activity can 
illicit a shift in pro-inflammatory and pro-resolving lipid mediator production that 
greatly favors the generation of pro-resolving mediators. Under these conditions, 
differential regulation of PPARɣ and SMAD2/3 were observed within ocular 
fibroblasts and corresponded with inhibition of inflammation-induced 
myofibroblast transdifferentiation. Together, these results suggest that the 
resolution of inflammatory and fibroproliferative signaling can be triggered within 
ocular fibroblasts by acetylation of COX2 at Ser516 and this effect appears to be 
augmented by stimulation of PLA2 activity. 
Inflammation induced myofibroblast transdifferentiation and activity remains one 
of the largest unanswered contributors to ocular morbidity. To our knowledge, this 
is the first report of COX2 Ser516 acetylating agents being used to trigger 
endogenous mechanisms of resolution within ocular fibroblasts causing an 
impairment of myofibroblast transdifferentiation and function. Immuno-resolvent 
interventions are theorized to be associated with fewer off target effects, as they 
function to promote the ordered return to homeostasis after inflammatory insult. 
Immuno-suppressive interventions, on the other hand, attempt to prevent the 
initial inflammation-induced deviation from homeostasis and hinder the 
endogenous resolution of inflammation. A subtle difference, but one which 
implies that immuno-resolvent interventions attempt to engage synergistically 
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with an endogenous process, whereas immuno-suppressive interventions 
attempt to counter an endogenously occurring process. The ready availability of 
safety data pertaining to ASA’s human use should provide a rapid path to 
assessing its efficacy in human ophthalmological pathologies. Based on the 
presented data, APHS has the potential to exhibit even greater efficacy, and 
animal studies assessing its ophthalmological safety and efficacy are warranted. 
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Chapter 6  
6 Summary and Future Directions 
 
6.1 Overall Findings and Implications 
Excessive myofibroblast transdifferentiation and activity within delicate ocular 
structures is a major impediment to successful ophthalmological outcomes 
across the discipline. This thesis focused on the critical wound healing that 
occurs within the post-operative subconjunctival tissues of glaucoma surgery 
patients, however wound healing is a fundamental process, and lessons from the 
subconjunctiva could easily be translated to the other non-nervous tissues of the 
eye. 
This thesis began with a survey of risk factors for glaucoma surgery revision. We 
used this large retrospective database study as a springboard for subsequent in 
vitro investigation. The subsequently generated data was enough to successfully 
fund a clinical trial that is scheduled to begin patient recruitment concurrent with 
this thesis’s evaluation. Looking ahead and based on what was learned about 
RMs impact on wound healing, we subsequently designed a novel immuno-
resolvent intervention that demonstrates significant efficacy in vitro at impairing 
cytokine-driven subconjunctival wound healing phenomena. 
The implications of this body of work are far reaching. Immediate benefit to 
patients may be gained should NSAIDs outperform corticosteroids in the planned 
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randomized controlled trial – as many NSAID eye drops are currently approved 
and could easily be switched to as current standard of care. Long term benefits 
may be derived from a deeper understanding of the interactions between 
inflammatory mediator production, resolving mediator production and the 
development of scarring. Understanding the effects of COX2 Ser516 acetylation 
within animal models of progressive fibrotic diseases is warranted – especially 
considering the recent discovery of an endogenous COX2 acetylating protein that 
contributes to the resolution of neuroinflammation in mice.249 Strategies that 
capitalize on the body’s endogenous resolving mechanisms to avoid the dangers 
associated with inflammation are likely to enjoy more success than those which 
act against endogenous systems. Such immuno-resolvent modalities should gain 
a prominent position in the future fight against chronic inflammatory or 
dysregulated inflammatory diseases. 
6.2 Limitations 
The study which inspired all subsequent investigations was retrospective in 
nature, thus we could only assess exposures to drugs that are available to the 
public. This resulted in a potential blind spot; the inability to investigate the effects 
of novel wound modulating agents. Fortunately, there were two anti-inflammatory 
drugs within the database records that exhibited significantly different 
associations with surgical success, and I was subsequently inspired by their 
differing mechanisms of action. However, this initial study set the direction for 
future work, and this limitation undoubtedly restricted the theoretical framework 
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upon which Chapters 3 to 7 are based. It was fortunate that NSAIDs and 
corticosteroids lead me to investigate the interactions of LMs with wound healing, 
as this is a novel area of research and supported much subsequent investigation. 
Although we make a case for fibroblasts themselves being immune cells – 
especially in the inflammatory and wound healing microenvironment – the 
presented studies do not incorporate more classical examples of immune cells in 
our models. The interaction of macrophages and other inflammatory cells with 
fibroblasts is critical to the wound healing process34 and future studies should 
incorporate co-cultures of the two cell types to more accurately recreate the in 
vivo microenvironment. However, one can take comfort in the fact that the 
interventions discussed within this thesis have a very high likelihood of mitigating 
the impact of inflammatory cells in a similar manner – as almost all immune cells 
express PLA2 and COX2. In fact the overall effects of these interventions may be 
even more pronounced in inflammatory cells – as they have been shown to be 
extremely sensitive to RM signals and subsequently function to locally amplify 
their presence in vivo – potentially initiating a feedforward pro-resolution signal 
from which any local fibroblasts would also benefit.18,265,266 
6.3 Future Directions 
In Chapter 6 we explored the intracellular signaling cascade mediating the effects 
of COX2 Ser516 acetylators. We demonstrated involvement of SMAD2/3 and 
PPARɣ in the transduced effects. Previous work has implicated miR-145 as 
mediating PPARɣ-induced interference with SMAD2/3 signaling within human 
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hypertrophic scar fibroblasts.264 Investigating the potential role of this microRNA 
in turning off myofibroblast associated gene sets in response to PPARɣ activation 
should yield new knowledge and strategies to impair myofibroblast 
transdifferentiation and activity. 
Results presented warrant further investigation in animal models of ophthalmic 
disease. There are several validated animal model systems in which these 
interventions could be assessed for their anti-fibrotic properties. Corneal stromal 
injury,267 posterior capsule opacification after cataract surgery,268 and ocular 
neovascularization269 all have validated animal models and are natural 
translations for the presented interventions. 
Given the results in Chapter 6, APHS should be explored further as an immuno-
resolvent agent. Subsequent animal safety and toxicity studies, should they prove 
promising, could open whole new avenues of research into more specific COX2 
acetylating molecules and a new frontier for immuno-resolvent interventions. 
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Appendices 
Appendix A:  STROBE Statement—Checklist of items to be included in reports of 
cohort studies 
 Item 
No. Recommendation 
Page  
No. 
 Title and abstract 1 (a) Indicate the study’s design with a commonly 
used term in the title or the abstract 
1 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what 
was found 
1 
Introduction  
Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported 
2 
Objectives 3 State specific objectives, including any 
prespecified hypotheses 
2 
Methods  
Study design 4 Present key elements of study design early in 
the paper 
3 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection 
3-4 
Participants 6 (a) Give the eligibility criteria, and the sources 
and methods of selection of participants. 
Describe methods of follow-up 
3-4 
(b) For matched studies, give matching criteria 
and number of exposed and unexposed 
N/A 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
4,5 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one 
group 
4-5, 
Appendices A-
F 
Bias 9 Describe any efforts to address potential 
sources of bias 
3-5 
Study size 10 Explain how the study size was arrived at Figure 1 
Quantitative 
variables 
11 Explain how quantitative variables were handled 
in the analyses. If applicable, describe which 
groupings were chosen and why 
4-5 
Statistical methods 12 (a) Describe all statistical methods, including 4-5 
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those used to control for confounding 
(b) Describe any methods used to examine 
subgroups and interactions 
4-5 
(c) Explain how missing data were addressed 4-5 
(d) If applicable, explain how loss to follow-up 
was addressed 
5, Figure 1 
(e) Describe any sensitivity analyses 4 
Results  
Participants 13* (a) Report numbers of individuals at each stage 
of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and 
analysed 
Figure 1 
(b) Give reasons for non-participation at each 
stage 
Figure 1 
(c) Consider use of a flow diagram Figure 1 
Descriptive data 14* (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on 
exposures and potential confounders 
6, 7, Table 1, 
S2 
(b) Indicate number of participants with missing 
data for each variable of interest 
 Table 2, Table 
S2 
(c) Summarise follow-up time (eg, average and 
total amount) 
6 
Outcome data 15* Report numbers of outcome events or summary 
measures over time 
6, Table 1 
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make 
clear which confounders were adjusted for and 
why they were included 
Table 3 
(b) Report category boundaries when continuous 
variables were categorized 
Table 2, Table 
S2 
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful 
time period 
N/A 
Other analyses 17 Report other analyses done—eg analyses of 
subgroups and interactions, and sensitivity 
analyses 
5,7 
Discussion  
Key results 18 Summarise key results with reference to study 
objectives 
8 
Limitations 19 Discuss limitations of the study, taking into 8,9 
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account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any 
potential bias 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
8-10 
Generalisability 21 Discuss the generalisability (external validity) of 
the study results 
8-10 
Other information  
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, 
for the original study on which the present article 
is based 
11 
 
*Information given separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives 
methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS 
Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, 
and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available 
at http://www.strobe-statement.org. 
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Appendix B: Index Events and Outcome Definitions 
Procedure Algorithm 
Solo-filtration surgery Record of OHIP billing code E132, with no add-on codes, without a 
prior record of E132 or E214 over the previous 10 years, in addition 
to any one of the following CCI procedural codes: 1.CJ.52.LA, 
1CJ.52.LA-SJ, 1.CJ.52.LA-QB and 1.CJ.52.WJ 
 
Filtration surgery 
+cataract extraction 
Record of OHIP billing code E214, with no add-on codes, without a 
prior record of E132 or E214 over the previous 10 years, in addition 
to any one of the following CCI procedural codes: 1.CJ.52.LA, 
1CJ.52.LA-SJ, 1.CJ.52.LA-QB and 1.CJ.52.WJ 
 
Filtration surgery 
+IDD 
Record of OHIP billing code E132, with the E136 add-on code, 
without a prior record of E132 or E214 over the previous 10 years, in 
addition to any one of the following CCI procedural codes: 
1.CJ.52.LA, 1CJ.52.LA-SJ, 1.CJ.52.LA-QB and 1.CJ.52.WJ 
 
Filtration Surgery 
+cataract extraction 
+IDD 
Record of OHIP billing code E214, with the E136 add-on code, 
without a prior record of E132 or E214 over the previous 10 years, in 
addition to any one of the following CCI procedural codes: 
1.CJ.52.LA, 1CJ.52.LA-SJ, 1.CJ.52.LA-QB and 1.CJ.52.WJ 
 
Revision Filtration Surgery Within the follow-up period, a record of OHIP billing code E983 or 
E984 and/or CCI intervention codes: 1.CJ.52.LA, 1CJ.52.LA-SJ, 
1.CJ.52.LA-QB, and 1.CJ.52.WJ (accompanied by the intervention 
attribute “revision”). 
 
Bleb Repair Within the follow-up period, record of OHIP billing code E212 or 
E213 and/or CCI intervention codes 1.CS.80, 1.CS.72, 1.CS.84, 
1.CS.87, 1.CS.52, 1.CC.80, 1.CD.80 revision, 1.CJ.54, 1.CJ.55, 
1.CJ.80, 1.CJ.87, and 1.CD.52.LA revision. 
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Appendix C: Comorbidity Coding Algorithms 
Comorbidity Algorithm 
Diabetes At least two OHIP claims bearing a diagnosis of diabetes or one OHIP fee 
code claim, or one CIHI admission within two years. OHIP diagnosis code: 
250 OHIP fee codes: K030, Q040, K045, K046, K029 CIHI ICD-9 code: 250 
CIHI ICD-10 codes: E10, E11, E13, E14 
 
Hypertension One hospital admission with a hypertension diagnosis or an OHIP claim 
with a hypertension diagnosis followed within two years by either an OHIP 
claim or hospital admission with a hypertension diagnosis. OHIP diagnosis 
codes: 401, 402, 403, 404, or 405 CIHI ICD-9 codes: 401x, 402x, 403x, 
404x, or 405x CIHI ICD-10 codes: I10, I11, I12, I13, or I15  
 
Asthma One hospital admission with an asthma diagnosis or two OHIP claims with 
asthma diagnosis within two years. CIHI ICD-9: 493 CIHI ICD-10: J45, J46 
OHIP diagnosis code: 493 
 
 
Stroke At least 2 OHIP claims within 1 year bearing any one of OHIP diagnostic 
codes (436, 432, 435) -or- if patient has any 1 CIHI-DAD ICD-10 code (I61 
or I63 or I64 or H34.1 or G45 [ICD-9: 431, 433, 36231, 435]) within 1 year 
 
Sleep Apnea Any one OHIP billing code (J696, J896, J890, J690, J898, J899, J990, 
J897, J697, J889, J689) or any one CIHI-DAD ICD-10 code (G4730, G4730 
[ICD-9: 32720, 78051, 78053, 78057) within 5 year lookback window 
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Appendix D: Ophthalmic Surgical History Variables 
Variable OHIP Definition OHIP Code 
Secondary Glaucoma Surgical Interventions 
 Sclera 
 
Sclerotomy, posterior E127 
  Removal of scleral implant E161 
  Scleral resection or buckling procedure (primary or 
secondary) 
E152 
 Vitreous Vitrectomy by infusion suction cutter technique E148 
  Vitrectomy by infusion suction cutter technique with 
transscleral retinal suturing  
E938 
  Preretinal membrane peeling or segmentation to include 
posterior vitrectomy and coagulation  
E142 
  Vitreous exchange E936 
 Retina 
 
Retinal and choroid re-attachment. Initial procedure E151 
  Retinal reattachment. Second time E153 
Conjunctival Disrupting   
 Sclera 
 
Sclerotomy, posterior E127 
  Removal of scleral implant E161 
  Scleral resection or buckling procedure (primary or 
secondary) 
E152 
 Vitreous Vitrectomy by infusion suction cutter technique E148 
  Vitrectomy by infusion suction cutter technique with 
transscleral retinal suturing  
E938 
  Preretinal membrane peeling or segmentation to include 
posterior vitrectomy and coagulation  
E142 
  Vitreous exchange E936 
 Retina 
 
Retinal and choroid re-attachment. Initial procedure E151 
  Retinal reattachment. Second time E153 
 Conjunctiva Excision of conjunctival lesion E210 
  Excision of conjunctival lesion w/mucous membrane graft E948 
  
 
 
Ciliary 
 
Excision of conjunctival lesion w/autogenous conjunctival 
transplant 
 
Ciliary body re-attachment  
E937 
 
 
E135 
Conjunctival Sparing   
 Lens Cataract extraction E140 
  Dislocated lens extraction or repositioning  E141 
  Excision of secondary membrane with corneal section 
following cataract extraction 
E143 
  Fixation of intra-ocular lens and/or capsular tension 
device by suturing 
E138 
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  Removal of intraocular lens E144 
  Repositioning dislocated intra-ocular lens E145 
  Insertion of secondary intra-ocular lens 
 
Capsulotomy 
E146 
 
E139 
 
 
 
 Cornea Corneal Transplant, Penetrating E121 
  Corneal transplant, lamellar E122 
 Iris Laser iridotomy  E131 
  Iridectomy E130 
 Laser Angle Surgery Laser Angle Surgery E134 
 Photocoagulation Photocoagulation, retina E154 
 Retina Cryopexy E155 
  Intravitreal injection for other than macular degeneration E149 
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Appendix E: Glaucoma Eye Drops 
Drug Class Generic Name Trade Name Strength DIN 
Beta-blocker LEVOBUNOLOL 
HCL 
APO-LEVOBUNOLOL 0.5% 0224157
4 
 LEVOBUNOLOL 
HCL 
SANDOZ-
LEVOBUNOLOL 
0.5% 0224171
6 
 LEVOBUNOLOL 
HCL 
APO-LEVOBUNOLOL 0.25% 0224157
5 
 LEVOBUNOLOL 
HCL 
SANDOZ-
LEVOBUNOLOL 
0.25% 0224171
5 
 TIMOLOL 
MALEATE 
RATIO-TIMOLOL 0.5% 0224024
9 
 BRIMONIDINE 
TARTRATE & 
TIMOLOL 
MALEATE 
COMBIGAN 0.2/0.5% 0224834
7 
 TIMOLOL 
MALEATE 
TIMOLOL MALEATE-EX 0.25% 0224227
5 
 TIMOLOL 
MALEATE 
TIMOLOL MALEATE-EX 0.5% 0224227
6 
 BRIMONIDINE 
TARTRATE & 
TIMOLOL 
MALEATE 
COMBIGAN 0.2/0.5% 0985729
8 
 BRINZOLAMIDE 
& TIMOLOL 
MALEATE 
AZARGA 1%/0.5% 0233162
4 
 TIMOLOL 
MALEATE 
APO-TIMOP GEL 0.5% 0229081
2 
 TIMOLOL 
MALEATE 
APO-TIMOP 0.25% 0081227
7 
 TIMOLOL 
MALEATE 
APO-TIMOP 0.5% 0081228
5 
 TIMOLOL 
MALEATE 
APO-TIMOP 0.25% 0089808
2 
 TIMOLOL 
MALEATE 
APO-TIMOP 0.5% 0089809
0 
 TIMOLOL 
MALEATE 
TIMOPTIC-XE 0.5% 0217188
9 
 TIMOLOL 
MALEATE 
APO-TIMOP GEL 0.25% 0231585
8 
 TIMOLOL 
MALEATE 
TIMOPTIC OCUDOSE 0.5% 6612398
8 
 TIMOLOL 
MALEATE 
APO-TIMOP 0.25% 6689809
0 
 LEVOBUNOLOL 
HCL 
BETAGAN 0.25% 0080129
1 
 LEVOBUNOLOL 
HCL 
BETAGAN 0.25% 0080130
5 
 LEVOBUNOLOL 
HCL 
BETAGAN 0.5% 0081173
4 
 LEVOBUNOLOL 
HCL 
BETAGAN 0.5% 0089573
3 
 LEVOBUNOLOL 
HCL 
BETAGAN 0.5% 0090759
6 
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 LEVOBUNOLOL 
HCL 
NOVO-LEVOBUNOLOL 0.25% 0219745
6 
 LEVOBUNOLOL 
HCL 
NOVO-LEVOBUNOLOL 0.5% 0219746
4 
 LEVOBUNOLOL 
HCL 
LEVOBUNOLOL HCL 0.25% 0223679
2 
 LEVOBUNOLOL 
HCL 
LEVOBUNOLOL HCL 0.5% 0223679
3 
 TIMOLOL 
MALEATE 
TIMOPTIC 0.5% 0088943
1 
 BETAXOLOL 
HCL 
BETOPTIC 0.5% 0089637
3 
 TIMOLOL 
MALEATE 
TIMOPTIC 0.25% 0089682
9 
 TIMOLOL 
MALEATE 
TIMOPTIC 0.5% 0089683
7 
 TIMOLOL 
MALEATE 
TIM-AK 0.5% 0201024
0 
 TIMOLOL 
MALEATE 
TIM-AK 0.25% 0201025
9 
 TIMOLOL 
MALEATE 
T-LO 0.25% 0220249
2 
 TIMOLOL 
MALEATE 
T-LO 0.5% 0220250
6 
 TIMOLOL 
MALEATE 
TIMOLOL 0.25% 0223002
8 
 TIMOLOL 
MALEATE 
TIMOLOL 0.5% 0223002
9 
 BETAXOLOL 
HCL 
SANDOZ-BETAXOLOL 0.5% 0223597
1 
 TIMOLOL 
MALEATE 
DOM-TIMOLOL 0.25% 0223877
0 
 TIMOLOL 
MALEATE 
DOM-TIMOLOL 0.5% 0223877
1 
 TIMOLOL 
MALEATE 
SANDOZ-TIMOLOL 0.25% 0224173
1 
 TIMOLOL 
MALEATE 
SANDOZ-TIMOLOL 0.5% 0224173
2 
 TIMOLOL 
MALEATE 
TIMOPTIC - 4945120
7 
 TIMOLOL 
MALEATE 
TIMOPTIC 0.25% 6688942
3 
 LEVOBUNOLOL 
HCL 
LEVOBUNOLOL HCL 5MG/ML 0063769
6 
 TIMOLOL 
MALEATE 
MED-TIMOLOL 0.25% 0208431
7 
 TIMOLOL 
MALEATE 
MED-TIMOLOL 0.5% 0208432
5 
 TIMOLOL 
MALEATE 
TEVA-TIMOLOL 0.25% 0209491
6 
 TIMOLOL 
MALEATE 
TEVA-TIMOLOL 0.5% 0209492
4 
 TIMOLOL 
MALEATE 
NU-TIMOLOL 0.25% 0209493
2 
 TIMOLOL 
MALEATE 
NU-TIMOLOL 0.5% 0209494
0 
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 LEVOBUNOLOL RATIO-LEVOBUNOLOL 0.5% 0213116
7 
 TIMOLOL 
MALEATE 
TIMOLOL 0.25% 0214747
5 
 TIMOLOL 
MALEATE 
TIMOLOL 0.5% 0214748
3 
 TIMOLOL 
MALEATE 
STORZ TIMOL 0.25% 0217602
5 
 TIMOLOL 
MALEATE 
STORZ TIMOL 0.5% 0217603
3 
 LEVOBUNOLOL 
HCL 
GEN-BUNOLOL 0.25% 0220081
3 
 LEVOBUNOLOL 
HCL 
GEN-BUNOLOL 0.5% 0220082
1 
 LEVOBUNOLOL 
HCL 
OPHTHO-BUNOLOL 0.25% 0220084
8 
 LEVOBUNOLOL 
HCL 
OPHTHO-BUNOLOL 0.5% 0220085
6 
 BETAXOLOL 
HCL 
ALTI-BETAXOLOL 0.5% 0223062
0 
 LEVOBUNOLOL 
HCL 
PMS-LEVOBUNOLOL 0.25% 0223799
0 
 TIMOLOL 
MALEATE 
CROWN-TIM 0.25% 0223930
0 
 TIMOLOL 
MALEATE 
CROWN-TIM 0.5% 0223930
1 
 BETAXOLOL 
HCL 
NOVO-BETAXOLOL 0.5% 0224005
0 
 TIMOLOL 
MALEATE 
RATIO-TIMOLOL 0.25% 0224024
8 
 LEVOBUNOLOL RATIO-LEVOBUNOLOL 0.5% 2031167
0 
 TIMOLOL 
MALEATE 
COMPOUND - TIMOLOL 
PRESERVATIVE FREE 
- 2212329
5 
 DORZOLAMIDE 
& TIMOLOL 
APO-DORZO/TIMOP 20MG/5MG/ML 0229961
5 
 DORZOLAMIDE 
& TIMOLOL 
CO DORZOTIMOLOL 2/0.5% 0240438
9 
 DORZOLAMIDE 
& TIMOLOL 
SANDOZ-
DORZOL/TIMOL 
1% 0234435
1 
 DORZOLAMIDE 
& TIMOLOL 
DORZOLAMIDE-
TIMOLOL 
1% 0235780
1 
 BETAXOLOL 
HCL & 
PILOCARPINE 
HCL 
BETOPTIC/PILO 0.25% & 1.75% 0223853
9 
 LATANOPROST 
& TIMOLOL 
XALACOM 5MG/5MCG/ML 0224661
9 
 TIMOLOL 
MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 0227825
1 
 TIMOLOL 
MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 0985733
3 
 LATANOPROST 
& TIMOLOL 
SDZ-
LATANOP/TIMOLOL 
5MG/5MCG/ML 0239468
5 
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 LATANOPROST 
& TIMOLOL 
GD-
LATANOPROST/TIMOL
OL 
5MG/5MCG/ML 0237306
8 
 TIMOLOL 
MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 0985751
2 
 TIMOLOL 
MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 0985751
3 
 LATANOPROST 
& TIMOLOL 
PMS-LATANOPROST-
TIMOLOL 
 
5MG/50MCG/M
L 
0240459
1 
CAI DORZOLAMIDE SANDOZ-
DORZOLAMIDE 
2% 0231630
7 
 BRINZOLAMIDE SANDOZ 
BRINZOLAMIDE 
20MG/ML 0236523
5 
 ACETAZOLAMID
E SODIUM 
DIAMOX 2% 0001467
2 
 ACETAZOLAMID
E SODIUM 
DIAMOX 20MG 0203924
9 
 ACETAZOLAMID
E SODIUM 
DIAMOX 2%/.5% 0223807
4 
 DORZOLAMIDE DORZOLAMIDE 2% 0236499
9 
 ACETAZOLAMID
E 
ACETAZOLAMIDE 2% 9910117
5 
 DORZOLAMIDE 
& TIMOLOL 
APO-DORZO/TIMOP 20MG/5MG/ML 0229961
5 
 DORZOLAMIDE 
& TIMOLOL 
CO DORZOTIMOLOL 2/0.5% 0240438
9 
 DORZOLAMIDE 
& TIMOLOL 
SANDOZ-
DORZOL/TIMOL 
1% 0234435
1 
 DORZOLAMIDE 
& TIMOLOL 
DORZOLAMIDE-
TIMOLOL 
 
1% 0235780
1 
Miotic PILOCARPINE 
HCL 
MINIMS PILOCARPINE 4% 0214847
1 
 DORZOLAMIDE 
HCL & TIMOLOL 
MALEATE 
COSOPT 20MG/5MG/ML 0225869
2 
 PILOCARPINE 
HCL 
PILOSTAT 4% 0077236
4 
 CARBACHOL ISOPTO CARBACHOL 0.75% 0000064
7 
 PILOCARPINE 
HBR 
ADSORBO-CARPINE 2% 0027883
1 
 PILOCARPINE 
HCL 
ISOPTO CARPINE 3% 0000087
6 
 CARBACHOL 
CHLORIDE 
MIOSTAT 0.01% 0004254
4 
 PILOCARPINE 
HCL 
ISOPTO CARPINE 8% 0025253
0 
 PILOCARPINE 
HCL 
AKARPINE 1% 0062773
9 
 PILOCARPINE 
HCL 
AKARPINE 2% 0062774
7 
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 PILOCARPINE 
HCL 
AKARPINE 4% 0062775
5 
 PILOCARPINE 
HCL 
ISOPTO CARPINE 1% 2212301
7 
 PILOCARPINE 
NITRATE 
P.V. CARPINE 1% 0000117
1 
 PILOCARPINE 
NITRATE 
P.V. CARPINE 2% 0000119
8 
 PILOCARPINE 
NITRATE 
P.V. CARPINE 4% 0000122
8 
 PILOCARPINE 
HCL 
MIOCARPINE 1% 0002896
7 
 PILOCARPINE 
HCL 
MIOCARPINE 2% 0002897
5 
 PILOCARPINE 
HCL 
MIOCARPINE 4% 0002899
1 
 PILOCARPINE 
HCL 
MIOCARPINE 6% 0002900
9 
 PILOCARPINE 
HCL 
MIOCARPINE 1% 0026509
8 
 PILOCARPINE 
HCL 
MIOCARPINE 2% 0026510
1 
 PILOCARPINE 
HCL 
MIOCARPINE 3% 0026512
8 
 PILOCARPINE 
NITRATE 
PILOCARPINE NITRATE 1% 0026911
5 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL 
E-PILO # 1 1% 0028167
0 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL 
E-PILO # 2 2% 0028168
9 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL 
E-PILO # 4 4% 0028170
0 
 PILOCARPINE 
HCL 
MIOCARPINE 0.5% 0028175
1 
 PILOCARPINE 
HCL 
MIOCARPINE 4% 0028177
8 
 PILOCARPINE 
HCL 
MIOCARPINE 6% 0028178
6 
 ECOTHIOPATE 
IODIDE 
PHOSPHOLINE IOD 3MG 0028330
4 
 CHYMOTRYPSI
N 
CATARASE 300U/VIAL 0052635
5 
 PILOCARPINE 
HCL 
MIOCARPINE 6% 0052673
8 
 PILOCARPINE 
HCL 
MIOCARPINE 0.5% 0052752
1 
 PILOCARPINE 
HCL 
MIOCARPINE 1% 0052754
8 
 PILOCARPINE 
HCL 
MIOCARPINE 2% 0052755
6 
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 PILOCARPINE 
HCL 
MIOCARPINE 3% 0052756
4 
 PILOCARPINE 
HCL 
MIOCARPINE 4% 0052757
2 
 PILOCARPINE 
HCL 
SPERSACARPINE 3% 0072542
0 
 PILOCARPINE 
HCL 
PILOSTAT 2% 0077237
2 
 PILOCARPINE 
HCL 
PILOSTAT 1% 0077238
0 
 ECOTHIOPATE 
IODIDE 
PHOSPHOLINE IOD 3MG 0086085
9 
 ACETYLCHOLIN
E HYDROXIDE 
CHLORIDE 
MIOCHOL-E 10MG/ML 0088933
4 
 PILOCARPINE 
HCL 
PILOCARPINE 2% 0190763
8 
 PILOCARPINE 
HCL 
PILOCARPINE 1% 0190765
4 
 PILOCARPINE 
HCL 
PILOCARPINE 4% 0190766
2 
 DAPIPRAZOLE 
HCL 
REV-EYES 25MG 0197034
8 
 ACETYLCHOLIN
E HYDROXIDE 
CHLORIDE 
MIOCHOL-E 10MG/ML 0213332
6 
 CARBACHOL CARBASTAT 0.01% 0219558
5 
 ECOTHIOPATE 
IODIDE 
PHOSPHOLINE IOD 6.25MG 0223807
6 
 DORZOLAMIDE 
& TIMOLOL 
TEVA-DORZOTIMOL 20MG/5MG/ML 0232052
5 
 PILOCARPINE 
HCL 
COMPOUND - 
PILOCARPINE 
0.25% 2212301
5 
 PILOCARPINE 
HCL 
COMPOUND - 
PILOCARPINE 
4% 2212301
9 
 PILOCARPINE 
HCL 
COMPOUND - 
PILOCARPINE 
- 2212329
4 
 PILOCARPINE 
HCL & 
EPINEPHRINE 
BITARTRATE 
E-PILO 2 2% & 1% 0002885
1 
 BETAXOLOL 
HCL & 
PILOCARPINE 
HCL 
 
BETOPTIC/PILO 0.25% & 1.75% 0223853
9 
PGA  TRAVOPROST TRAVATAN 0.004% 0224489
6 
 BIMATOPROST LUMIGAN 0.03% 0224586
0 
 TRAVOPROST TRAVATAN Z 0.004% 0231800
8 
 TRAVOPROST TRAVATAN Z 0.004% 0985733
2 
 BIMATOPROST LUMIGAN RC 0.01% 0232499
 207 
 
7 
 BIMATOPROST LUMIGAN RC 0.01% 0985736
8 
 LATANOPROST APO-LATANOPROST 50MCG/ML 0229652
7 
 LATANOPROST GD-LATANOPROST 50MCG 0237304
1 
 BIMATOPROST LUMIGAN RC 0.01% 0985739
8 
 LATANOPROST CO LATANOPROST 0.05MG/ML 0225478
6 
 LATANOPROST SANDOZ-
LATANOPROST 
50MCG/ML 0236733
5 
 TRAVOPROST TEVA-TRAVOPROST Z 0.004% 0241206
3 
 TRAVOPROST TEVA-TRAVOPROST Z 0.004% 0985750
4 
 TRAVOPROST SANDOZ 
TRAVOPROST 
0.004% 0241316
7 
 TRAVOPROST APO-TRAVOPROST Z 0.004% 0241573
9 
 LATANOPROST PMS-LATANOPROST 50MCG/ML 0231712
5 
 BIMATOPROST LUMIGAN 0.03% 0099014
6 
 BIMATOPROST LUMIGAN 0.03% 9224586
0 
 LATANOPROST LATANOPROST 50MCG/ML 0237550
8 
 LATANOPROST 
& TIMOLOL 
XALACOM 5MG/5MCG/ML 0224661
9 
 TIMOLOL 
MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 0227825
1 
 TIMOLOL 
MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 0985733
3 
 LATANOPROST 
& TIMOLOL 
SDZ-
LATANOP/TIMOLOL 
5MG/5MCG/ML 0239468
5 
 LATANOPROST 
& TIMOLOL 
GD-
LATANOPROST/TIMOL
OL 
5MG/5MCG/ML 0237306
8 
 TIMOLOL 
MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 0985751
2 
 TIMOLOL 
MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 0985751
3 
 LATANOPROST 
& TIMOLOL 
PMS-LATANOPROST-
TIMOLOL 
 
5MG/50MCG/M
L 
0240459
1 
Sympathomimeti
cs 
BRIMONIDINE 
TARTRATE RATIO-BRIMONIDINE 0.2% 
0224302
6 
 BRIMONIDINE 
TARTRATE ALPHAGAN P 0.15% 
0224815
1 
 BRIMONIDINE PMS-BRIMONIDINE 0.2% 0224628
 208 
 
TARTRATE 4 
 BRIMONIDINE 
TARTRATE APO-BRIMONIDINE 0.2% 
0226007
7 
 
BRIMONIDINE SANDOZ-BRIMONIDINE 0.2% 
0230542
9 
 BRIMONIDINE 
TARTRATE APO-BRIMONIDINE P 0.15% 
0230133
4 
 BRIMONIDINE 
TARTRATE ALPHAGAN 0.5% 
0223687
7 
 BRIMONIDINE 
TARTRATE DOM-BRIMONIDINE 0.2% 
0224628
5 
 BRIMONIDINE 
TARTRATE BRIMONIDINE 0.2% 
0224945
6 
 BRIMONIDINE 
TARTRATE 
BRIMONIDINE 
TARTRATE 0.2% 
0224594
2 
 KETOTIFEN 
FUMARATE KETOTIFEN 0.25MG/ML 
0240087
1 
 EPINEPHRYL 
BORATE EPINAL 1% 
0000073
6 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL E-PILO # 2 2% 
0003592
0 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL E-PILO # 4 4% 
0003594
7 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL E-PILO # 3 3% 
0028169
7 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL E-PILO # 6 6% 
0028185
9 
 EPINEPHRYL 
BORATE EPPY 0.5% 
0032364
0 
 EPINEPHRYL 
BORATE EPPY 1% 
0032365
9 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL E-PILO # 1 1% 
0052636
3 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL E-PILO # 2 2% 
0052637
1 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL E-PILO # 3 3% 
0052639
8 
 EPINEPHRINE 
BITARTRATE & 
PILOCARPINE 
HCL E-PILO # 4 4% 
0052640
1 
 EPINEPHRINE E-PILO # 6 6% 0052642
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BITARTRATE & 
PILOCARPINE 
HCL 
8 
 BRIMONIDINE 
TARTRATE 
BRIMONIDINE 
OPHTHALMIC 0.2% 
0224628
3 
 BRIMONIDINE 
TARTRATE APX-BRIMONIDINE P 0.15% 
0235073
4 
 PILOCARPINE 
HCL & 
EPINEPHRINE 
BITARTRATE 
E-PILO 2 2% & 1% 0002885
1 
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Appendix F: Other Eye Drop Medications 
Drug Class Generic Name Trade Name Strength DIN 
 
 
Antibiotic FUSIDIC ACID FUCITHALMIC W/O 
PRES 
1% 02243861 
 GRAMICIDIN & 
POLYMYXIN B SULFATE 
POLYSPORIN 10MU 02239156 
 BACITRACIN ZINC & 
POLYMYXIN B SULFATE 
POLYSPORIN 10MU 02239157 
 FUSIDIC ACID FUCITHALMIC W/ 
PRES 
1% 02243862 
 CHLORAMPHENICOL CHLOROPTIC 1% 00001341 
 BACITRACIN ZINC & 
POLYMYXIN B SULFATE 
POLYSPORIN 10MU 00004847 
 CHLORTETRACYCLINE 
HCL 
AUREOMYCIN 1% 00015075 
 TETRACYCLINE HCL ACHROMYCIN 1% 00015083 
 ERYTHROMYCIN ILOTYCIN   00015997 
 CHLORAMPHENICOL PENTAMYCETIN 10MG 00024317 
 OXYTETRACYCLINE HCL 
& POLYMYXIN B 
SULFATE 
TERRAMYCIN   00024791 
 BORIC ACID BORIC ACID NOT AVLE 00050504 
 SULFISOXAZOLE 
DIOLAMINE 
GANTRISIN 4% 00115460 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
CHLOROMYCETIN 
W/HC 
  00155977 
 CHLORAMPHENICOL PENTAMYCETIN 2.5MG 00163503 
 ERYTHROMYCIN PDP-ERYTHROMYCIN 5MG 00191275 
 BACITRACIN & 
POLYMYXIN B SULFATE 
NEO BACE   00221392 
 CHLORAMPHENICOL ISOPTO FENICOL 0.5% 00239879 
 GRAMICIDIN & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
NEOSPORIN 10MU 00243183 
 SULFACETAMIDE 
SODIUM 
SULFACETAMIDE 10% 00269069 
 SULFACETAMIDE 
SODIUM 
SULF-10 10% 00281867 
 SULFACETAMIDE 
SODIUM 
OPTOSULFEX 10% 00343986 
 CHLORAMPHENICOL MINIMS 
CHLORAMPHENICOL 
0.5% 00387525 
 FLUOROMETHOLONE & 
NEOMYCIN SULFATE 
FML-NEO LIQUIFILM 0.1% 00395153 
 CHLORAMPHENICOL SOPAMYCETIN   00402974 
 BORIC ACID & SODIUM 
BORATE 
COLLYRE 
HYGIENIQUE SOKER 
11.1MG & 
1.89MG 
00425745 
 CHLORAMPHENICOL SOPAMYCETIN 2MG 00438650 
 CHLORAMPHENICOL SOPAMYCETIN 50MG 00438677 
 CHLORAMPHENICOL PENTAMYCETIN 2.5MG 00446521 
 CHLORAMPHENICOL PENTAMYCETIN 45MG 00504785 
 ALLANTOIN & BORIC OPTREX   00520101 
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ACID & HAMAMELIS & 
SALICYLIC ACID & 
SODIUM BORATE & ZINC 
SULFATE 
 ALLANTOIN & BORIC 
ACID & GLYCEROL & 
HAMAMELIS & SODIUM 
BORATE 
OPTREX   00520128 
 BORIC ACID EYE WASH 2.5% 00524468 
 SULFACETAMIDE 
SODIUM 
SULF-10 10% 00527963 
 BORIC ACID BORIC ACID 2.5% 00540994 
 SULFACETAMIDE 
SODIUM 
SULFEX 10% 00554022 
 BORIC ACID & SODIUM 
BORATE 
EYE EZE 1.11% 00581836 
 GRAMICIDIN & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
NEOSPORIN 10MU 00601659 
 CEFAZOLIN SODIUM CEFAZOLIN NOT AVLE 00622360 
 CHLORAMPHENICOL AK-CHLOR 0.5% 00622958 
 SULFACETAMIDE 
SODIUM 
AK-SULF 10% 00622966 
 CHLORAMPHENICOL AK-CHLOR 1% 00627720 
 BORIC ACID & 
BUTACAINE SULFATE 
EYE LOTION 2.3% & 
0.14% 
00629014 
 GRAMICIDIN & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
AK-SPOR 1.75MG 00635065 
 ERYTHROMYCIN AK-MYCIN 5MG 00641324 
 GRAMICIDIN & 
POLYMYXIN B SULFATE 
OPTIMYXIN 10MU 00701785 
 CHLORAMPHENICOL PENTAMYCETIN 10MG 00704571 
 CHLORAMPHENICOL SPERSANICOL 0.5% 00725528 
 CHLORAMPHENICOL SPERSANICOL 1% 00725536 
 SULFACETAMIDE 
SODIUM 
SPERSACET 10% 00729299 
 SULFACETAMIDE 
SODIUM 
PMS-
SULFACETAMIDE 
30% 00762059 
 CHLORAMPHENICOL CEBENICOL 0.4% 00763454 
 CHLORAMPHENICOL SOPAMYCETIN 2MG 00763535 
 ERYTHROMYCIN ERYTHROTOPIC 5MG 00772305 
 SULFACETAMIDE 
SODIUM 
BALSULPH 10% 00772313 
 SULFACETAMIDE 
SODIUM 
SULAMYD 10% 00778053 
 SULFACETAMIDE 
SODIUM 
SULAMYD 30% 00778061 
 SULFACETAMIDE 
SODIUM 
SULAMYD 10% 00778347 
 ERYTHROMYCIN ERYTHROMYCIN 5MG 00785725 
 SULFACETAMIDE BALSULPH 10% 00790842 
 TETRACYCLINE HCL TETRACYCLINE 1% 00792594 
 GRAMICIDIN & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
OPTIMYXIN PLUS 10MU 00807435 
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 BACITRACIN ZINC & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
BACITRACIN-
NEOMYCIN-POLY 
10MU 00811971 
 SULFACETAMIDE 
SODIUM 
SULFACETAMIDE 
SODIUM 
10% 00811998 
 CHLORAMPHENICOL SOPAMYCETIN 2MG 00837369 
 SULFACETAMIDE 
SODIUM 
PMS-
SULFACETAMIDE 
10% 00838934 
 CHLORAMPHENICOL PMS-
CHLORAMPHENICOL 
0.5% 00861383 
 OXYMETAZOLINE HCL VISINE L.R.   00892025 
 GRAMICIDIN & 
POLYMYXIN B SULFATE 
POLYSPORIN 10MU 00898805 
 POLYMYXIN B SULFATE BIODERM 10000U/500G 00899380 
 AMIKACIN SULFATE AMIKACIN EYE 
DROPS 
NOT AVLE 00903067 
 CEFAZOLIN SODIUM CEFAZOLIN NOT AVLE 00903081 
 CYCLOSPORINE CYCLOSPORIN NOT AVLE 00903083 
 VANCOMYCIN HCL VANCOMYCIN NOT AVLE 00903088 
 CLARITHROMYCIN CLARITHROMYCIN NOT AVLE 00903092 
 CYCLOSPORINE RESTASIS 0.05% 00903127 
 ERYTHROMYCIN ILOTYCIN   00904082 
 ERYTHROMYCIN ERYTHROMYCIN 5MG/G 00906840 
 ERYTHROMYCIN PDP-ERYTHROMYCIN 5MG 00912755 
 OXYMETAZOLINE HCL VISINE L.R.   01942484 
 BORIC ACID EYE WASH 1.2% 01943464 
 BACITRACIN ZINC & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
DIOSPORIN   02023792 
 SULFACETAMIDE 
SODIUM 
DIOSULF 10% 02023830 
 CHLORAMPHENICOL DIOCHLORAM 0.5% 02023857 
 PHENIRAMINE MALEATE 
& PHENYLEPHRINE HCL 
& POLYVINYL ALCOHOL 
DIOROUGE 0.5% 02026511 
 ERYTHROMYCIN DIOMYCIN 5MG/GM 02141574 
 CHLORAMPHENICOL MINIMS 
CHLORAMPHENICOL 
0.5% 02148374 
 BACITRACIN ZINC & 
POLYMYXIN B SULFATE 
OPTIMYXIN 10MU 02160889 
 CHLORAMPHENICOL PENTAMYCETIN 0.5% 02164051 
 ALLANTOIN & BORIC 
ACID & GLYCEROL & 
HAMAMELIS & SODIUM 
BORATE 
OPTREX   02185482 
 ALLANTOIN & BORIC 
ACID & HAMAMELIS & 
SALICYLIC ACID & 
SODIUM BORATE & ZINC 
SULFATE 
OPTREX   02186853 
 ERYTHROMYCIN ERYTHROMYCIN 0.5% 02212935 
 BORIC ACID EYE WASH 1.2% 02212994 
 GRAMICIDIN & 
POLYMYXIN B SULFATE 
POLYCIDIN 10MU 02229903 
 BACITRACIN ZINC & 
POLYMYXIN B SULFATE 
POLYCIDIN 10MU 02230193 
 213 
 
 ERYTHROMYCIN ERYTHROMYCIN 5MG 02237041 
 POLYMYXIN B SULFATE 
& TRIMETHOPRIM 
SULFATE 
SANDOZ-
POLYTRIMETHOPRIM 
1% 02239234 
 POLYMYXIN B SULFATE 
& TRIMETHOPRIM 
SULFATE 
PMS-
POLYTRIMETHOPRIM 
1% 02240363 
 AZITHROMYCIN AZASITE 1% 02321661 
 ERYTHROMYCIN OPHTH 
ERYTHROMYCIN 
5MG 02326663 
 BESIFLOXACIN HCL BESIVANCE 0.6% 02336847 
 AZITHROMYCIN AZASITE 1% 02345498 
 CYCLOSPORINE RESTASIS 0.05% 02355655 
 VANCOMYCIN HCL COMPOUND - 
VANCOMYCIN 
NOT AVLE 22123297 
 CYCLOSPORINE CYCLOSPORIN 4% 66123446 
 ERYTHROMYCIN 
STEARATE 
ERYTHROMYCINE 0.5% 99100766 
 OFLOXACIN APO-OFLOXACIN 0.3% 02248398 
 OFLOXACIN PMS-OFLOXACIN 0.3% 02252570 
 NORFLOXACIN NOROXIN 0.3% 00908294 
 NORFLOXACIN NOROXIN 0.3% 01908294 
 NORFLOXACIN NOROXIN 0.3% 01918294 
 OFLOXACIN OPHTHO-FLOX .30% 02243025 
 OFLOXACIN SANDOZ-OFLOXACIN 0.3% 02247189 
 MOXIFLOXACIN HCL VIGAMOX 0.5% 02252260 
 CIPROFLOXACIN HCL PMS-
CIPROFLOXACIN 
0.3% 02253933 
 GATIFLOXACIN ZYMAR 0.3% 02257270 
 CIPROFLOXACIN HCL APO-CIPROFLOX 0.3% 02263130 
 CIPROFLOXACIN HCL NU-CIPROFLOX .3% 02333228 
 CIPROFLOXACIN HCL SANDOZ-
CIPROFLOXACIN 
0.3% 02387131 
 MOXIFLOXACIN HCL SANDOZ 
MOXIFLOXACIN 
0.5% 02411520 
 PHENYLEPHRINE HCL & 
SODIUM BORATE & 
BORIC ACID 
OCCU-CAL 0.2MG/ML & 
1.9MG/ML & 
11.16MG/ML 
00540935 
 BETAMETHASONE 
SODIUM PHOSPHATE & 
GENTAMICIN SULFATE 
SANDOZ-
PENTASONE 
3MG/ML 02244999 
 DEXAMETHASONE & 
FRAMYCETIN SULFATE 
& GRAMICIDIN 
SANDOZ-OPTICORT 5MG 02247920 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
BLEPHAMIDE 
LIQUIFILM 
10% 00807788 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
CETAPRED 10% 00042617 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
CETAPRED 10% 00042625 
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 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
ISOPTO CETAPRED 10% 00042633 
 DEXAMETHASONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
MAXITROL 0.1% 00042668 
 DEXAMETHASONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
MAXITROL 0.1% 00042676 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
BLEPHAMIDE 
LIQUIFILM 
10% 00045632 
 BACITRACIN ZINC & 
HYDROCORTISONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
CORTISPORIN 1% 00068772 
 DEXAMETHASONE & 
NEOMYCIN SULFATE 
NEO-DECADRON 0.1% 00140732 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
OPHTHOCORT 10MG 00156175 
 HYDROCORTISONE & 
OXYTETRACYCLINE HCL 
TERRA-CORTRIL   00158178 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
PENTAMYCETIN HC 10MG 00163511 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
PENTAMYCETIN HC 10MG 00163538 
 DEXAMETHASONE & 
FRAMYCETIN SULFATE 
& GRAMICIDIN 
SOFRACORT 5MG 00173592 
 DEXAMETHASONE & 
FRAMYCETIN SULFATE 
& GRAMICIDIN 
SOFRACORT 5MG 00173606 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
METIMYD 0.5% 00177024 
 HYDROCORTISONE 
ACETATE & NEOMYCIN 
SULFATE 
NEO-CORTEF 0.5% 00194883 
 HYDROCORTISONE 
ACETATE & NEOMYCIN 
SULFATE 
NEO-CORTEF 1.5% 00194921 
 HYDROCORTISONE 
ACETATE & NEOMYCIN 
SULFATE 
NEO-CORTEF 1.5% 00194948 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
& SULFACETAMIDE 
SODIUM 
VASOCIDIN 0.25% 00218812 
 HYDROCORTISONE & 
NEOMYCIN SULFATE & 
CORTISPORIN   00243140 
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POLYMYXIN B SULFATE 
 BETAMETHASONE & 
SULFACETAMIDE 
SODIUM 
CELESTONE-S 3MG 00271012 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
& SULFACETAMIDE 
SODIUM 
VASOCIDIN 0.25% 00281824 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
BLEPHAMIDE S.O.P. 10% 00307246 
 DEXAMETHASONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
MAXITROL 0.1% 00358177 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
BLEPHAMIDE 
LIQUIFILM 
10% 00395145 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
SOPAMYCETIN HC 2MG 00438669 
 HYDROCORTISONE & 
OXYTETRACYCLINE HCL 
TERRA-CORTRIL   00443298 
 BACITRACIN ZINC & 
HYDROCORTISONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
CORTISPORIN 1% 00520322 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
& SULFACETAMIDE 
SODIUM 
VASOCIDIN 0.25% 00527998 
 BETAMETHASONE & 
SULFACETAMIDE 
SODIUM 
CELESTONE-S 3MG 00575194 
 BETAMETHASONE 
SODIUM PHOSPHATE & 
GENTAMICIN SULFATE 
GARASONE 0.3% 00586692 
 BETAMETHASONE 
SODIUM PHOSPHATE & 
GENTAMICIN SULFATE 
GARASONE 0.3% 00586706 
 DEXAMETHASONE & 
NEOMYCIN & 
POLYMYXIN B SULFATE 
AK-TROL 10MU 00626597 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
AK-CIDE 10/0.5% 00630640 
 HYDROCORTISONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
CORTISPORIN   00666211 
 BACITRACIN ZINC & 
HYDROCORTISONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
CORTISPORIN 1% 00701904 
 CHLORAMPHENICOL & PENTAMYCETIN HC 10MG 00704563 
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HYDROCORTISONE 
ACETATE 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
CORTIPHENAL H 1% & 1% 00750670 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
& SULFACETAMIDE 
SODIUM 
VASOCIDIN 0.25% 00760056 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
SOPAMYCETIN HC 2MG 00763543 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
BLEPHAMIDE S.O.P. 10% 00806617 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
BLEPHAMIDE 
LIQUIFILM 
10% 00807982 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
& SULFACETAMIDE 
SODIUM 
VASOCIDIN 0.25% 00808199 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
ISOPTO CETAPRED 10% 00810894 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
SOPAMYCETIN HC 10MG 00837350 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
& SULFACETAMIDE 
SODIUM 
VASOCIDIN 0.25% 00843741 
 PREDNISOLONE 
ACETATE & 
SULFACETAMIDE 
SODIUM 
BLEPHAMIDE 
LIQUIFILM 
10% 00903124 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
& SULFACETAMIDE 
SODIUM 
VASOCIDIN 0.25% 00903477 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
PENTAMYCETIN HC 10MG 01980572 
 CHLORAMPHENICOL & 
HYDROCORTISONE 
ACETATE 
PENTAMYCETIN HC 10MG 01980580 
 DEXAMETHASONE & 
FRAMYCETIN SULFATE 
& GRAMICIDIN 
SOFRACORT 5MG 01987720 
 DEXAMETHASONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
DIOPTROL 3.5MG 02023806 
 PREDNISOLONE DIOPTIMYD 5MG 02023814 
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ACETATE & 
SULFACETAMIDE 
SODIUM 
 DEXAMETHASONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
DIOPTROL 3.5MG 02023849 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
& SULFACETAMIDE 
SODIUM 
VASOCIDIN 0.25% 02133342 
 DEXAMETHASONE & 
FRAMYCETIN SULFATE 
& GRAMICIDIN 
SOFRACORT 5MG 02224631 
 GENTAMICIN SULFATE & 
BETAMETHASONE 
SODIUM PHOSPHATE 
DOM-GENTAMICIN-
BETAMETHASONE 
0.3% & 0.1% 02238818 
 GENTAMICIN SULFATE & 
BETAMETHASONE 
SODIUM PHOSPHATE 
PMS-GENTAMICIN-
BETAMETHASONE 
0.3% & 0.1% 02238819 
 BACITRACIN & 
HYDROCORTISONE & 
NEOMYCIN SULFATE & 
POLYMYXIN B SULFATE 
SANDOZ-
CORTIMYXIN 
10MU 02242485 
 GENTAMICIN SULFATE & 
BETAMETHASONE 
SODIUM PHOSPHATE 
BETAMYCIN 3MG/ML & 
1MG/ML 
02247446 
 SULFACETAMIDE 
SODIUM & 
PHENYLEPHRINE HCL 
VASOSULF 15% & .125% 00191965 
 PHENYLEPHRINE HCL & 
SULFACETAMIDE 
SODIUM 
VASOSULF 15% 00265152 
 PHENYLEPHRINE HCL & 
SULFACETAMIDE 
SODIUM 
 
VASOSULF 15% 00760048 
Aminoglycoside TOBRAMYCIN SULFATE SANDOZ-
TOBRAMYCIN 
0.3% 02241755 
 TOBRAMYCIN APO-TOBRAMYCIN 0.3% 02245698 
 FRAMYCETIN SULFATE SOFRAMYCIN 5MG 02224887 
 FRAMYCETIN SULFATE SOFRAMYCIN 5MG 02224895 
 GENTAMICIN SULFATE GARAMYCIN 0.3% 00028126 
 GENTAMICIN SULFATE GARAMYCIN 0.3% 00512912 
 GENTAMICIN SULFATE GENTAMYTREX 5MG/ML 00717940 
 GENTAMICIN SULFATE GENTAMYTREX 5MG/GM 00717959 
 GENTAMICIN GENTROSULF 3% 00772429 
 GENTAMICIN SULFATE PMS-GENTAMICIN 0.5% 00777781 
 GENTAMICIN SULFATE OPHTAGRAM 0.3% 00789100 
 GENTAMICIN GENTROSULF 3% 00790753 
 GENTAMICIN SULFATE OPHTAGRAM 0.3% 00794317 
 GENTAMICIN GENTACIDIN 0.3% 00810282 
 GENTAMICIN SULFATE GENTAK 0.3% 00832162 
 GENTAMICIN RATIO-GARATEC 3MG 00880191 
 TOBRAMYCIN TOBRAMYCIN - 00903080 
 GENTAMICIN SULFATE GENTAMICIN 
FORTIFIED 
- 00903082 
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 NETILMICIN SULFATE NATACYN 5% 00910911 
 GENTAMICIN CIDOMYCIN 0.3% 01932330 
 GENTAMICIN CIDOMYCIN 0.3% 01932349 
 GENTAMICIN SULFATE GENTAMICIN 0.3% 01933299 
 GENTAMICIN OCUGRAM 3MG 01987461 
 GENTAMICIN OCUGRAM 3MG 01987488 
 FRAMYCETIN SULFATE SOFRAMYCIN 5MG 01987666 
 GENTAMICIN SULFATE GENTAK 0.3% 01989073 
 GENTAMICIN SULFATE MINIMS GENTAMICIN 
SULF 
0.3% 02009900 
 GENTAMICIN SULFATE GENTAMICIN 
SULFATE 
0.3% 02014548 
 GENTAMICIN SULFATE DIOGENT 0.3% 02023776 
 GENTAMICIN SULFATE GENTAMICIN 
SULFATE 
0.3% 02024500 
 GENTAMICIN GENTACIDIN 0.3% 02133245 
 GENTAMICIN SULFATE MINIMS GENTAMICIN 
SULF 
0.3% 02148404 
 GENTAMICIN SULFATE GENTAMICIN 
SULFATE 
0.3% 02229440 
 GENTAMICIN SULFATE GENTAMICIN 
SULFATE 
0.3% 02230888 
 GENTAMICIN SULFATE PMS-GENTAMICIN 0.3% 02237689 
 TOBRAMYCIN CROWN AK-TOBRA 0.3% 02238710 
 TOBRAMYCIN TOBREXAN 0.3% 02261243 
 TOBRAMYCIN SULFATE COMPOUND - 
TOBRAMYCIN 
- 22123296 
 TOBRAMYCIN TOBRAMYCIN 
 
300MG 99100845 
Antifungal VORICONAZOLE VORICONAZOLE 1% 09854663 
 VORICONAZOLE 
 
VORICONAZOLE - 00903740 
Antiviral INTERFERON INTERFERON 1MU/ML 09852751 
 INTERFERON INTERFERON 1MU/ML 00903448 
 IDOXURIDINE STOXIL 1MG/ML 00027014 
 TRIFLURIDINE VIROPTIC 1% 00589055 
 TRIFLURIDINE APO-TRIFLURIDINE 1% 02248119 
 TRIFLURIDINE SANDOZ-
TRIFLURIDINE 
 
1% 02248529 
Mydriatic ATROPINE SULFATE ISOPTO ATROPINE 1% 00000639 
 ATROPINE SULFATE SMP ATROPINE 1% 00028800 
 ATROPINE SULFATE MINIMS ATROPINE 1% 00269255 
 ATROPINE SULFATE SMP ATROPINE 1% 00281603 
 ATROPINE SULFATE SMP ATROPINE 0.5% 00281611 
 ATROPINE SULFATE SMP ATROPINE 2% 00281638 
 ATROPINE SULFATE SMP ATROPINE 1% 00344842 
 ATROPINE PLUS ISOPTO MYDRAPRED 1% 00358215 
 ATROPINE SULFATE SMP ATROPINE 0.5% 00527939 
 ATROPINE SULFATE SMP ATROPINE 1% 00527947 
 ATROPINE SULFATE SMP ATROPINE 2% 00527955 
 ATROPINE SULFATE ATROPINE AK 1% 00622907 
 ATROPINE SULFATE ATROPINE SULFATE 1% 00811963 
 ATROPINE SULFATE ATROPINE 1% 01901311 
 ATROPINE SULFATE ATROPINE 1% 01948601 
 ATROPINE SULFATE ATROPINE 1% 02023695 
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 ATROPINE SULFATE MINIMS ATROPINE 1% 02148358 
 ATROPINE SULFATE ATROPINE 1% 02212951 
 ATROPINE SULFATE & 
HYDROCORTISONE 
HC-ATROPINE 1% 00062251 
 ATROPINE SULFATE & 
HYDROCORTISONE 
HC-ATROPINE 1% 00062278 
 SCOPOLAMINE ISOPTO HYOSCINE 0.25% 00000957 
 TROPICAMIDE MYDRIACYL 0.5% 00000981 
 HOMATROPINE HBR HOMATROPINE HBR 5% 00028916 
 PHENYLEPHRINE HCL NEO-SYNEPHRINE 0.125% 00033502 
 PHENYLEPHRINE HCL NEO-SYNEPHRINE 10% 00033529 
 CYCLOPENTOLATE HCL CYCLOGYL 1% 00252506 
 CYCLOPENTOLATE HCL CYCLOGYL 0.5% 00252549 
 PHENYLEPHRINE HCL PHENYLEPHRINE 
HCL 
10% 00269123 
 HOMATROPINE HBR MINIMS 
HOMATROPINE 
2% 00269158 
 CYCLOPENTOLATE HCL CYCLOPENTOLATE 0.05% 00269204 
 PHENYLEPHRINE HCL PHENYLEPHRINE 10% 00281808 
 PHENYLEPHRINE HCL PREFRIN LIQUIFILM 0.12% 00385161 
 PHENYLEPHRINE HCL & 
PYRILAMINE MALEATE 
PREFRIN-A LIQUIFLM 0.1% 00400408 
 PHENYLEPHRINE HCL NEO-SYNEPHRINE 0.125% 00482684 
 CYCLOPENTOLATE HCL CYC 1% 00506230 
 CYCLOPENTOLATE HCL MYDPLEGIC 1% 00527580 
 HYPROMELLOSE MURO TEARS   00544787 
 TROPICAMIDE TROPICAMIDE 1% 00544825 
 PHENYLEPHRINE HCL NEO-SYNEPHRINE 0.125% 00561886 
 PHENYLEPHRINE HCL NEO-SYNEPHRINE 10% 00561894 
 TROPICAMIDE TROPICACYL 1% 00622885 
 PHENYLEPHRINE HCL AK-DILATE 2.5% 00622915 
 CYCLOPENTOLATE HCL AK-PENTOLATE 1% 00626627 
 CYCLOPENTOLATE HCL AK-PENTOLATE 0.5% 00626635 
 TROPICAMIDE TROPICACYL 0.5% 00627704 
 PHENYLEPHRINE HCL & 
TROPICAMIDE 
PHENYLTROPE 5% 00629693 
 CYCLOPENTOLATE HCL SPERSAPENTOL 1% 00751758 
 TROPICAMIDE TROPICAMIDE 1% 00751774 
 PHENYLEPHRINE HCL SPERSAPHRINE 2.5% 00751820 
 TROPICAMIDE PMS-TROPICAMIDE 1% 00872946 
 CYCLOPENTOLATE HCL PMS-
CYCLOPENTOLATE 
HCL 
1% 00878189 
 TROPICAMIDE TROPICAMIDE 1% 00896446 
 CYCLOPENTOLATE HCL DIOPENTOLATE 1% 02023644 
 TROPICAMIDE DIOTROPE 0.5% 02023660 
 TROPICAMIDE DIOTROPE 1% 02023679 
 CYCLOPENTOLATE HCL DIOPENTOLATE 0.5% 02023687 
 PHENYLEPHRINE HCL & 
TROPICAMIDE 
DIOPHENYL-T 0.8% 02023717 
 PHENYLEPHRINE HCL DIONEPHRINE 0.12% 02026473 
 PHENYLEPHRINE HCL DIONEPHRINE 2.5% 02027100 
 CYCLOPENTOLATE HCL MINIMS 
CYCLOPENTOLATE 
0.5% 02148331 
 CYCLOPENTOLATE HCL MINIMS 
CYCLOPENTOLATE 
1% 02148382 
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 HOMATROPINE HBR MINIMS 
HOMATROPINE 
2% 02148420 
 PHENYLEPHRINE HCL MINIMS 
PHENYLEPHRINE 
2.5% 02148447 
 PHENYLEPHRINE HCL MINIMS 
PHENYLEPHRINE 
10% 02148455 
 TROPICAMIDE MINIMS 
TROPICAMIDE 
1% 02148536 
 CYCLOPENTOLATE HCL DOM-
CYCLOPENTOLATE 
HCL 
1% 02181436 
 TROPICAMIDE 
 
TROPICAMIDE 1% 02212919 
NSAID KETOROLAC 
TROMETHAMINE 
KETOROLAC 
TROMETHAMINE 
0.5% 02247461 
 KETOROLAC 
TROMETHAMINE 
KETOROLAC 
TROMETHAMINE 
0.5% 02245821 
 KETOROLAC 
TROMETHAMINE 
KETOROLAC 
TROMETHAMINE 
0.45% 02369362 
 DICLOFENAC SODIUM DICLOFENAC 
SODIUM 
0.1% 00903755 
 DICLOFENAC SODIUM DICLOFENAC 
SODIUM 
0.1% 00940414 
 KETOROLAC 
TROMETHAMINE 
KETOROLAC 
TROMETHAMINE 
0.5% 00961272 
 SUPROFEN SUPROFEN 1% 02132710 
 INDOMETHACIN INDOMETHACIN 0.1% 02219506 
 DICLOFENAC SODIUM DICLOFENAC 
SODIUM 
0.1% 02238145 
 KETOROLAC 
TROMETHAMINE 
KETOROLAC 
TROMETHAMINE 
0.4% 02248722 
 NEPAFENAC NEPAFENAC 0.1% 02308983 
 KETOROLAC 
TROMETHAMINE 
KETOROLAC 
TROMETHAMINE 
0.5% 02336693 
 NEPAFENAC NEPAFENAC 0.3% 02411393 
 BROMFENAC SODIUM BROMFENAC 
SODIUM 
 
0.7% 02439123 
Steroids DEXAMETHASONE MAXIDEX 1MG 00000698 
 BETAMETHASONE BETNESOL 0.1% 00012173 
 HYDROCORTISONE 
ACETATE 
CORTRIL 0.5% 00024775 
 HYDROCORTISONE 
ACETATE 
CORTRIL 2.5% 00024783 
 MEDRYSONE & 
POLYVINYL ALCOHOL 
HMS LIQUIFILM 1% 00036676 
 PREDNISOLONE 
ACETATE 
PREDNICON 1% 00252492 
 FLUOROMETHOLONE FML-NEO 0.1% 00259454 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
INFLAMASE 0.125% 00281735 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
INFLAMASE FTE 1% 00281743 
 HYDROCORTISONE 
ACETATE 
CORTAMED 2.5% 00283231 
 HYDROCORTISONE CORTAMED   00283258 
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ACETATE 
 METHYLPREDNISOLONE MEDROL 0.1% 00358711 
 FLUOROMETHOLONE SANDOZ-
FLUOROMETHOLONE 
0.1% 00432814 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
INFLAMASE 0.125% 00526452 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
INFLAMASE FTE 1% 00526460 
 HYDROCORTISONE 
ACETATE 
CORTAMED 2.5% 00704458 
 PREDNISOLONE 
ACETATE 
ULTRACORTENOL 0.5% 00727466 
 DEXAMETHASONE DEXAMETHASONE 0.1% 00739839 
 DEXAMETHASONE 
SODIUM 
CEBEDEX 0.1% 00741752 
 PREDNISOLONE 
ACETATE 
BALPRED 1% 00764639 
 PREDNISOLONE 
ACETATE 
PREDOLONE FORTE 1% 00801186 
 PREDNISOLONE 
ACETATE 
PREDOLONE 1% 00809152 
 FLUOROMETHOLONE & 
POLYVINYL ALCOHOL 
FML LIQUIFILM 0.1% 00893188 
 FLUOROMETHOLONE & 
POLYVINYL ALCOHOL 
FML LIQUIFILM 0.1% 00894931 
 PREDNISOLONE 
ACETATE 
PRED FORTE 1% 00894958 
 PREDNISOLONE 
ACETATE 
AK-TATE 1% 00896144 
 FLUOROMETHOLONE FML FORTE 0.25% 00897469 
 PREDNISOLONE 
ACETATE 
OPHTHO-TATE 1% 00898732 
 PREDNISOLONE 
DISODIUM PHOSPHATE 
INFLAMASE FTE 1% 00907626 
 PREDNISOLONE 
ACETATE 
R.O.-PREDPHATE 
FORTE 
1% 00908266 
 PREDNISOLONE 
ACETATE 
PREDNISOLONE 
ACETATE 
- 00961264 
 PREDNISOLONE 
ACETATE 
PREDNISOLONE 
ACETATE 
0.12% 01916181 
 PREDNISOLONE 
ACETATE 
PREDNISOLONE 
ACETATE 
1% 01916203 
 PREDNISOLONE 
SODIUM PHOSPHATE 
PREDNISOLONE 1% 01924400 
 DEXAMETHASONE 
SODIUM PHOSPHATE 
DEXAMETHASONE 0.1% 01947044 
 PREDNISOLONE 
SODIUM PHOSPHATE 
PMS-PREDNISOLONE 
SOD/PHO 
1% 01954237 
 HYDROCORTISONE 
ACETATE 
CORTAMED 2.5% 01980661 
 DEXAMETHASONE 
SODIUM PHOSPHATE 
OCUDEX 0.1% 01995022 
 BETAMETHASONE BETNESOL 0.1% 02060868 
 PREDNISOLONE 
SODIUM PHOSPHATE 
MINIMS 
PREDNISOLONE SOD 
0.5% 02148498 
 RIMELOXONE VEXOL 1% 02163691 
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 PREDNISOLONE 
SODIUM PHOSPHATE 
PREDNISOLONE 1% 02213079 
 FLUOROMETHOLONE PMS-
FLUOROMETHOLONE 
0.1% 02238568 
 PREDNISOLONE 
SODIUM PHOSPHATE 
SAB-PREDNASE 1% 02245858 
 LOTEPREDNOL 
ETABONATE 
ALREX 0.2% 02320924 
 LOTEPREDNOL 
ETABONATE 
LOTEMAX 0.5% 02321114 
 LOTEPREDNOL 
ETABONATE 
LOTEMAX OINTMENT 5MG 02421941 
 PREDNISOLONE 
ACETATE 
PRED FORTE 1% 99100258 
 PREDNISOLONE 
SODIUM PHOSPHATE 
PREDNISOLONE 1% 99100839 
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Appendix G: Benzalkonium Chloride Content of Anti-Glaucoma Drugs 
Generic Name Trade Name Strength DIN 
BAK 
(%vol.) 
PILOCARPINE HCL ISOPTO CARPINE 0.5% 00000833 0 
PILOCARPINE HCL MINIMS 
PILOCARPINE 
2% 00269107 0 
PILOCARPINE HCL MINIMS 
PILOCARPINE 
2% 02148463 0 
PILOCARPINE HCL MINIMS 
PILOCARPINE 
4% 02148471 0 
LATANOPROST SANDOZ-
LATANOPROST 
50MCG/ML 02367335 0 
TRAVOPROST TEVA-
TRAVOPROST Z 
0.004% 02412063 0 
TRAVOPROST TEVA-
TRAVOPROST Z 
0.004% 09857504 0 
TIMOLOL MALEATE APO-TIMOP 0.25% 00755826 0 
TIMOLOL MALEATE APO-TIMOP 0.5% 00755834 0 
TIMOLOL MALEATE TIMOPTIC-XE 0.25% 02171880 0 
TIMOLOL MALEATE TIMOPTIC-XE 0.5% 02171899 0 
DORZOLAMIDE & TIMOLOL CO 
DORZOTIMOLOL 
2/0.5% 02404389 0.0001 
LEVOBUNOLOL HCL BETAGAN 0.5% 00637661 0.004 
LEVOBUNOLOL HCL BETAGAN 0.25% 00751286 0.004 
LEVOBUNOLOL RATIO-
LEVOBUNOLOL 
0.25% 02031159 0.004 
LEVOBUNOLOL RATIO-
LEVOBUNOLOL 
0.5% 02031167 0.004 
DIPIVEFRINE HCL PROPINE 0.1% 00529117 0.004 
EPINEPHRINE HCL EPIFRIN 2% 00001112 0.004 
DIPIVEFRINE HCL & 
LEVOBUNOLOL HCL 
PROBETA 0.5% 02209071 0.004 
LEVOBUNOLOL HCL SANDOZ-
LEVOBUNOLOL 
0.5% 02241716 0.004 
LEVOBUNOLOL HCL SANDOZ-
LEVOBUNOLOL 
0.25% 02241715 0.004 
CARBACHOL ISOPTO 
CARBACHOL 
1.5% 00000655 0.005 
CARBACHOL ISOPTO 
CARBACHOL 
3% 00000663 0.005 
EPINEPHRINE HCL EPIFRIN 0.5% 00001090 0.005 
EPINEPHRINE HCL EPIFRIN 1% 00001104 0.005 
BRIMONIDINE TARTRATE ALPHAGAN 0.2% 02236876 0.005 
DIPIVEFRINE HCL DPE 0.1% 02152525 0.005 
DIPIVEFRINE HCL APO-DIPIVEFRIN 0.1% 02242232 0.005 
BRIMONIDINE TARTRATE RATIO-
BRIMONIDINE 
0.2% 02243026 0.005 
BIMATOPROST LUMIGAN 0.03% 02245860 0.005 
BRIMONIDINE TARTRATE & 
TIMOLOL MALEATE 
COMBIGAN 0.2/0.5% 02248347 0.005 
BRIMONIDINE TARTRATE ALPHAGAN P 0.15% 02248151 0.005 
BRIMONIDINE TARTRATE PMS-BRIMONIDINE 0.2% 02246284 0.005 
BRIMONIDINE TARTRATE APO-BRIMONIDINE 0.2% 02260077 0.005 
BRIMONIDINE TARTRATE & 
TIMOLOL MALEATE 
COMBIGAN 0.2/0.5% 09857298 0.005 
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BRIMONIDINE SANDOZ-
BRIMONIDINE 
0.2% 02305429 0.005 
BRIMONIDINE TARTRATE APO-BRIMONIDINE 
P 
0.15% 02301334 0.005 
PILOCARPINE HCL RATIO-
PILOCARPINE 
1% 02229393 0.0075 
DORZOLAMIDE HCL & 
TIMOLOL MALEATE 
COSOPT 20MG/5MG/ML 02258692 0.0075 
DORZOLAMIDE SANDOZ-
DORZOLAMIDE 
2% 02316307 0.0075 
DORZOLAMIDE & TIMOLOL SANDOZ-
DORZOL/TIMOL 
1% 02344351 0.0075 
TIMOLOL MALEATE TIMOLOL MALEATE-
EX 
0.5% 02242276 0.01 
BRINZOLAMIDE & TIMOLOL 
MALEATE 
AZARGA 1%/0.5% 02331624 0.01 
TIMOLOL MALEATE TIMOPTIC 0.5% 00451207 0.01 
BETAXOLOL HCL BETOPTIC 0.5% 00695688 0.01 
TIMOLOL MALEATE TIMOPTIC 0.25% 00451193 0.01 
TIMOLOL MALEATE MYLAN-TIMOLOL 0.5% 00893781 0.01 
TIMOLOL MALEATE MYLAN-TIMOLOL 0.25% 00893773 0.01 
BETAXOLOL BETOPTIC S 0.25% 01908448 0.01 
TIMOLOL MALEATE SANDOZ-TIMOLOL 0.5% 02166720 0.01 
TIMOLOL MALEATE SANDOZ-TIMOLOL 0.25% 02166712 0.01 
TIMOLOL MALEATE PMS-TIMOLOL 0.5% 02083345 0.01 
TIMOLOL MALEATE PMS-TIMOLOL 0.25% 02083353 0.01 
BRINZOLAMIDE AZOPT 2% & .5% 02238873 0.01 
PILOCARPINE HCL ISOPTO CARPINE 1% 00000841 0.01 
PILOCARPINE HCL ISOPTO CARPINE 2% 00000868 0.01 
PILOCARPINE HCL ISOPTO CARPINE 4% 00000884 0.01 
PILOCARPINE HCL PILOPINE HS 4% 00575240 0.01 
PILOCARPINE HCL ISOPTO CARPINE 6% 00000892 0.01 
PILOCARPINE HCL MINIMS 
PILOCARPINE 
4% 00269085 0.01 
DIPIVEFRINE HCL DPE 0.1% 02145324 0.01 
TIMOLOL MALEATE TIMOLOL MALEATE-
EX 
0.25% 02242275 0.01 
TRAVOPROST TRAVATAN 0.004% 02244896 0.015 
TIMOLOL MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 02278251 0.015 
TRAVOPROST TRAVATAN Z 0.004% 02318008 0.015 
TRAVOPROST TRAVATAN Z 0.004% 09857332 0.015 
TIMOLOL MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 09857333 0.015 
TIMOLOL MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 09857512 0.015 
TIMOLOL MALEATE & 
TRAVOPROST 
DUOTRAV PQ 0.004/0.5% 09857513 0.015 
LATANOPROST XALATAN 0.005% 02231493 0.02 
LATANOPROST & TIMOLOL XALACOM 5MG/5MCG/ML 02246619 0.02 
BIMATOPROST LUMIGAN RC 0.01% 02324997 0.02 
BIMATOPROST LUMIGAN RC 0.01% 09857368 0.02 
LATANOPROST APO-
LATANOPROST 
50MCG/ML 02296527 0.02 
BIMATOPROST LUMIGAN RC 0.01% 09857398 0.02 
LATANOPROST & TIMOLOL SDZ- 5MG/5MCG/ML 02394685 0.02 
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LATANOP/TIMOLOL 
TRAVOPROST SANDOZ 
TRAVOPROST 
0.004% 02413167 0.02 
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Appendix H: Death Competing Risk Analysis – Primary Outcome vs. Death 
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Appendix I: 
 
 
Protocol / Funded Grant: An Investigator-Initiated Multi-Center 
Prospective Clinical Trial to Examine the Efficacy of Peri-
Operative NSAID vs. Steroid Treatment in Trabeculectomy 
Wound Management 
 
 
Given the results described in Chapter 2 and Chapter 3, a randomized clinical 
trial comparing the effects of steroidal and NSAID anti-inflammatory modalities 
after glaucoma surgery is warranted. There was a desire to “close the 
translational loop” and bring our retrospective clinical data-inspired in vitro 
findings back to the clinical setting, however the duration of my PhD studies 
denies the opportunity to collect any clinical trial results. Hence, the results of this 
RCT are outside the scope of my PhD, however, the following RCT protocol is 
included. It was submitted as a grant to the Glaucoma Research Society of 
Canada and funded in 2018. Fifteen glaucoma surgeons from across Canada 
have been recruited and patient enrollment is scheduled to begin summer 2019. 
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Introduction, Purpose & Objectives 
Perioperative inflammation control is essential to both the short and long-term 
success of glaucoma surgery. Currently, this is accomplished with the use of 
topical steroidal anti-inflammatory drugs, such as dexamethasone or 
florometholone. Although these drugs have proven anti-inflammatory action, 
there are associated adverse effects such as steroid associated intraocular 
pressure (IOP) spikes and inhibition of wound healing.175,270 As elevation of IOP 
following glaucoma surgery is undesirable, there is a need to explore alternatives 
to corticosteroids with similar efficacy in inflammation control. 
There have been recent studies to suggest non-steroidal anti-inflammatory drugs 
(NSAIDs), such as diclofenac, may be a promising alternative to corticosteroids 
following glaucoma surgery.90,175 A recent study by Yuen et al. compared 
treatment with corticosteroids versus NSAIDs after Ahmed glaucoma valve 
surgery and found the steroid group showed a greater mean IOP at all measured 
follow-up points postoperatively.90 Yuen et al. conducted a similar comparison 
and found that although there were no significant group differences in IOP at any 
of the follow-up visits, there was a clinical trend toward lower IOP values in the 
NSAID-treated group compared to the steroid-treated cohort.90 More interestingly 
however, Levkovitch-Verbin et al. observed that the average number of glaucoma 
medications being taken at the eight-month follow-up point was significantly 
greater in the cohort treated with steroids post-phacotrabeculectomy compared to 
the NSAID-treated group.  
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This study aims to examine the efficacy of bromfenac (0.07%) relative to 
dexamethasone (0.1%) anti-inflammatory therapy in trabeculectomy wound 
management. Previous in vitro results suggested that indomethacin was 
preferable to dexamethasone for sub-conjunctival wound healing.223 The novel 
ophthalmic NSAID bromfenac, contains bromine hydrophilic moieties such that its 
penetration into sub-conjunctival and sub-corneal tissues is higher.271,272 It is 
hypothesized that substitution of bromfenac (0.07%) NSAID anti-inflammatory 
therapy one week after trabeculectomy will result in non-inferior IOP control with 
the need for fewer post-operative interventions compared to patients remaining 
on steroid only. 
Study Objectives 
• To compare the effects of steroid only to steroid followed by NSAID peri-
operative therapy in achieving target IOP success following 
trabeculectomy 
• To compare event-free survival time with an event defined as a post-op 
intervention required to achieve target IOP in the two patient groups 
• To compare the bleb morphology in the two patient groups using the 
standardized Moorfields bleb grading scale 
 
Study Design & Outcomes 
Description of Study Design 
This will be a multi-center randomized prospective clinical trial. Figure I-1 
illustrates the study treatment schedule. 
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Figure I-1: RCT Drug Treatment Protocol 
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Study Outcomes 
Main Outcome 
The primary outcome is difference in event free survival (minimal and significant 
events; Table 0-1) between the two arms over the first post-operative year. An 
event is defined as a post-operative (secondary) intervention that is necessary to 
achieve a patient’s target IOP. 
Secondary Outcomes 
Absolute intra-ocular pressure and percent reduction from baseline will be 
monitored at all follow up visits to assess non-inferiority between experimental 
groups in terms of IOP control.  
Additional survival curves will be prepared to illustrate the difference in event free 
survival between treatment groups – curves will be prepared based on time to 
either a significant or minimal secondary intervention (Table 0-1). 
 
Table I-1. Post-operative (secondary) interventions qualifying as minimal or 
significant 
QUALIFICATION GROUP DEFINITION 
Minimal Medical 
Intervention 
Require fewer (but non-zero) glaucoma 
medications post-op than pre-op 
Minimal Surgical 
Intervention 
Require needling ± 5-FU, etc. 
  
Significant Medical 
Intervention 
Require more glaucoma medications than pre-op 
to achieve target IOP 
Significant Surgical 
Intervention 
Require a new glaucoma surgical intervention – 
i.e. tube shunt, trab at new clock hour, etc. 
Notes: laser suture lysis is not considered a secondary intervention 
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Sample Size Analysis 
The primary outcome is difference in event (defined within Table I-1) free survival 
between the two arms over the first post-operative year. We will power our study 
according to the primary outcome – an event from any qualification group 
occurring. Secondary outcomes (time to the specific type of secondary 
intervention) will be calculated based on the sample size attained – and are 
expected to require more statistical power than the primary outcome due to their 
lower individual occurrence rates. The logrank test will be used to compare the 
survival curves generated for the primary and each secondary outcome. The 
closest matching previous study was published by Levkovitch-Verbin et. al. 2013 
in the Journal of Glaucoma, with 21 patients per arm. Ten percent of the 
dexamethasone treated patients’ surgeries failed and 5% of the NSAID treated 
patients’ surgeries failed.175 This gives an effective hazard of 0.1 for the control 
arm and 0.05 for the experimental arm – with hazard ratio of 2. This was a 
relatively large treatment effect reported by this study with others reporting 
smaller differences to no significant difference – likely an artifact of all these 
studies’ small sample sizes. This would suggest the true effect lies somewhere in 
the middle, with a hazard ratio of 1 to 2. We want to power our study sufficiently 
to detect a more modest/realistic treatment effect, that is still clinically relevant, so 
we intend to use a more conservative estimated hazard ratio of 1.25 within our 
sample size calculations. This will give us the ability to be more accurate than the 
previously mentioned studies. Using the Rubinstein et al. 1981 approach to the 
 234 
 
logrank test sample size estimation (using: alpha = 0.05, beta = 0.8, minimum 
hazard ratio = 1.25, equal randomization, and estimated mean survival time of 8 
months) we calculated approximately 74 patients necessary per group.273 
Study Enrollment & Withdrawal 
Participant Inclusion Criteria 
In order to be eligible to participate in this study, an individual must meet all of the 
following criteria: 
1. Adult patient over the age of 18 years 
2. Uncontrolled open angle glaucoma 
3. Scheduled to undergo stand-alone trabeculectomy 
4. No previous: 
a. incisional glaucoma surgery 
b. vitrectomy 
c. strabismus surgery 
d. extracapsular cataract extraction (ECCE) 
5. No ocular surgery of any kind in prior 6 months 
Participant Exclusion Criteria 
An individual who meets any of the following criteria will be excluded from 
participation in this study: 
1. Steroids contraindicated 
2. NSAIDs contraindicated 
3. Poor corneal epithelial health  
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Participant Withdrawal or Termination 
Reasons for Withdrawal or Termination 
Participants are free to withdraw from participation in the study at any time upon 
request. An investigator may terminate participation in the study if: 
• Any clinical adverse event (AE), laboratory abnormality, or other medical 
condition or situation occurs such that continued participation in the study 
would not be in the best interest of the participant. 
• The participant meets an exclusion criterion (either newly developed or not 
previously recognized) that precludes further study participation. 
Handling of Participant Withdrawals or Termination 
Participants will be asked to notify their study doctor in the event they wish to 
withdraw their consent and discontinue study participation. Participants will be 
able to withdraw data pertaining to their study participation up until dissemination 
of study results (e.g. study publication). In the event study results have already 
been disseminated, the participant will be reassured that any published study 
data are completely non-identifiable.  
In the event a participant must be terminated from the study, the participant will 
be contacted by their treating study team and the reason for termination will be 
clearly disclosed. If the termination is pertaining to a medical issue, the 
participant will be directly followed by the study team and/or referred for 
additional treatment, if required.  
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Study Drugs 
Overall Study Drug Regimen 
Pre-Operative Course 
All study participants will complete a one-week course of topical dexamethasone 
0.1% QID prior to the scheduled trabeculectomy.  
Post-Operative Course 
On the day after trabeculectomy (Day 1), all participants will resume 
dexamethasone 0.1% QID for one additional week. At the investigator’s 
discretion, the dexamethasone dose frequency may be increased up to q2h 
during the one-week postoperative period. 
At the Day 7 visit, participants will be randomized to one of two treatment groups: 
Table I-2. Randomized Study Drug Regimen 
Group One: Bromfenac 0.07% Group Two: Continue Dexamethasone 0.1% 
TID to one month post-op QID to one month post-op 
BID for two months  
(from 1 month post-op to 3 months 
post-op) 
BID for one month 
QD for one month 
Participants will dose with their assigned study treatment until three months post-
trabeculectomy.   
Antibiotic Use 
Participants will also complete a one-week course of fluoroquinolone antibiotic 
(gatifloxacin ophthalmic solution 0.3%, QID) during the one-week postoperative 
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period. Antibiotic use is considered standard of care for trabeculectomy 
management.  
Dosing and Administration 
Study participants, or their caregiver, will administer study drug. Study 
participants, and/or caregiver, will be instructed on study drug administration to 
encourage proper study drug use. 
Study participants will be provided with a Dosing Guide which outlines the study 
drug regimen. This guide will be reviewed with each study participant to 
encourage proper study drug dosing. 
Route of Administration 
Topical dexamethasone and bromfenac will be used for this study (eye drops). 
Duration of Therapy 
Study participants will dose with study drug for a total duration of three months 
plus one week.  
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Study Procedures & Schedule 
Schedule of Events Table 
 
Table I-3. Schedule 
of Events Table 
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Informed Consent x          
Inc/Exclu. Criteria x          
Demographics1 x          
Medical History2 
including medications 
x          
IOP x3  x x x x x x x x 
BCVA x4  x x x x x x x x 
Slit Lamp Exam x  x x x x x x x x 
Bleb Grading Scale 
(Moorfields) 
  x x x x x x x x 
C/D Ratio x         x 
Humphrey Perimetry x         x 
Trabeculectomy  x         
Review Concomitant 
Meds/Procedures5 
  x x x x x x x x 
Review AEs   x x x x x x x x 
GQL-15 x     x  x  x 
GSS x   x   x x   
 
1Including: age, sex and race 
2Inclusive of use and number of IOP-lowering medication(s)                                                       
3Baseline IOP: mean of 3 Goldmann applanation readings taken on different days                                              
4Best-corrected visual acuity (VA) by the Snellen chart and converted to logarithm 
of the minimum angle of resolution VA 
5Inclusive of all postoperative medications, procedures and surgeries 
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Visit Windows 
Study visits may occur within the following acceptable visit windows: 
Table I-4. Study Visit Windows 
STUDY VISIT ACCEPTABLE WINDOW 
Day 1 Must occur on the day after trabeculectomy 
Week 1 Must occur one week from trabeculectomy 
Week 2 +/- 3 days 
Month 1 +/- 7 days 
Month 3 +/- 7 days 
Month 6 +/- 14 days 
Month 9 +/- 14 days 
Month 12 +/- 14 days 
 
Study Procedures & Evaluations 
Study procedures and evaluations conform to the standards set out by the World 
Glaucoma Association for the Design and Reporting of Glaucoma Surgical 
Trials.274 
Informed Consent 
Informed consent is a process that is initiated prior to the individual’s agreeing to 
participate in the study and continues throughout the individual’s study 
participation. Extensive discussion of risks and possible benefits of participation 
will be provided to the participants. Consent forms will be ethics-approved prior to 
use and the participant will be asked to read and review the document. The 
Investigator, or their delegate, will explain the research study to the participant 
and answer any questions that may arise. 
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Participants will have the opportunity to carefully review the written consent form 
and ask questions prior to signing. The participant will sign the informed consent 
document prior to any procedures being done specifically for the study.  
The participants may withdraw consent at any time throughout the course of the 
trial. A copy of the informed consent document will be given to the participants for 
their records. The rights and welfare of the participants will be protected by 
emphasizing to them that the quality of their medical care will not be adversely 
affected if they decline to participate in this study 
Inclusion/Exclusion Criteria 
The inclusion and exclusion criteria will be reviewed following the Informed 
Consent discussion to determine if the participant is eligible to continue study 
participation. In the event a participant is deemed ineligible, the reason for 
Screen Failure will be documented. 
Demographics 
Patient demographics will be collected including age, sex and race. 
IOP 
IOP is to be measured using Goldmann applanation. The individual reading the 
tonometer dial and recording the numerical value should not be the same person 
who is manipulating the Goldmann tonometer. 
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The baseline IOP will be the mean of three Goldmann readings taken on different 
days. These readings should occur within a maximum period of one month. 
For each Goldmann applanation reading, two measurements should be taken 
and averaged to determine the mean IOP. Three measurements should be taken 
if the first two measurements are greater than 3 mmHg difference. If more than 
two measurements are taken, the median (rather than mean) IOP value will be 
used. 
Trabeculectomy & Mitomycin C Use 
The following information pertaining to trabeculectomy is to be recorded for each 
study participant: 
• MMC dose: 0.2 – 0.4 mg/mL 
• Limbal or fornix approach 
• Suture type to close conjunctiva 
Study participants will receive MMC (0.2 – 0.4 mg/mL) delivered to the 
subconjunctival space using injection.  
Concomitant Medications & Procedures 
The use of any concomitant medications or procedures will be assessed at each 
study visit following the trabeculectomy. All concomitant medications and 
procedures will be recorded on a designated study source worksheet.  
Concomitant medications to be recorded include concomitant prescription 
medications, over-the-counter medications and non-prescription medications. 
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It will be documented whether the concomitant medication or procedure was 
initiated as an intervention toward target IOP. 
Adverse Events 
The occurrence of any adverse events will be assessed at each study visit 
following the trabeculectomy. If a Serious Adverse Event (SAE) has occurred, the 
investigator will follow the reporting procedures as outlined in section 4.6. 
Assessment of Safety 
Specification of Safety Parameters 
Definition of Adverse Events (AEs) 
Adverse event means any untoward medical occurrence associated with the use 
of an intervention in humans, whether or not considered intervention related. 
Definition of Serious Adverse Events (SAEs) 
An AE or suspected adverse reaction is considered "serious" if, in the view of the 
investigator, it results in any of the following outcomes:  
• death 
• a life-threatening adverse event 
• inpatient hospitalization or prolongation of existing hospitalization 
• a persistent or significant incapacity or substantial disruption of the 
ability to conduct normal life functions, or  
• a congenital anomaly/birth defect 
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Important medical events that may not result in death, be life-threatening, or 
require hospitalization may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospitalization, or the development of 
drug dependency or drug abuse. 
Reporting Procedures 
Adverse Event Reporting 
All adverse events will be recorded within the designated source worksheets and 
Case Report Form (CRF). 
Serious Adverse Event Reporting 
The site investigator will complete a SAE Form within the following timelines: 
• All deaths and immediately life-threatening events, whether related or 
unrelated to the study intervention, will be recorded on the SAE Form 
and submitted to the Lead Site within 24 hours of site awareness, if 
reasonably possible. 
• Other SAEs will be submitted to the Lead Site within 72 hours of site 
awareness. 
All SAEs will be followed until satisfactory resolution or until the site investigator 
deems the event to be chronic or the adherence to be stable.  
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The site investigator will determine if the SAE is reportable per the guidelines of 
their overseeing ethics committee and institution. A report to all necessary parties 
will be prepared and submitted within the institution-specified timeline. 
Safety Oversight 
Safety oversight will be under the direction of the Lead Site study team. The Lead 
Site will meet quarterly to review and assess safety data on each arm of the 
study. The Lead Site will be responsible for distributing quarterly safety reports 
and notifying study investigators of any ongoing study safety issues.  
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Curriculum Vitae 
Education 
Post-Secondary  
2014 - present MD/PhD, Schulich School of Medicine and Dentistry, London, Ontario 
Modulating Inflammation and Wound Healing in the Surgical Management of Glaucoma 
Laboratory of: Dr. Cindy Hutnik, Ivey Eye Institute, Departments of Ophthalmology and Pathology, 
Schulich School of Medicine 
 
2013 Honors Bachelor of Science. Major in Medical Cell Biology and Major in Biology, Western 
University, London, Ontario 
Other 
2016 
 
CSTAR Inter-Professional Summer Surgery School 2016 
Schulich School of Medicine, Arthur Labatt Family School of Nursing and Fanshawe College School 
of Nursing 
 
Master Class on Writing Research for Publication 2016 
Center for Education Research and Innovation (CERI), Schulich School of Medicine, Continuing 
Professional Development 
  
Research Interests 
 
 Wound healing, inflammation and fibrosis 
Microinvasive glaucoma surgery 
Fibroproliferative and myofibroblast pathophysiology 
Tissue engineering for disease modeling applications 
Systematic review and meta-analysis 
Electronic health records big data health analytics (ICES-Western) 
Machine learning applications to medical record keeping and quality indicators 
Blockchain applications for distributed, private medical record keeping 
Clinical practice guideline development, methodological quality and their implementation 
 
Research Profiles 
 
Mendeley https://tinyurl.com/JJA-Mendeley  
 
Scopus 
 
Author ID: 57061621900 
OrcID 
 
https://orcid.org/0000-0002-0848-7496 
Research Gate 
 
 
https://www.researchgate.net/profile/James_Armstrong14  
 
 
Research Grants/Scholarships (successful in bold) 
 
2018 
 
 
Glaucoma Research Society of Canada. Funding to support a randomized controlled trial evaluating 
the efficacy NSAIDs vs steroidal anti-inflammatory therapy after trabeculectomy – awarded $19,818 
The McGrath Research Scholarship. Funding to provide graduate students with an opportunity to 
undertake vision science research projects with established researchers in an environment that 
provides strong mentorship - awarded $8,000. 
AMOSO Innovation Fund. Lipid mediators of inflammation and resolution: investigating the 
association with abnormal wound healing and surgical outcome – Awarded $146,560 over 2yrs 
2017 
 
Nomination - Vanier Canada Doctoral Scholarship. The proposal I put forward was nominated by 
the University of Western Ontario’s Vanier Selection Committee for the 2018 competition – 
nominated to receive $150,000. Ultimately ranked 75 of 100 national finalists, with the top 55 
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receiving funding 
Investigator initiated proposal – Alcon Canada. Modeling Aqueous Drainage through the 
Supraciliary Space: a Tissue Engineering and Microfluidics Approach – applied for $56,000 
Glaucoma Research Society of Canada. Funding to support Tenon’s capsule tissue mimetic model 
validation. – awarded $20,000. 
Private Fundraising Initiative. Funding to support ICES database research costs. Assessing 
neuroprotective effects of Trazodone and other promising agents in an Ontario-based retrospective 
cohort - raised $10,000 in private donations. 
2016 
 
 
 
 
 
The McGrath Research Scholarship. Funding to provide graduate students with an opportunity to 
undertake vision science research projects with established researchers in an environment that 
provides strong mentorship. - awarded $8,000. 
Lawson Internal Research Fund. Funding to investigate patient and surgeon risk factors associated 
with trabeculectomy failure – awarded $15,000. 
Allergan Educational Grant. PhD stipend supplementation for research in novel methods of wound 
healing modulation for glaucoma surgical patients - awarded $18,500. 
Ivey Eye Institute. PhD stipend supplementation for research on microinvasive glaucoma surgery 
optimization - $18,500/year for 3 years. 
 
2015 
 
Schulich Summer Research Training Program. Supported for one summer of epidemiological 
research and a subsequent summer of tissue engineering and fibrosis related research - awarded 
$9,000. 
  
Patents / Provisional Patents 
 
2018 
 
Armstrong, J.J. and Hutnik, C.M.L. 2018. Compositions and methods for treating ocular 
inflammation and ocular scarring. U.S. Provisional Patent Application No. 62/677,284, filed May 
2018. Provisional status until May 2019. 
 
Peer-Reviewed Publications 
  
2019 Armstrong, J.J., Denstedt, J., Trelford, C., Li, E.A. and Hutnink, C.M.L. Differential effects of 
dexamethasone and indomethacin on Tenon’s capsule fibroblasts: implications for glaucoma 
filtration surgery. Experimental Eye Research, Volume 182, May 2019; 65-73. 
DOI: https://doi.org/10.1016/j.exer.2019.03.015  
Contribution: Developed research question with CH, designed experimental methods, 
executed experiments with JC, CT and EL. Drafted manuscript, with edits from JD, CT, 
EL and CH. 
 
Kiatos, E., Armstrong, J.J., Tsioros, S., Hutnik, C.L.M., Malvankar-Mehta, M. and Hodge, W.G. Of 
phaco and pain management: our review and meta-analysis of intravenous sedation in modern 
cataract surgery. Ophthalmology Management Jan 2019, 46-54.  
Contribution: Assisted with data collection and analysis, and drafting of manuscript 
 
2018 Armstrong, J.J., Welk, B., Reid, J.N.S., Kansal, V. and Hutnik, C.M.L. Secondary surgical intervention 
after primary glaucoma filtration surgery: an Ontario population-based study. Canadian Journal of 
Ophthalmology, June 2018.  
DOI: https://doi.org/10.1016/j.jcjo.2018.04.004 
Contribution: Originator of research question, recruited authors, drafted database coding 
strategy, first authored ICES DCP, created experimental groups, participated in data analysis, 
and first authored manuscript. 
 
Armstrong, J.J. and Hutnik, C.M.L. Comment re: Selective laser trabeculoplasty as replacement 
therapy in medically controlled glaucoma patients. International Glaucoma Review 2018;18:4 52-3.  
http://www.e-igr.com/ES/index.php?issue=184&ComID=1799  
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Contribution: completed first and contributed to final drafts after consultation with Dr. Hutnik 
and discussion of original article. 
 
Kansal, V., Armstrong, J.J., Pintwala, R. and Hutnik, C.M.L.  Optical Coherence Tomography for 
Glaucoma Diagnosis: An Evidence Based Meta-Analysis. PLoSOne. Jan 2018. 
DOI: https://doi.org/10.1371/journal.pone.0190621 
Contribution: assisted in development of research question, recruited authors, developed 
database search strategy and screening questions, participated in screening, collected and 
analyzed data, edited manuscript. 
 
2017 Michaelov, E., Armstrong. J.J., Nguyen, M., Instrum, B., Lam, T., Denstedt, J. and Hutnik, C.M.L. 
Assessing the Methodological Quality of Glaucoma Clinical Practice Guidelines and their 
Recommendations on Microinvasive Glaucoma Surgery: a Systematic Review and AGREE II 
Assessment. Journal of Glaucoma.  
DOI: 10.1097/IJG.0000000000000820 
Contribution: Originator of research question, recruited authors, developed database search 
strategy and screening questions, assisted in screening and data analysis, edited manuscript. 
*Awarded: Canadian Glaucoma Society best paper of 2017 
 
Kiatos, E., Armstrong, J. J., Hutnik, C.M.L., Tsioros, S., Malvankar-Mehta, M. S. and Hodge, W. G. 
The value of corneoscleral rim cultures in keratoplasty: a systematic review and cost-effectiveness 
analysis. ClinicoEconomics and Outcomes Research 2017:9 459-474. 
Contribution: Participated in screening, data extraction and manuscript preparation. 
 
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The effects of 
phacoemulsification on intra-ocular pressure and topical medication use in patients with glaucoma: 
a systematic review and meta-analysis of three-year data, Journal of Glaucoma 2017;26:511-522. 
Contribution: Originator of research question, recruited authors, developed database search 
strategy and screening questions, carried out screening, collected and analyzed data, drafted 
manuscript 
 
2016 Rodrigues, I. B., Armstrong, J. J., MacDermid, J. C. Facilitators and barriers to exercise adherence in 
patients with osteoporosis: a systematic review, Osteoporosis International 27(10):1-11 (2016). 
Contribution: Optimized database search strategy, refined inclusion criteria and screening 
questions, reference screening, GRADE quality assessment, edited manuscript 
 
Armstrong, J. J., Goldfarb, A. M., Instrum, R. S., MacDermid, J. C. Improvement evident, but still 
necessary in clinical practice guideline quality: a systematic review, Journal of Clinical Epidemiology 
81:13-2 (2016),  
DOI: 10.1016/j.jclinepi.2016.08.005. 
Contribution: Originator of research question, recruited authors, developed database search 
strategy and screening questions, carried out screening, collected and analyzed data, drafted 
manuscript 
 
Armstrong, J. J., Rodrigues, I. B., Wasiuta, T. & MacDermid, J. C. Quality assessment of   
osteoporosis clinical practice guidelines for physical activity and safe movement: an AGREE II  
appraisal. Arch. Osteoporos. 11, 6 (2016). 
Contribution: Originator of research question, developed methods, recruited authors, 
collected and analyzed data, drafted manuscript 
 
Publications Submitted/Under Review/In Press 
  
2018 Trelford, C., Denstedt, J., Armstrong, J.J. and Hutnik, C.M.L. Using a 3D bioartificial tissue of human 
Tenon’s capsule fibroblasts to assess the fibrogenic and inflammatory properties of the Tenon’s 
Capsule. Submitted to: Clinical and Experimental Ophthalmology, Nov 2018. 
 
Rejected and Re-Submitted Submissions 
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2018 Kansal, V., Armstrong, J.J., and Hutnik, C.M.L. Canadian Trends in Glaucoma Filtration Procedures 
from 2003 to 2016: Potential Impact of Minimally Invasive Glaucoma Surgery. Submitted to 
Canadian Journal of Ophthalmology, Oct 2018. 
 
Budure, A., Armstrong, J.J., Belrose, J., Ly, C. and Hutnik, C.M.L. Incidence of Perioperative 
Hypertension in Phacoemulsification Surgery. Submitted to: Journal of Cataract & Refractive 
Surgery. Sept 2018. 
 
Michaelov, E, Armstrong, J.J., Kansal, V., Ly, C., Denstedt, J. and Hutnik. C.M.L. Evaluation of Micro-
invasive Glaucoma Surgery Devices: A Systematic Review and Meta-analysis. Submitted to: 
Canadian Journal of Ophthalmology / Journal Canadien d’Ophtalmologie, December 2017. 
Rejected: March 2018. 
  
Rejected and Abandoned Submissions 
  
2017 Armstrong, J. J., Pintwala, R., Michaelov, E. and Hutnik, C.M.L. Risk factors for bleb-forming 
glaucoma surgery failure: a systematic review and meta-analysis. International Journal of 
Ophthalmology (submitted Sept 1, 2017) 
Contribution: Originator of research question, recruited authors, developed database search 
strategy and screening questions, carried out screening, collected and analyzed data, drafted 
manuscript. 
 
Armstrong, J. J., Diaz, A. P., O’Gorman, D. B. Palmar fascia mimetics as novel models of Dupuytren’s 
disease cord development, Advances in Wound Care (submitted, April 22, 2017) 
Contribution: Collaboratively developed research question and methods with DO, carried out 
experimental work with AD, drafted the manuscript and finalized it collaboratively with DO. 
 
Abstracts: Podium Presentations 
 
2019 
 
Armstrong, J.J., Li, E., Vinokurtseva, A. and Hutnik, C.M.L. Repurposing COX-2: an immuno-resolving 
and anti-cicatrizing therapy. Presented at the Canadian Ophthalmological Society Annual Meeting & 
Exhibition 2019, June 13-16; Quebec City, Qc 
 
Armstrong, J.J., Li, E., Vinokurtseva, A. Liu, H. and Hutnik, C.M.L. Acetylsalicylic acid reduces TGFb-
induced myofibroblast transdifferentiation and activity. Presented at London Health Research Day 
2019; April 30; London, On 
 
Armstrong, J.J., Li, E. and Hutnik, C.M.L. Acetylsalicylic acid reduces collagen contraction, 
remodeling and myofibroblast proliferation in a 3D Tenon's capsule tissue mimetic. Presented at 
the American Glaucoma Society Annual Meeting 2019, March 14-17; San Francisco, CA, USA 
 
Armstrong, J.J., Denstedt, J., Li, E., Dube, J., Trelford, C., Liu, H. and Hutnik, C.M.L. Modulating 
wound healing after glaucoma surgery. Presented at Lawson Health Research InstituteTalks on 
Fridays, February 1; London, On 
 
Armstrong, J.J., Boyd, E. and Hutnik, C.M.L. Proposal for a Canadian Trial evaluating NSAIDs vs. 
Steroid post-glaucoma Surgery. Presented at the Canadian Glaucoma Society Annual Meeting 2019, 
January 8-19; Paradise Valley, AZ, USA 
 
2018 
 
Armstrong, J.J., Denstedt, J., Li, E., Tingey, D. and Hutnik, C.M.L. Development of a novel 
acetylsalicylic acid-based adjuvant for glaucoma surgery. Presented at the Ivey Eye Institute 
Research Day 2018; November 2; London, On 
*Awarded Best Oral Presentation by a Graduate Student ($1000) 
 
Denstedt, J., Armstrong, J. J. and Hutnik, C.M.L. Modulating wound healing in trabeculectomy with 
SB-431542. Presented at the Ivey Eye Institute Research Day 2018; November 2; London, On 
*Awarded Best Oral Presentation by a Medical Student ($1000) 
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Armstrong, J.J., Trelford, C., Denstedt, J. and Hutnink, C.M.L. Modulation of wound healing after 
glaucoma filtration surgery: a 3-minute thesis. Presented at the Schulich Summer Research Training 
Program/Summer Research Opportunities Program Symposium; August 14; London, On 
 
Armstrong, J.J. and Hutnik, CML. Acetylsalicylic acid reduces collagen contraction, remodeling and 
myofibroblast proliferation in subconjunctival tissue mimetic. Presented at the Canadian 
Ophthalmological Society Annual Meeting; 2018 June 3; Toronto, On 
*COS Award for Excellence in Ophthalmic Research, 2nd place ($2000)  
 
Kansal, V., Armstrong, J.J., Pintwala, R. and Hutnik, CML. Optical Coherence Tomography for 
Glaucoma Diagnosis: an Evidence Based Meta-Analysis. Presented at the Canadian 
Ophthalmological Society Annual Meeting; 2018 June 3; Toronto, On 
 
Denstedt, J., Armstrong, J.J., Trelford, C. and Hutnik, CML. Assessing the effects of indomethacin 
and dexamethasone on wound healing using a 3D bioartificial tissue of human Tenon’s capsule 
fibroblasts. Presented at the Canadian Ophthalmological Society Annual Meeting; 2018 June 3; 
Toronto, On 
 
Kiatos, E., Armstrong, J.J., Hodge, W., Malvankar-Mehta, M. and Hutnik, CML. A systematic review 
and meta-analysis of intravenous sedation in modern cataract surgery. Presented at the Canadian 
Ophthalmological Society Annual Meeting; 2018 June 3; Toronto, On 
 
Armstrong, J.J. and Hutnik, C.L.M. Why MD/PhD and why ophthalmology: research and your future 
career. Co-presented to the Schulich School of Medicine MD/PhD students and prospective 
students; 2018 Jan 27; London, On 
 
2017 
 
Michaelov, E., Armstrong. J.J., Nguyen, M., Instrum, B., Lam, T., Denstedt, J. and Hutnik, C.M.L. 
Assessing the Methodological Quality of Glaucoma Clinical Practice Guidelines and their 
Recommendations on Microinvasive Glaucoma Surgery: a Systematic Review and AGREE II 
Assessment. Presented at Ivey Eye Institute Departmental Research Day; 2017 Nov 3; London, On 
 
Denstedt, J., Armstrong, J.J., Trelford, C. and Hutnik, C. The Effects of Indomethacin and 
Dexamethasone on Tenon’s Capsule Tissue Mimetics: avoidance of fibrotic outcomes. Presented at 
Ivey Eye Institute Departmental Research Day; 2017 Nov 3; London, On 
*Awarded 1st place 
 
Armstrong, J.J., Welk, B., Reid, J.N.S., Kansal, V. and Hutnik, C.M.L. Risk Factors for Secondary 
Surgical Intervention after Glaucoma Filtration Surgery: a population-based study. Presented at Ivey 
Eye Institute Departmental Research Day; 2017 Nov 3; London, On 
 
Kansal, V., Armstrong, J. J., Pintwala, R. and Hutnik, C.M.L.  Optical Coherence tomography for 
Glaucoma Diagnosis and Monitoring. Presented to the London Optometry Association; 2017 Sept. 
20; London, On 
 
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The Effects of 
Phacoemulsification on Intra-Ocular Pressure and Topical Medication Use in Patients with 
Glaucoma: A Systematic Review and Meta-Analysis of Three Year Data. Presented at the Canadian 
Ophthalmological Society Annual Meeting; 2017 June 18; Montreal, Qb 
*Designated ‘Hot Topic’ 
 
Kiatos, E., Armstrong, J. J., Hutnik, C.M.L., Tsioros, S., Malvankar-Mehta, M. S. and Hodge, W. G. 
The value of corneoscleral rim cultures in keratoplasty: a systematic review and cost-effectiveness 
analysis. Presented at the Canadian Ophthalmological Society Annual Meeting; 2017 June 18; 
Montreal, Qb 
 
Trelford, C. B., Armstrong, J. J., Hutnik, C.M.L. Using transcriptome analysis to compare Tenon’s 
capsule of patient derived samples, 2D monolayer cell culture and a novel bioartificial tissue 
construct. Presented at Lawson Health Research Institute “Talks on Friday’s”; 2017 Jan 13; London, 
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On 
 
 
2016 
 
Trelford, C. B., Armstrong, J. J., Hutnik, C.M.L. Validation of a novel bioartificial tissue model of 
Tenon’s capsule through whole transcriptome comparison with ex vivo Tenon’s capsule and 
Tenon’s capsule fibroblasts in 2D monolayer cell culture. Presented at the Department of Pathology 
Honors Thesis Symposium; 2016 Dec 7; London, On 
 
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The Effects of 
Phacoemulsification on Intra-Ocular Pressure and Topical Medication Use in Patients with 
Glaucoma: A Systematic Review and Meta- Analysis of Three-Year Data. Presented at Ivey Eye 
Institute Departmental Research Day; 2016 Nov 4; London, On 
 
Armstrong, J.J., Diaz, A. P., O’Gorman, D. B. Creation of an in vitro model of fibrosis using 
Dupuytren’s disease patient explant tissues. Presented at: Schulich School of Medicine Summer 
Research Training Program (SRTP) Seminar Series; 2016 Aug 9; London, On 
 
Armstrong J. J., Diaz, A. P., O’Gorman, D., B. Dupuytren’s disease: toward an in vitro model of 
fibroproliferative disease. Presented at: 2016 Canadian Bone and Joint Conference; 2016 April 9; 
London, On 
*Awarded top oral presentation (value $250) 
 
2015 Armstrong, J. J., Rodrigues, I. B., Wasiuta, T. & MacDermid, J. C. Quality assessment of osteoporosis 
clinical practice guidelines for physical activity and safe movement: an AGREE II appraisal. 
Presented at: Schulich School of Medicine Summer Research Training Program (SRTP) Seminar 
Series; 2015 July 7; London, On 
 
Abstracts: Poster Presentations 
 
2019 Denstedt, J., Armstrong, J.J. and Hutnik, C.M.L. Improving glaucoma surgery with the small 
molecule ALK-5 inhibitor SB-431542. Presented at the Canadian Ophthalmological Society Annual 
Meeting & Exhibition 2019, June 13-16; Quebec City, Qc 
*Awarded Second Place for Best Overall Poster 
 
Armstrong, J.J. and Hutnik, C.M.L. Repurposing COX-2: an immunoresolving therapy. Accepted to 
the Keystone Symposia for Lipidomics and Functional Metabolic Pathways in Disease 2019, March 
31 – April 4; Steamboat Springs, Colorado, USA 
*unpublished 
 
Armstrong, J.J., Li, E.A., Vinokurtseva, A. and Hutnik, C.M.L. Repurposing COX-2: an immuno-
resolving and anti-cicatrizing therapy. Presented at the Schulich School of Medicine and Dentistry, 
Department of Pathology and Laboratory Medicine Research Day 2019, March 29; London, On 
 
Li, E.A., Armstrong, J.J., Vinodurtseva, A. and Hutnik, C.M.L. Acetylsalicylic acid inhibits 
inflammation induced myofibroblast transdifferentiation in human tenons capsule fibroblasts. 
Presented at the Schulich School of Medicine and Dentistry, Department of Pathology and 
Laboratory Medicine Research Day 2019, March 29; London, On 
 
Denstedt, J., Michaelov, E., Armstrong, J.J. and Hutnik, C.M.L. A Systematic Review and Meta-
Analysis of Minimally Invasive Glaucoma Surgery Devices. Presented at the American Glaucoma 
Society Annual Meeting 2019, March 14-17; San Francisco, CA, USA 
 
2018 Budure, A., Armstrong, J.J., Belrose, J. and Hutnik, C.M.L. The incidence of perioperative 
hypertension during routine cataract surgery. Presented at the Ivey Eye Institute Research Day 
2018; November 2; London, On 
 
Armstrong, J.J., Welk, B., Reid, J., Kansal, V. and Hutnik, C.M.L. Risk Factors for Secondary Surgical 
Intervention after Glaucoma Filtration Surgery: A Population-Based Study. Presented at the 
Canadian Ophthalmological Society Annual Meeting & Exhibition; June 1-3; Toronto, On 
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Armstrong, J.J., Pena-Diaz, A. and O’Gorman, D.B. Palmar fascia mimetics as novel models of 
Dupuytren’s Disease cord development. Presented at the Canadian Connective Tissue Conference 
of Canada; May 25-27; Montreal, Qc 
 
Denstedt, J., Armstrong, J.J. and Hutnik, C. The functional response of Tenon’s capsule fibroblast 
cells to treatment with fibrotic growth factors in a 3D collagen lattice. Presented at London Health 
Research Day; May 10, 2018; London, Ontario 
 
Armstrong, J. J., Denstedt, J and Hutnik, C. Acetylsalicylic acid reduces collagen contraction, 
remodelling and myofibroblast proliferation in subconjunctival tissue mimetic. Presented at ARVO; 
2018 May 1; Honolulu, Hawaii 
 
Denstedt, J., Armstrong, J.J., Trelford, C. and Hutnik, C. The Effects of Indomethacin and 
Dexamethasone on Tenon’s Capsule Tissue Mimetics: avoidance of fibrotic outcomes. Presented at 
ARVO; 2018 April 29; Honolulu, Hawaii 
 
Armstrong, J. J., Denstedt, J. and Hutnik, C. M. L. Acetylsalicylic acid reduces collagen contraction, 
remodelling and myofibroblast proliferation in subconjunctival tissue mimetic. Presented at the 
Department of Pathology and Laboratory Medicine Research Day, Schulich School of Medicine; 
April 13; London, On 
 
Hutnik, C. M. L., Michaelov, Evan, Armstrong, J.J., Kansal, Vinay and Denstedt, James. Evaluation of 
Micro-invasive Glaucoma Surgery Devices: A Systematic Review and Meta-analysis. Presented at 
the American Glaucoma Society Annual Meeting; March 1-3; New York, NY  
 
Armstrong, J.J., Welk, B., Reid, J.N.S., Kansal, V. and Hutnik, C.M.L. Risk Factors for Secondary 
Surgical Intervention after Glaucoma Filtration Surgery: a population-based study. Presented at the 
American Glaucoma Society Annual Meeting; March 1-3; New York, NY 
 
Denstedt, J., Armstrong, J.J., Trelford, C. and Hutnik, C. The Effects of Indomethacin and 
Dexamethasone on Tenon’s Capsule Tissue Mimetics: avoidance of fibrotic outcomes. Presented at 
the American Glaucoma Society Annual Meeting; March 1-3; New York, NY 
 
2017 
 
Michaelov, E., Armstrong. J.J., Nguyen, M., Instrum, B., Lam, T., Denstedt, J. and Hutnik, C.M.L. 
Assessing the Methodological Quality of Glaucoma Clinical Practice Guidelines and their 
Recommendations on Microinvasive Glaucoma Surgery: a Systematic Review and AGREE II 
Assessment. Presented at the American Academy of Ophthalmology Annual Meeting; November 
11-14; New Orleans 
*Awarded best poster 
 
Kansal, V., Armstrong, J.J., Pintwala, R. and Hutnik, C.M.L. Optical Coherence Tomography for 
Glaucoma Diagnosis: An Evidence Based Meta-Analysis. Presented at the American Academy of 
Ophthalmology Annual Meeting; November 11-14; New Orleans 
 
Armstrong, J. J., Dang, B., Liu, H., Tellios, V., Tellios, N., Cejic, N. Cronk, A. and Hutnik, C. Bio-
modulation of Primary Human Tenon's Capsule Fibroblasts Using a Novel Application of Coated 
Magnesium. Presented at the Canadian Ophthalmological Society Annual Meeting & Exhibition; 
June 15-18; Montreal, Quebec 
 
Armstrong, J. J. and Hutnik, C.M.L. Effect of Glaucomatous Aqueous Humor Cytokines on Tenon’s 
Capsule Fibroblast Populated Collagen Lattices. Presented at The Department of Pathology and 
Laboratory Medicine Research Day; March 30; London, Ontario 
 
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The Effects of 
Phacoemulsification on Intra-Ocular Pressure and Topical Medication Use in Patients with 
Glaucoma: A Systematic Review and Meta-Analysis of Three Year Data. Presented at the London 
Health Research Day; March 28, 2017; London, Ontario 
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Trelford, C., Armstrong, J. J., Hutnik, C.M.L. The Validation of a 3D Bioartificial Tissue of the Tenon's 
Capsule. Presented at the London Health Research Day; March 28, 2017; London, Ontario 
 
Michaelov, E., Armstrong, J. J., Nguyen, M. and Hutnik, C.M.L. The quality of ophthalmology clinical 
practice guidelines and a review of recommendations for micro-invasive glaucoma surgical 
procedures: an AGREE II appraisal. Presented at the London Health Research Day; March 28, 2017; 
London, Ontario 
 
Kiatos, E., Armstrong, J. J., Hutnik, C.M.L., Tsioros, S. M., Malvankar-Mehta, M. S. and Hodge, W. G. 
The Value of Corneoscleral Rim Cultures in Keratoplasty: A Systematic Review and Cost-
Effectiveness Analysis. Presented at the London Health Research Day; March 28, 2017; London, 
Ontario 
 
Trelford, C., Armstrong, J. J., Hutnik, C.M.L. The Validation of a 3D Bioartificial Tissue of the Tenon's 
Capsule. Presented at The Department of Pathology and Laboratory Medicine Research Day; March 
30; London, Ontario 
 
Armstrong, J. J., Wasiuta, T., Kiatos, E., Malvankar, M. and Hutnik, C.M.L. The Effects of 
Phacoemulsification on Intra-Ocular Pressure and Topical Medication Use in Patients with 
Glaucoma: A Systematic Review and Meta-Analysis of Three-Year Data. Presented at the Canadian 
Society for Epidemiology and Biostatistics: 2017 Biennial Conference; May 30 – June 2; Banff, 
Alberta 
 
2016 Armstrong J. J., Diaz, A. P., O’Gorman, D., B. Dupuytren’s disease: toward an in vitro model of 
fibroproliferative disease. Poster presented at: Canadian National Medical Students Research 
Symposium; 2016 June 8; Winnipeg, MB 
 
Armstrong J. J., Diaz, A. P., O’Gorman, D., B. Dupuytren’s disease: toward an in vitro model of 
fibroproliferative disease. Poster presented at: Canadian Connective Tissue Conference; 2016 June 
3; Hamilton, On 
 
2013 Armstrong, J. J., Dragunas, A. J., Dickey, J. P. Early or late kick: a biomechanical comparison of two 
breaststroke underwater swimming techniques. Poster presented at: University of Western 
Ontario, in partial fulfillment of requirements for biology 4970G; 2013 April 10; London, On. 
*Awarded a mark of 95% 
 
Training/Safety Policy Documents 
 
2018 Armstrong, J.J. Safe Work Practices / Standard Operating Procedure for Persons Working with 
Varicella Zoster or Herpes Simplex Virus in vitro. Prepared for: Lawson Health Research Institute, 
London, On, Canada. 
 
Student Supervision (co-supervision under Dr. Cindy Hutnik) 
 
2019 A. Budure (MD3), J. Denstedt (MD3), M. Fung (MD2), E. Li (HBSc), G. Ge (MD4), E. Boyd (MD2), D. 
Rabinovitch (HBSc), A. Vinokurtseva (MD1), M. Wai (HBSc), C. Christian (High School Co-op) 
 
2018 A. Budure (MD3), J. Denstedt (MD3), R. McInnis (MD2), M. Fung (MD2), E. Li (HBSc), G. Ge (MD4), E. 
Boyd (MD2), D. Rabinovitch (HBSc), A. Vinokurtseva (MD1), M. Wai (HBSc) 
 
2017 A. Budure (MD2), J. Dube (HBSc), J. Denstedt (MD2), E. Michaelov (MD4), M. Nguyen (HBSc), S. 
Tsioros (HBSc), T. Lam (MD2), R. McInnis (MD1), M. Fung (MD1), E. Boyd (MD1) 
 
2016 V. Kansal (MD4), J. Denstedt (MD1), E. Michaelov (MD3), C. Trelford (HBSc), 
Ethics Applications 
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2019 Boyd, E., Armstrong J. J., Denstedt, J. and Hutnik, C. A national multi-center randomized controlled 
trial evaluating efficacy of dexamethasone versus [NSAID] for wound modulation after 
trabeculectomy. 
 
Armstrong J. J., Belrose, J., Hutnik, C. Incidence of perioperative hypertension and management 
strategies employed for patients undergoing cataract surgery. 
 
2017 Armstrong J. J., Denstedt, J., Hutnik, C. Growth factors in the aqueous humor and subsequent 
trabeculectomy failure 
 
Armstrong J. J., Belrose, J., Hutnik, C. Incidence of perioperative hypertension and management 
strategies employed for patients undergoing cataract surgery. 
 
Research Awards/Accolades 
 
2018 Ivey Eye Institute Best Presentation by a Graduate Student. Awarded to the best presentation at 
research day as judged by the panel. Value: $1000 
 
Canadian Glaucoma Society Best Paper Award – Medical Student Category 2018. Awarded to the 
best paper published by a Canadian medical student within the topic of Glaucoma. Value: $500 
*Second Author 
 
Canadian Ophthalmological Society Paper Presentation Award 2018. Awarded for excellence in 
ophthalmic research. Value: $2,000. 
 
2016 Dr. Glen S. Wither Award for Research. Awarded for outstanding participation and research 
excellence in the Schulich Summer Research Training program. Value: $600. 
 
Research featured by The US Agency for Healthcare Research and Quality’s Effective Healthcare 
Program’s Scientific Resource Center (SRC) newsletter. 
 
Research featured by The British Dupuytren’s Society. 
www.dupuytrens-society.org.uk/ongoing-research/  
 
Top Oral Presentation. Novel Therapies: Biological Repair and Tissue Regeneration.  
Canadian Bone and Joint Conference 2016. Value: $200. 
 
 
Supervisors/Mentors 
 
 Dr. Cindy Hutnik, MD, PhD, Ivey Eye Institute, Departments of Ophthalmology and Pathology, 
Schulich School of Medicine 
 
Dr. David O’Gorman, PhD, Roth|MacFarlane Hand and Upper Limb Center, Departments of Surgery 
and Biochemistry, Schulich School of Medicine 
 
Dr. Blayne Welk, MD, MSc, Departments of Surgery and Epidemiology & Biostatistics, Schulich 
School of Medicine 
 
Dr. Jim Lewis, MD, PhD, Director of Clinical Research Training, Schulich School of Medicine 
 
 
Other Research Experience 
 
Judge 
 
Pathology & Toxicology 4980E – Judge for honors thesis poster presentations, Schulich School of 
Medicine. March 27, 2017. 
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Reviewer Osteoporosis International (3), Toxicology in Vitro (2), International Journal of Molecular Sciences 
(1), Canadian Journal of Ophthalmology (1), BMJ Open (1),  
 
Lab Manager Import/export/customs for human, animal and cell culture derived specimens: infectious and non-
infectious. 
 
 
Business / Industry Involvement 
  
2018/19 Appili Therapeutics. Partnership encompassing mentorship and guidance to attain venture capital 
funding and build drug development pipeline for downstream applications of patented 
intervention. 
 
Aequus Pharma. Consultation and development relating to novel ophthalmic applications for 
repurposed drugs. Work done on anti-fibrotic/anti-inflammatory surgical adjuvants. Preparation of 
pre-clinical development plan for a chitosan based thermosensitive injectable gel, loaded with an 
anti-inflammatory/anti-fibrotic agent, as an adjuvant for glaucoma filtration surgery. 
 
2017 Alcon Canada. Expert opinion and intellectual contribution to wound healing as it relates to the 
Cypass glaucoma stent. 
 
2016 
 
Allergan Canada. Expert opinion and intellectual contribution to wound healing instructional 
presentation relating to the XEN glaucoma stent. 
 
Medical Electives 
 
2016 Ophthalmology (300hrs research) 
Dr. Cindy Hutnik, St. Joseph’s Hospital, London, Ontario 
Meds 5010 Non-Credit Pre-Clerkship Summer Research Elective 
 
2015 Plastic Surgery (100hrs Surgery/Clinic) 
Dr. Brian Evans, University Hospital, London, Ontario 
Meds 5010 Non-Credit Pre-Clerkship Summer Clinical Elective 
 
Medical Observerships 
 
2016 Ophthalmology (8hrs) 
Dr. Devesh Varma, Prism Eye Institute, Credit Valley Hospital, Mississauga, Ontario 
Ophthalmology (32hrs) 
Dr. David Tingey, St. Joseph’s Hospital, London, Ontario 
Plastic Surgery (12hrs) 
Dr. Brian Evans, University Hospital, London, Ontario 
Oral and Maxillofacial Surgery (12hrs) 
Dr. Joe Armstrong, University Hospital, London, Ontario 
2015 Plastic Surgery (8hrs) 
Dr. Bing Gan, St. Joseph’s Health Care, London, Ontario 
 Plastic Surgery (32hrs) 
Dr. Damir Matic, Victoria Hospital, London, Ontario 
 Neurosurgery (9hrs) 
Dr. Stephen Lownie, University Hospital, London, Ontario 
Oral and Maxillofacial Surgery (8hrs) 
Dr. Joe Armstrong, University Hospital, London, Ontario 
 Emergency Medicine (12hrs) 
Dr. Denis Atoe, Blenheim, Ontario 
Family Medicine (8hrs) 
Dr. Martha Clendenning, Blenheim, Ontario 
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2014 Orthopedic Surgery (35hrs) 
Dr. Robert Litchfield, University Hospital, London, Ontario 
 Emergency Medicine (6hrs) 
Dr. Behzad Hassani, University Hospital, London, Ontario 
 Radiology (6hrs) 
Dr. Mark Landis, Victoria Hospital, London, Ontario 
 
Employment Experience 
  
2016-Present 
 
Graduate Research Assistant. Deps. of Ophthalmology and Pathology, Schulich School of Medicine  
Private Tutor. Grade 11/12 physics. 
2015-2016 Security. Belfort Nightclub. 
2013-2014 Personal Trainer. Goodlife Fitness. #1 performing level 2 trainer – city wide, London, On 
2013-2016 Security. Gatsby Soundhouse and Bar. Broke up 5 physical altercations without the use of force. 
2011-2014 Exam Proctor. London Public Library. 
 
 
Leadership and Community Involvement 
 
2017-2018 Polymerase Spiral Reaction Technology Group, founding member. Coordinate weekly meetings for 
all Lawson affiliated labs currently working on diagnostic applications for novel PSR technology. 
 SMART committee, founding member. MD/PhD students mentoring MD students who wish to 
undertake research endeavors 
MD Curriculum Development - Research Integration Experience: Pilot Project. Helped develop a 
pilot project to integrate MD students into health research labs, fostering inter-professional 
cooperation and the early development of critical research skills in medical students. Medical 
school-wide implementation schedule for 2019. 
2015-2016 Oral Symposium Chair, Canadian National Medical Student Research Symposium. 
 Schulich Summer Research Training Program Committee, Student Representative. 
 Mentor, Altitude: Healthcare Mentorship. 
 Surgery Interest Group Executive, Schulich School of Medicine. 
 Inter-professional Summer Surgery School, Chair of Organizing Committee, Schulich School of 
Medicine. 
 
2003-2014 Emergency Department Volunteer, London Health Sciences Center, University Hospital. 
 Athlete, London Aquatic Club. 
 Reading Tutor, London Public Library. 
 Team Captain (twice elected), Western Mustangs Swimming Team. 
 
2008-2013 Athlete, Western Mustangs Swimming. 
 
2011-2012 Athletes Representative, Swim Ontario Fundraising Committee. 
 Team Canada Member (Swimming), Pan American Games, Guadalajara, Mexico. 
 Team Canada Member (Swimming), Nations Cup, Montreal, Quebec. 
2002-2015 London Aquatic Club, Athlete 
 
Other Awards 
 
Academic 
2011-2013 CIS Academic All Canadian 
Qualify for CIS championships and achieve an average greater than 80%. 
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2011-2013 Deans Honor List 
Obtain an average greater than 80%. 
2008 Western University Scholarship of Excellence 
Given to students entering university with an average of 90% or more. 
Athletic 
2013 Western Mustangs Purple Blanket Award 
Selected by Committee: Western athlete with greatest athletic and academic achievement. 
2013 OUA Graduating Athlete Award of Distinction 
Selected by Committee. 
2010-2013 OUA All-Star (5 time)  
Given to athletes who receive silver or better in one or more events. 
2009-2013 OUA Medalist (18 times) and CIS Medalist (3 times) 
Western Mustangs Swimming Team. 
2012 Canada Games Aquatic Center Hall of Fame Inductee 
Chosen by Committee. 
2011 Western Mustangs Bronze W Award 
Given to athletes who qualify for their sports’ OUA team three years in a row. 
2009 Western Mustangs Rookie of the Year 
Top ranked swimmer in first year of varsity eligibility. 
Volunteer 
2014 Ontario Volunteer Service Award 
Nomination then Chosen by Committee. 
2011 Volunteer of Distinction, London Public Library.  
Chosen by Committee. 
 
Extracurricular Activities 
 
Memberships CMA, since Aug 2014 
OMA, since Aug 2014 
Canadian Connective Tissue Society, since June 2016 
Clinician Investigator Trainee Association of Canada, since June 2016 
Canadian Society for Clinical Investigation, since June 2016 
 
Sports Ballroom Dancing – Fred Astaire Studios, Intermural Softball – Schulich Medicine Team, Intermural 
Inner Tube Water Polo – Schulich Medicine Team, Schulich Inter-Class Hockey League, Schulich 
Meds Golf League, Schulich Weightlifting Club 
 
Clubs Medical Skills Club, Microsurgery Interest Club, Neurology and Neurosurgery Interest Group, 
Oncology Interest Group, Ophthalmology Interest Group, Point and Shoot Billiards Club, Point of 
Care Ultrasound Interest Group, Radiology Interest Group, Sports and Rehabilitative Medicine 
Interest Group, Surgery Interest Group, Surgically Oriented Anatomy Prosectors (SOAP), Western 
Emergency Medicine Interest Group 
  
Academic Affiliations 
 
2014-2021 
2016-2019 
2016-2019 
2016-2019 
2016-2019 
Student, Department of Undergraduate Medical Education, Schulich School of Medicine 
Student, Department of Pathology and Laboratory Medicine, Schulich School of Medicine 
Student, Department of Ophthalmology, Schulich School of Medicine 
Student, Ivey Eye Institute, St. Joseph’s Healthcare, London, On 
Student, Institute for Clinical and Evaluative Sciences (ICES Western), LHSC, London, On 
 
 
